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Cerebral Palsy 
 
Cerebral palsy (CP) is a term used to describe a clinical syndrome, characterised 
by a persistent movement or posture disorder that results from a non-progressive 
disorder of the immature brain1. CP is the most common motor disability in 
childhood, with an incidence of 1.5 - 3.0 per 1000 live births in western countries2. 
For the population of the Netherlands, the prevalence in 1986-1988 was estimated 
at 2.4 per 1000 live births3.  
 
Classification 
Although the diagnosis of CP suggests an entity, it is a heterogeneous condition 
in terms of the type of movement disorder and the severity of impaired muscle 
functions4.  
Type of movement disorder: CP can be classified according to the type of 
movement disorder into three groups: spastic paresis, dyskinetic paresis and ataxic 
paresis, but mixed movement disorders are also common. Classification, as such, is 
useful because for each group there is a different prognosis, and different methods 
of medical treatment are used for each group5.   
The spastic paresis is the most common movement disorder (85%)2,6. This is 
defined as a posture and movement-dependent tone-regulation disorder7. The most 
important clinical symptom of a spastic paresis is the loss or absence of muscle 
tone in a lying position, and an increase in muscle tone in a sitting position, or 
when standing, walking or running, depending on the degree of involvement. 
Spastic paresis can further be classified as unilateral or bilateral, according to the 
body parts involved. The unilateral group is referred to as hemiplegia, in which one 
arm and one leg on the same side of the body are involved, and the bilateral group 
is referred to as diplegia (e.g. the primary involvement is in the legs) and 
quadriplegia (e.g. all four extremities are involved: the arms are just as severely, or 
more severely, involved as the legs, or more). Another way to classify children with 
CP is according to their severity of gross motor limitations, by means of the Gross 
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Motor Function Classification System (GMFCS)8. The GMFCS classifies children 
according to their functional abilities and their need for assistive technology and 
wheeled mobility. The GMFCS is a five-level system, based on age-specific criteria 
(age-range 0 - 12 years). From the age of 6, children with levels I and II walk 
without an assistive device, children with levels III and IV walk with an assistive 
device for respectively long or short distances, and children with level V are not 
able to walk. This thesis will focus on children with a hemiplegic and diplegic 
spastic paresis, with GMFCS levels from I to IV.  
Impaired muscle functions: The impaired muscle functions that occur with 
spastic paresis are many, and secondary to a variety of neurological conditions 
resulting from the upper motor neuron syndrome that is inherent to the CP. They 
can be classified into two groups: (1) impairments of muscle activation, and (2) 
changes in biomechanical properties of muscles and connective tissues9. The 
impairments of muscle activation can be divided into a series of abnormal muscle 
activities or 'excess symptoms' (e.g. spasticity, hypertonia, hyperreflexia) and 
performance deficits caused by the reduction of voluntary muscle function, referred 
to as 'deficit symptoms' (e.g. paresis, loss of selective motor control). 
 
Mobility and gait limitations 
Impaired muscle functions lead to limitations in the activities of a child, which 
are experienced by the majority of children with CP10,11. One of the most prominent 
activity limitations concerns mobility, described as movement by changing body 
position or location, or by transferring from one place to another12. Mobility 
limitations are often related a deviated gait pattern, due to gait impairments. 
Many different gait patterns have been described in children with spastic paresis13. 
They are clinically classified according to the joint position(s) during a particular 
phase of gait (e.g. at the level of the ankle, the knee and/or the hip)7,14-17. 
Chapter 1 
Figure 1: The normal gait pattern in the different phases of the gait cycle 
(according to  Perry20) 
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Gait patterns which are characterised by knee flexion during the midstance 
phase of gait are thought to be particularly disturbing, since the natural course of 
development in these children is further deterioration in the flexion pattern18. This 
is generally accompanied by a deterioration in mobility19. This makes it important 
to identify these children at an early stage, and to start appropriate rehabilitation 
treatment in order to prevent deterioration in mobility by improving their gait 
pattern. Therefore, children with CP who walk with this so-called ‘flexed knee gait’ 
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are of special interest in the field of rehabilitation, and will be the focus of this 
thesis.   
 
Figure 2: Different types of gait pattern of knee flexion during midstance, 
classified according to Rodda and Graham16 and the Amsterdam Gait 
Classification7 
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Flexed knee gait 
The flexed knee gait is specifically characterised by flexion of the knee (> 10˚) 
during midstance, with simultaneous flexion of the hip. The position of the ankle 
may vary from equinus (plantar flexion of the ankle and the foot) to dorsal flexion. 
The midstance is defined as the phase in the standing period during stride where 
there is only single limb support (Figure 1). 
This phase starts when the contralateral leg is in initial swing, and ends when 
the contralateral leg passes the reference leg.  Depending on the position of the 
ankle, the flexed knee gait can be classified as either type IV (knee flexion in 
midstance with heel-rise) or type V (knee flexion in midstance without heel-rise), 
according to the Amsterdam Gait Classification7 (Figure 2).  
 
Other classifications of these gait patterns (see Rodda and Graham, 2001) are 
‘jump knee’ or ‘apparent equinus’ for type IV, or ‘crouch gait’ for type V (Figure 
2)16. The participants in the study described in this thesis were children with type 
IV and type V gait patterns.  
  
 
Clinical assessment of spasticity 
 
With respect to the cause of the flexed knee gait, it is postulated to be 
attributable to an underlying combination of decreased strength of the extensor 
muscles (i.e. glutei, quadriceps and/or tibialis posterior muscle), reduced length of 
the flexor muscles (i.e. psoas, hamstrings, gastrocnemius and/or soleus muscles)13 
and/or abnormal involuntary muscle overactivity. With regard to the latter, 
spasticity (defined as ‘a motor disorder characterised by a velocity-dependent 
increase in tonic stretch reflexes [muscle tone] with exaggerated tendon jerks, 
resulting from hyperexcitability of the stretch reflex, as one component of the 
upper motor neuron syndrome’23), is also considered to be causative. The presence 
of spasticity can be assessed during clinical examination. However, for many years 
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there has been an ongoing discussion with respect to the assessment of spasticity. 
In this thesis we will add to that discussion. 
Of  all the different methods to assess spasticity, clinical scales are the most 
frequently used in clinical practice24. Spasticity is clinically characterised by a 
velocity-dependent increase in muscle tone, demonstrated at a certain angle in the 
range of motion (ROM) in response to passive muscle stretch. In order to 
demonstrate the velocity-dependency, the instrument should assess spasticity by 
applying both a slow and a fast stretch. In an extensive review, described in 
Chapter 2 of this thesis, we found that different clinical spasticity scales have been 
developed and used in the evaluation of CP. Unfortunately, most scales are of 
limited value as a measure of spasticity because they only use one, usually 
undefined, velocity of stretch. This makes them unsuitable to discriminate between 
spasticity and other symptoms of abnormal involuntary muscle overactivity which 
also lead to increased muscle tone, but which are typically non-velocity-dependent, 
such as hypertonia due to tonic stretch reflex (TSR) activity, or even hypertonia 
due to a change in biomechanical properties25-27. Each of these symptoms may 
require a different method of medical treatment. Therefore, when the aim is anti-
spasticity treatment, assessment of the velocity-dependent character of spasticity 
seems crucial. A new clinical spasticity scale was therefore needed. This lead to the 
development of the Spasticity Test, which will be presented in Chapter 3. 
 
 
Treatment of flexed knee gait  
 
As has already been explained, the flexed knee gait is thought to result from an 
underlying combination of different impairments. Due to the heterogeneity of CP, 
the presence and severity of spasticity and the other impaired muscle functions 
varies per patient. Nonetheless, what is characteristic for all patients with CP is 
that the impairments are not equally spread throughout their muscles. This 
results in a muscle imbalance, i.e. in a agonist-antagonist couple (such as flexor-
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extensor) there is generally more spasticity and/or muscle shortening in one than 
in the other. Treatment of this muscle imbalance is considered to be the main 
prerequisite for potential improvement in mobility. The treatment rationale is 
therefore to aim at decreasing muscle activity in the spastic (usually flexor) 
muscles, stretching the shortened (usually flexor) muscles and strengthening the 
weakened (usually extensor) muscles, at the same time. To decrease spasticity, 
botulinum toxin type A (BTX-A) can be injected in the muscle, and a 
comprehensive rehabilitation treatment, consisting of intensive physical therapy, 
orthosis and serial casting, can be used to train the weaker extensor muscles, 
stretch the shorter flexor muscles and increase mobility training. Such treatment 
has been evaluated in this thesis, and for this purpose we performed a randomised 
controlled trial, the BOLIEN study, in which we evaluated the effect of multilevel 
BTX-A injections and comprehensive rehabilitation, compared to usual care (low-
frequency physical therapy). Multilevel BTX-A treatment refers to the injection of 
multiple muscles (around the hip, knee and ankle) within one treatment session, 
which is particularly indicated in children with a gait which is characterised by 
flexion of the knee in midstance. 
The effects of this intervention on the domain of body function and stucture; e.g. 
spasticity, muscle length and gait pattern, has been described in Chapter 4. From 
the perspective of rehabilitation, it is particularly relevant to improve the mobility 
of children who walk with flexed knees. Establishing the effectiveness of this 
treatment on mobility, as part of the domain of activity, was therefore the main 
goal of the BOLIEN study, and this will be described in Chapter 5. 
 
14 
Introduction and outline 
Botulinum toxin type A injections 
The neurotoxin BTX-A is produced by the anaerobic bacterium Clostridium 
Botulinum. Injected in a muscle, BTX-A acts at the neuromuscular junction by 
blocking the release of acetylcholine28 (Figure 3). The dose-dependent muscle-
relaxation that is induced is temporal. After a period of 2 to 4 months, the muscle 
is re-innervated, first by nerve-sprouting and the formation of new synaptic 
contacts, and later by recovery of the originally affected nerve-endings29.  
 
Figure 3: Action of botulinum toxin type A (BTX-A) 
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So far, there have been no reports on effectiveness of this treatment in children 
with a flexed knee gait. The flexed knee gait is considered to be due to the presence 
of spasticity in several muscles, which act over different joints (e.g. knee, hip 
and/or ankle). Therefore, to improve this gait pattern, all these muscles should be 
injected with BTX-A. When this is done in one session, this is referred to as 
‘multilevel BTX-A injection’.  
 
Comprehensive rehabilitation 
As has already been mentioned, injection with BTX-A is rarely an isolated 
treatment, because it only acts on one component of the muscle imbalance: i.e. 
spasticity. Other components of the muscle imbalance, such as muscle paresis and 
muscle shortening, remain unaffected. Therefore, the total treatment plan should 
also aim to improve muscle length and muscle strength. This is achieved by means 
of a comprehensive rehabilitation approach, including a period of intensive 
physical therapy after the BTX-A injections, the prescription of an appropriate 
orthosis, and, if necessary, serial casting.  
 
The aim of intensive physical therapy after multilevel BTX-A treatment is to 
improve the mobility of the child by increasing muscle length and muscle strength 
and training motor activities. This should be achieved by a variety of safe, effective 
and fun training methods. However, there are no scientific reports that define the 
optimal intensity or contents of such a physical therapy program. The contents of 
the program should be adapted to the individual child, and should involve a timely 
progression in intensity. A 1-hour training schedule two to three times per week is 
recommended, for maintaining and improving muscle strength and flexibility37. 
Intensified physical therapy following after BTX-A is also recommended. To benefit 
from the muscle relaxation effect38, exercises to stretch the agonist spastic muscles 
and to strengthen the antagonistic weakened muscles can be performed more 
easily, and new motor activities can be re-learned with the aim to improve 
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mobility. Subsequently it is important that the intensity is increased in the period 
during which the toxin is most active (e.g. three to six weeks post-injection).  
Ankle-foot-orthoses (AFOs) are also prescribed for children with spastic CP to 
correct their gait pattern39,40. There are different AFO configurations, and the type 
of AFO depends on what needs to be corrected. When gait is characterised by 
persistent flexion of the knee, AFOs could be prescribed to support full knee-
extension in terminal stance and to block the third rocker (heel-rise to toe-off)40. 
These are either rigid (does not allow ankle dorsiflexion) or hinged (allows some 
ankle dorsiflexion) with a stiffened carbon sole, floor-reaction orthoses (FRO), or 
stiffened carbon inlays.  
Finally, serial casting is prescribed if the passive dorsiflexion range is restricted 
by shortening of the gastrocnemius muscle (i.e. does not exceed 0° dorsiflexion).   
 
Note; It should be obvious that the formulation of a total treatment plan for a 
child with CP, including the target muscle identification for multilevel BTX-A 
injection, the focus of the physical therapy program, the type of AFO prescribed, and 
the need for serial casting, is directly related to the child’s underlying muscle 
imbalance. This is identified by means of gait-analysis and clinical examination, 
and is therefore highly child specific. This means that, in the study described in this 
thesis, the treatment plan for every child was unique, even though they all walked 
with a flexed knee gait. To illustrate how each individual treatment plan was 
formulated, a clinical case presentation for one of the participants in the study is 
presented in Appendix I. 
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Purpose of the thesis 
 
The primary aim of this thesis was to determine the effectiveness of multilevel 
BTX-A injections and comprehensive rehabilitation on the mobility of children with 
spastic CP who walk with flexed knees. The second aim was to develop a new 
instrument for the clinical assessment of spasticity. 
 
Outline of the thesis  
 
The first part of this thesis describes the clinical assessment of spasticity. 
Chapter 2 gives an overview of all the instruments that can be used for the clinical 
assessment of spasticity in children with CP. The compliance of each instrument 
with the concept of spasticity was evaluated, and this resulted in the 
identifications of a number of concerns regarding the use of these instruments for 
the evaluation of spasticity.  
Chapter 3 presents a clinical spasticity scale, the Spasticity Test (SPAT). The 
assessment procedure, the feasibility for use in clinical practice, and the intra-
rater and inter-rater reliability of the scale are described.  
The second part of this thesis describes the efficacy of multilevel BTX-A 
injections and comprehensive rehabilitation in children with a spastic paresis, who 
walk with flexed knee gait. Chapter 4 presents the results of the randomised 
controlled trial of the effect of multilevel BTX-A and comprehensive rehabilitation 
on gait pattern, spasticity and muscle length in these children, and Chapter 5 
describes the results with regard to mobility. Since the characteristics of patients 
with CP differ widely, it is likely that certain patients will benefit more from this 
treatment than others. Therefore, the predictors for a favourable outcome of 
multilevel BTX-A and comprehensive rehabilitation on mobility and gait pattern in 
these children are evaluated in Chapter 6.  
The final part of this thesis, Chapter 7, is the general discussion.  
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Basic information about the child 
Personal information 
The patient is a small 4½ year old boy (115 cm, 18.5 kilos). 
 
Educational situation 
He attends a regular elementary school.  
 
Medical diagnosis 
He has a symmetric bilateral spastic paresis. 
 
Medical history 
The patient was born at 30 weeks after a normal pregnancy. Brain-computed 
tomography and Magnetic Resonance Imaging scans showed white-matter damage of 
immaturity in the periventricular area (periventricular leukomalacia). The patient has 
been treated with physical therapy since the age of 6 months and has worn orthosis 
since the age of 3 years. He has not received any other treatments.  
 
Aids and adaptations 
The patient wears ankle foot orthosis (AFOs) indoors and outdoors. He has a two-
wheeled bicycle with additional side-wheels, but the parents put him in a buggy for 
longer-distances, and have recently applied for a hand-driven wheelchair. 
 
Present situation of the child 
Present needs 
The patient was referred to one of the four hospitals participating in the study for 
clinical evaluation, in order to determine the appropriate AFOs configuration to 
improve his gait pattern. He has had increasing difficulty in the fitting of his Floor 
Reaction AFOs and increased daily tripping and falling, secondary to excessive ankle 
plantar flexion (equinus) and flexed knee gait. He has no pain in the knees or feet when 
walking.  
 
Introduction and outline 
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Current abilities 
Mobility 
The patient is classified as level II according to the Gross Motor Function Classification 
System.  
 
He walks indoors, and for balance, he uses walls and furniture. He attains a sitting 
position through a supine position and a standing position through a sitting position. 
He maintains stand for 1 to 3 seconds, but in stand he cannot lift one leg, even with 
assistance. He can crawl alternately. He maintains a high-knee position and can walk 
10 steps with high knees. Assistance is needed when he wants to maintain a half-knee 
position or wants to attain stand through a half-knee position with either knee. 
Outdoors, he can walk for 30 minutes (with little assistance), but he cannot stop and 
turn from walking without assistance, so needs help when crossing the street. He is not 
able to run.  
 
Personal care 
The patient is able to dress and undress without any assistance, but he needs complete 
assistance with tying and untying his shoe-laces and AFOs.   
 
Learning, communication, social emotional functioning 
The patient has good cognition, good communication and good social emotional 
functioning. 
 
Impairments 
Passive range of motion (ROM)  
The patient has 130° hip flexion in both hips, and has 60° of hip abduction with his hips 
flexed. His prone hip extension is 0° bilaterally. His internal rotation is 60° in his right  
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hip and 40° in his left hip, and his external rotation is 25° bilaterally. His popliteal  
angles are 70° bilaterally. He has a 10° flexion-contracture in both knees. Both his 
ankles dorsiflex to 0° with knee flexion and to -5° with his knees extended.   
  
Muscle function 
Spasticity, as shown by the occurrence of a clear catch in response to a fast passive 
stretch, is present in the adductor muscles at 20° and in the rectus femoris at 60° 
bilaterally, in the right and left hamstrings muscles at 100° and 80°, respectively, and 
in the right and left gastrocnemius/soleus muscles at 50° and 40°, respectively. 
He has good selective motor control in ankles, knees and hips bilaterally. 
 
Gait analysis  
Clinical observation 
The patient stands and walks with a bilateral gait pattern type IV (hip and knee 
flexion, ankle plantar flexion in midstance) according to the Amsterdam Gait 
Classification. He has bilateral toe-landing on initial contact, fore-foot varus rotation 
during loading response, and severe equinus without heel contact during the total 
stance phase. The knee flexion during midstance is 25° in the right leg and 30° in the 
left leg. There is endorotation of the foot during both the stance and the swing phase.  
During swing there is reduced progress towards knee extension, and he walks with 
slight endorotation-abduction in terminal swing (left  > right). The step-length is 
reduced bilaterally.  
 
Dynamic electromyogram (EMG) recordings 
There is continuous bilateral activity of the rectus femoris muscles in both swing and 
stance; the vastus lateralis muscles demonstrate excessive activity during stance; there 
is prolonged activity of the hamstrings muscles in stance; the gastrocnemius are active 
during midstance, but not in terminal stance; and the tibialis anterior are continuously 
active, with an increase of phasic activity in terminal swing and loading response. 
Introduction and outline 
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Interpretation 
Perry20 and Gage13 have described five prerequisites for normal gait. We will use these 
prerequisites as a basis for our interpretation of the patient’s needs and clinical 
problems, in order to recommended adequate treatment.  
Prerequisites of normal gait:  
(1) Stability in the stance phase of gait 
(2) Clearance of the foot in the swing phase 
(3) Proper foot preposition in swing 
(4) An adequate step-length 
(5) Conservation of energy 
 
According to these five prerequisites, the specific problems of this patient are:  
(1) a bilateral instable base of support in stance, due to equinovarus position of the feet 
caused by abnormal activity (spasticity) and shortening of the gastrocnemius muscles; 
(2) an insufficient clearance caused by insufficient bilateral knee flexion during initial 
swing,  resulting from an early onset of stretch reflex activity (spasticity) of the rectus 
femoris muscles in initial swing, which is confirmed by EMG; 
(3) an improper foot preposition due to both incomplete bilateral knee extension and 
endorotation/adduction of the hips, as well as insufficient bilateral foot-lift in terminal 
swing, resulting in an equinovarus position of the foot, caused by shortening of the 
gastrocnemius and hamstrings muscles, and abnormal hamstrings activity (spasticity) 
in terminal swing;  
(4) an inadequate step-length, caused by the lack of knee propulsion towards extension 
of the swinging leg;  
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(5) an energy-consuming gait pattern, due to bilateral knee flexion in midstance, 
caused by abnormal activity and shortening of the gastrocnemius and hamstrings  
muscles, for which the prolonged vastus lateralis activity is compensating. There is also 
a bilateral lack of active toe-off in terminal stance, due to insufficient gastrocnemius 
power, which is confirmed by EMG. 
 
Treatment plan 
With respect to the five gait prerequisites and the patient’s complaint of falling (mainly 
prerequisites no. 1, 2 and 3) and difficulty of AFO fitting, not only new orthosis, but 
also multilevel BTX-A injections and serial casting are indicated for this patient:  
(1) BTX-A injections in the gastrocnemius muscles to reduce the equinovarus,  
serial casting to improve gastrocnemius muscle lengths, and 
prescription of AFOs to improve the base of support;  
(2) BTX-A injections in the rectus femoris muscles to improve clearance in initial swing;  
(3) BTX-A injections in the gastrocnemius muscles to reduce the equinovarus,  
BTX-A injections in the medial hamstring muscles to reduce the 
endorotation/adduction in terminal swing, and prescription of AFOs to reduce the 
equinovarus in terminal swing; 
(4) BTX-A injections in the hamstrings muscles to improve the knee extension during 
midstance, 
prescription of AFOs to improve knee extension during terminal stance, and 
(see treatment recommendation for prerequisite 2 ‘clearance of the foot in swing 
phase’); 
(5) BTX-A injections in the hamstrings muscles to improve the flexed knee gait pattern,  
BTX-A injections in the gastrocnemius* muscles to improve the flexed knee gait 
pattern, bilateral serial castings to improve gastrocnemius muscle lengths, and  
prescription of AFOs to improve knee extension during terminal stance.  
 
* note that the gastrocnemius power is insufficient in terminal stance: to prevent this 
from getting worse, the gastrocnemius should be injected with a low dose. 
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Treatment received 
Multilevel BTX-A 
Dosage and injected muscles: The maximum age-adjusted dose for injection is 25U * 18 
kilos = 450U Botox®. The maximum dose is 108U (6U/kg) per large muscle group and 
72U (4U/kg) per small muscle group. The total dose injected in this patient was 400U 
(hamstrings (2 legs x 6 injection sites x 15U) [gracilis (2x2x15U), semimembranosus 
(2x2x15U), semitendinosus (2x2x15U)], rectus femoris (2 legs x 2 injections sites x 
25U), gastrocnemius medialis (2 legs x 2 injections sites x 15U), gastrocnemius lateralis 
(2 legs x 2 injections sites x 15U)  
 
Orthosis 
Bilateral, non-hinged, Floor Reaction AFOs.  
 
Serial casting 
Bilateral serial castings, applied two weeks after injections, until 0˚ ankle dorsiflexion 
is reached with knee extended. 
 
Intensive physical therapy 
The patient is treated with a 12-week standardised physical therapy protocol. This 
starts one week after the injections, with a varying frequency of 3 (weeks 1 to 3, and 
weeks 7 to 12) to 5 (weeks 4 to 6) times a week. The physical therapy has three main 
aims: 
 (1) improve the length of the iliopsoas, hamstrings, gastrocnemius and soleus muscles 
by means of passive and active stretches, as well as daily stretching exercises 
performed at home. 
(2) improve the strength of the quadriceps, gluteus medius and gluteus maximus 
muscles. Insufficient strength in these muscles is indicated by the patient’s difficulties 
with the half knee position and standing on one leg.  
(3) improve functional mobility and gait pattern. The patient has difficulty in 
maintaining stand, stop and turn with arms free. He will be trained in this, with 
subsequent focus on the gait pattern.  
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Chapter 2 
Abstract 
 
This study reviews the instruments used for the clinical assessment of spasticity 
in children with cerebral palsy, and evaluates their compliance with the concept of 
spasticity, defined as a velocity-dependent increase in muscle tone to passive 
stretch. Searches were performed in Medline, Embase, and Cinahl, including the 
keywords ‘spasticity’, ‘child’, and ‘cerebral palsy’, to identify articles in which a 
clinical method to measure spasticity was reported. Thirteen clinical spasticity 
assessment instruments were identified and evaluated using predetermined 
criteria. This review consists of reports on the standardization applied for 
assessment at different velocities, testing posture, and quantification of spasticity. 
Results show that most instruments do not comply with the concept of spasticity; 
standardization of assessment method is often lacking, and scoring systems of 
most instruments are ambiguous. Only the Tardieu Scale complies with the 
concept of spasticity, but this instrument has a comprehensive and time-
consuming clinical scoring system.  
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Introduction 
 
Cerebral palsy (CP) is defined as a clinical syndrome characterized by a 
persistent disorder of posture or movement due to a non-progressive disorder of the 
immature brain1. The most common movement disorder in CP is a spastic paresis2, 
defined as a posture and movement-dependent tone regulation disorder. The 
clinical manifestations of spastic paresis vary widely, depending on the various 
impairments of muscle function that can be distinguished. Clinical symptoms of 
impaired muscle function can either be related to an impairment of muscle 
activation, leading to both deficit (or negative) and excess (or positive) symptoms, 
or to a change in biomechanical properties of muscles and connective tissues (Table 
1)3.  
The functional abilities of the child with spastic paresis often deteriorate during 
development. It is generally postulated that spasticity, a prominent symptom in 
spastic paresis, is related to this decline. Therefore, anti-spasticity treatment5-7 
plays an important role in treating the child with CP. However, many other 
symptoms, such as muscle paresis8 (Table 1), also interfere, but remain unaffected 
by these anti-spasticity treatments. Careful assessment of which symptoms of 
impaired motor function are functionally limiting the individual patient is, 
therefore, essential in selecting the appropriate treatment. Clinical assessment to 
distinguish spasticity from other symptoms is only possible if a clear and 
unambiguous definition is given. Many different definitions have been proposed9-11.  
The most commonly used definition of spasticity is probably that of Lance: ‘a 
motor disorder characterized by a velocity dependent increase in tonic stretch 
reflexes (muscle tone) with exaggerated tendon jerks, resulting from 
hyperexcitability of the stretch reflex, as one component of the upper motor neuron 
syndrome’9. In this definition the clinical symptom of spasticity is a velocity-
dependent increase in muscle tone. Stretching a muscle at a sufficiently high 
velocity is essential to elicit a stretch reflex at a certain angle in the range of  
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Table 1: Summary of clinical symptoms of impaired muscle function in spastic 
paresis4 
Impairment of muscle activation  
Deficit symptoms (signs of reduction or loss of normal voluntary muscle activation)  
 Paresis Inadequate force  
 Loss of selective motor 
control 
Impaired ability to activate and control selective or isolated movements across 
specific joints  
 Loss of dexterity of 
movement 
Impaired ability to coordinate temporal and spatial activation of many muscles  
 Enhanced fatigability Inadequate sustained force  
Excess symptoms (signs of abnormal involuntary muscle activation)  
 Passive movement    
 Hypertonia (TSR) Non-velocity-dependent resistance to passive movement experienced by the examiner 
as increased muscle tone, caused by continuous muscle activation (Tonic Stretch 
Reflex activity) 
 Spasticity Velocity-dependent resistance to passive movement experienced by the examiner as 
increased muscle tone, caused by an increase in stretch reflex activity 
 Clonus Involuntary rhythmic muscle contraction 
 Active movement   
 Mirror movements Involuntary, simultaneous, contralateral movement of a muscle caused by voluntary 
movement of the same muscle on the ipsilateral side of the body  
 Associated abnormal 
postures 
Involuntary abnormal muscle activity related to posture or the performance of any 
task 
 Co-contraction Simultaneous involuntary contraction of the antagonist at voluntary contraction of the 
agonist  
 Abnormal reflexes   
 Hyperreflexia of tendon 
jerks 
Raised reaction to tendon tap, extension of the reflexogenic zone, spread of reflexes  
 Abnormal nociceptive 
flexion reflexes 
Abnormal pathological reflexes to painful stimuli (i.e. Babinski reflex)  
 
 Abnormal 
musculocutaneous reflexes 
Abnormal pathological reflexes to cutaneous stimuli (i.e. adductor reflex)  
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Table 1: Summary of clinical symptoms of impaired muscle function in spastic 
paresis4 – continued  
Changes in biomechanical properties of muscle and other connective tissues  
 Contractures Fixed shortening of muscle and tendon, resulting in a reduced range of motion  
 Hypertonia Non-velocity-dependent resistance to passive stretch experienced by examiner as increased muscle 
tone, caused by biomechanical changes within muscle itself  
 
motion, and the faster the stretch, the earlier and stronger the reflex component  
of the increased muscle tone will be12. Many studies have shown this stretch-
related muscle activity, validating the velocity-dependency13-15.  
To assess spasticity clinically (without the use of special devices) and to verify 
the velocity-dependency, the intensity of the muscle tone elicited at very slow and 
at rapid passive joint movement is compared and graded. However, spasticity can 
also be quantified by measuring the joint angle at which the increase in muscle 
tone is encountered in a fast stretch10,15and comparing it with the joint angle in a 
slow passive range of motion (ROM). As the severity of spasticity increases, this 
increase in muscle tone reflex is elicited earlier in the ROM16. It can lead to a 
‘catch’12,17 of the muscle, defined as the sudden appearance of increased muscle 
tone, which leads to an abrupt stop during the dynamic phase of movement in a 
joint, somewhere before the end of the ROM.  
Of significant influence on the increase in muscle tone and the joint angle of 
appearance, although ignored in Lance’s definition9, are the testing posture and 
the initial length from which the muscle is stretched14,18-20, as well as any sensory 
stimulation (e.g. laughing) during the assessment21,22. Various clinical instruments 
are used to evaluate spasticity. However, it is not known whether these 
instruments assess spasticity in accordance with the velocity-dependency defined 
by Lance. As other factors can modulate both the presence and the intensity of 
spasticity, standardization of the test protocol is required. This review focuses on 
the different instruments used to assess spasticity in children with spastic CP in 
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the clinical setting, and their report on a standardized test protocol. Questions 
addressed in this review include: which instruments for the clinical assessment of 
spasticity are used in children with CP?; Is there standardization for the 
assessment at different velocities of passive joint movement and the testing 
posture of the patient?; How is spasticity quantified?  
 
 
Method  
 
Search strategy   
A comprehensive computerized sensitive search of the electronic databases 
Medline (January 1980 to March 2004), Embase (January 1980 to March 2004), 
and Cinahl (January 1982 to March 2004) was performed by two reviewers (VS 
and AB). The search strategy included the terms ‘spasticity’, ‘cerebral palsy’, and 
‘child’. The references of retrieved articles were checked. All citations identified by 
this search were entered into a bibliographic management software programme, 
Reference Manager.  
 
Selection 
The titles and abstracts were screened by one reviewer (VS). References were 
included if: (1) they included children (younger than 18 years) with a diagnosis of 
CP; (2) a clinical assessment of spasticity was described; (3) they were published as 
a full report or an abstract; and (4) the language was English, German, French, or 
Dutch.  
 
Data extraction 
A data-extraction form was used to register: (1) patient characteristics; (2) the 
clinical spasticity instrument(s) used; (3) whether the test protocol reported on 
different velocities of testing and on the testing posture of the patient; and (4) the 
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method of quantification. Some references did not describe the test protocol of the 
spasticity assessment, but reference was made to the original (or another) 
publication concerning the applied instrument. In that case, the publication that 
was referred to was retrieved and from this, the relevant data were extracted.  
 
 
Results  
 
Included studies 
The search strategy resulted in the retrieval of 937 citations from the electronic 
databases. Screening these citations on diagnosis and assessment of spasticity 
resulted in 193 studies, and reference tracking resulted in 18 additional studies. 
Thus, 211 references were identified, 119 of which fulfilled the inclusion criteria. 
The references that were included comprised 12 review or overview articles, 103 
studies, and 4 case reports. In these 119 publications, 13 different clinical 
spasticity assessment instruments were used (Table 2), which form the basis for 
this review.  
Clinical grading scales for either spasticity or muscle tone have primarily been 
used to assess spasticity. Measurements of other excess symptoms that are related 
to spasticity (clonus and reflexes) were also reported in some of the references as 
being an ‘assessment of spasticity’. Because these are not true spasticity measures, 
but other symptoms of impaired muscle activation (see Table 1) we did not include 
them in this review.  
 
Available assessment instruments of clinical spasticity  
All of the instruments used for the clinical assessment of spasticity could be 
categorized into three main groups, according to their assessment technique and 
quantification (Table 3). The first group is referred to as the ‘Ashworth-like scales’, 
after Ashworth23, who first described the principle of muscle tone assessment by 
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scoring the resistance encountered in a specific muscle group by passively moving 
a limb at one (non-) specified velocity through its ROM on a 5-point scoring scale. 
This is the original Ashworth scale (AS)23. The AS has three modifications, all 
sharing the same principle. The first modification was made by the addition of an 
intermediate score, making it a 6-point scale: the Modified Ashworth scale-
Bohannon (MAS-B)24. A second modification combined the AS23 with the MAS-B24, 
and added grading for the severity of spasticity: the Modified Ashworth scale-
Peacock (MAS-P)25. A third modification, the New York University Tone Scale 
(NYU)26, combined the AS23 with the ROM at a fast velocity stretch.  
The second group is referred to as ‘Tardieu-like scales’, after Tardieu27, who 
described the principle of spasticity assessment by joint-angle measurement at 
different velocities of muscle stretch. Derived assessments are the Tardieu Scale 
(TS)28 with which spasticity is clinically assessed by passive movement of the joints 
at three specified velocities and the intensity and duration of the muscle reaction 
to stretch (X) is rated on a 5-point scale, with the joint-angle (Y) at which this 
muscle reaction is first felt. This method is very time consuming. Therefore it was 
simplified to the Modified Tardieu Scale (MTS)29. The MTS only defines the 
moment of the ‘catch’, seen in the ROM at a particular joint angle at a fast passive 
stretch.  
The third group, ‘Other Clinical Grading Scales’, is a combination of clinical 
spasticity assessment scales or tests that can be distinguished from the other two 
groups, either because of their assessment technique or the method of 
quantification. A description of all scales is presented in Appendix I.  
Some references reported more than one clinical spasticity grading scale. As a 
consequence, spasticity was clinically assessed 135 times in the 119 included 
references. ‘Ashworth-like scales’ were used in 83% (112/135), ‘Tardieu-like scales‘ 
in 10% (13/135), and ‘Other Clinical Grading Scales‘ in 7% (10/135) of all reports of 
grading scales. The results will be reviewed for these three groups.  
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Assessment with different standardized velocities  
Of the ‘Ashworth-like scales’, only the original publication of NYU26 described the 
assessment of each muscle performed by stretching the muscle at two velocities: 
‘slow’ and ‘fast’, without further standardization. Of all references reporting on 
using the NYU, two references30,31 confirmed this multiple velocity stretching 
protocol, whereas two others32,33 simply referred to its original publication26. In the 
other ‘Ashworth-like scales’, as well as in the ‘Other Clinical Grading Scales’, the 
assessment involves stretching the muscle at only one (non-standardized) velocity.  
Of the ‘Tardieu-like scales’, the original publication of the TS28 stated that 
muscle stretch should be performed at three specified velocities: ‘slow’, ‘under 
gravity’, and ‘fast’ (without further standardization), referred to as V1, V2, and V3 
respectively. Two references34,35 reporting on using the TS assessed the muscle 
stretch only at two velocities of stretch (V1 and V3). The MTS29 was originally 
described as a muscle assessment at only a fast passive velocity stretch (V3). 
However, one reference36 reporting on using the MTS described the assessment of 
muscle stretch at both slow and fast velocity (respectively V1 and V3).  
 
Standardized testing posture of the patient   
The original publications presenting the TS28, the MTS29, the NYU26, and the 
Duncan Ely Test (DET)39 defined a standardized posture of the patient while 
assessing muscle spasticity. They all emphasized the importance of a consistent 
position of the patient during assessment, as well as a consistent starting position 
of the tested limb with the TS and MTS. With the TS, MTS, and the NYU the 
patient should be assessed in a supine position with the head in midline, although 
the TS may also be performed sitting. For the DET, quadriceps should be assessed 
with the patient in a prone position.  
Three references29,41,42 reporting on using the MTS confirmed supine testing or 
the use of a standardized testing protocol, whereas most others referred to the 
original MTS publication29, or to the original publication reporting on the TS28, in  
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Table 2: Abbreviations and full names of instruments used for clinical 
assessment of spasticity and their original reference  
AS Ashworth Scale Ashworth (1964)23  
MAS-B Modified Ashworth Scale - Bohannon Bohannon and Smith (1987)24 
MAS-P Modified Ashworth Scale - Peacock Peacock and Staudt (1991)25  
NYU New York University Tone Scale Johann-Murphy (1990)26 
TS Tardieu Scale* Held and Pierrot-Deseilligny (1969)28 
MTS Modified Tardieu Scale† Boyd and Graham (1999)29 
SG Spasticity Grading Sindou and Jeanmonod (1989)37 
MCSP Modified Composite Spasticity Index Levin and Hui-chan (1992)38 
DET Duncan Ely Test‡ Bleck (1987)39 
 Nameless clinical grading scale Trombly (1983)40 
 Three nameless clinical grading scales No references  
*Also called ‘Held Scale’; †also called ‘Dynamic Muscle Length’, ‘Dynamic Muscle Range’, ‘Dynamic Range of 
Motion’, or ‘R1’; ‡also called ‘Ely Test’.  
 
which a sitting testing posture is also described. One of the references35 reporting 
on using the TS described assessment of the patient while supine lying; another 
only assessed the patient in a prone position (triceps surae testing)34. Four 
references reporting on using the NYU30-33 just referred to the original NYU 
publication26. All references43-45 reporting on using the DET described a prone 
position. 
A description of the standardized posture of a patient during testing was lacking 
in the original publications of the AS23, the MAS-B24, the MAS-P25, and other 
‘Other Clinical Grading Scales’. Only 12 of the references reporting on using 
‘Ashworth-like scales’ and one of the references reporting on using ‘Other Clinical 
Grading Scales’ described a specified testing posture: ‘lying supine’ was the most 
common posture during both lower and upper extremity assessment for the other 
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‘Ashworth-like scales’46-54. Three references42,55,56 in which these scales were 
reported described a ‘specified‘ protocol, but no further details.  
 
Quantification of spasticity  
The common feature of all ‘Ashworth-like scales’ is grading the intensity of the 
muscle tone at one (non-) specified velocity. Even the NYU restricts its grading to a 
combined score for ROM and muscle tone intensity only at the fast velocity, despite 
assessment at both a slow and a fast velocity stretch (Appendix I). Over half of the 
references that reported on using an ‘Ashworth-like scale’ either gave a description 
of the scoring scale or referred to the original publication, or both. However, 
inconsistencies exist in the number of scoring options (e.g. MAS-P can be used 
either as a 5-point or a 6-point scale) as well as in the score ranges. Despite these 
different applications, the original scoring scales, as presented in Appendix I, are 
most frequently used.  
Both ‘Tardieu-like scales’ grade spasticity by measuring the joint angle at a fast 
velocity stretch (V3) at which an increase in muscle tone is encountered. The TS is 
more comprehensive, because it also measures the ROM at a slow velocity stretch, 
and the joint angle at which an increase in muscle tone is encountered at a 
moderate velocity stretch. The intensity of the muscle response is also scored on a 
5-point scale at each of the three specified velocities. The joint angles measured 
during the slow and fast velocity stretches are referred to as ‘R2’ and ‘R1’ 
respectively (Appendix I). Of all the references reporting on using the TS, one34 
involved the complete original scoring, and all the others36,49 only parts of it. One 
reference36 reporting on using the MTS measured both the joint angles ‘R1’ and 
‘R2’. Two references29,126 reporting on using the MTS suggested that the ‘dynamic 
component’6,29 should be used as a clinical measure of spasticity, calculated as the 
difference between the joint angles R2 and R1. This can easily be calculated with 
the TS, but also with the MTS if passive ROM is tested.  
Apart from the DET39, in which quadriceps spasticity is graded by shown buttock 
elevation, spasticity grading with the six different ‘Other Clinical Rating Scales’ 
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Table 3: Instruments used for the clinical assessment of spasticity……………. 
Group and instrument  Publication referred to Different 
velocities 
specified? 
Posture specified? 
     
Ashworth-like scales          
Ashworth scale  (35) 5,43,46,57-88 Ashworth (1964) (22) 
other (40) 
none (9) 
N 
Y 
(35) 
(0) 
N  
Y  
 
(34) 
(1) 
Modified  
Ashworth scale/  
Bohannon scale 
(60) 6,29,36,41,42,47-
50,55,56,71,89-125 126-136 
Bohannon (1987) (48) 
other   (1)  
none (11) 
 
 
 
N 
Y 
(60) 
(0) 
N 
Y 
(54) 
(6) 
Modified  
Ashworth scale/  
Peacock Scale 
(11) 25,51-54,137-142 Peacock (1987, 1991) (5) 
Bohannon (1987) (5) 
none  (1) 
 
 
 
N 
Y 
(11) 
(0) 
N 
Y 
(7) 
(4) 
Modification of 
Ashworth: NYU 
Tone scale 
(6) 30-33,127,143 Johann-Murphy (1990) (4) 
Arens and Peacock (1989) (1) 
Ashworth (1964) (1) 
 
 
N 
Y 
(2) 
(2+2‡) 
N 
Y 
(2) 
(4‡) 
* Number of references that specified scoring scale and/or grading scale, but did not define a corresponding 
response definition. 
† Number of references specified a scoring scale and/or grading scale with the corresponding response 
definition. 
‡ Not described in the reference, but reference is made to the original (or another) publication.  
N, no; Y, yes; S, scoring scale and/or grading; S + D, scoring scale an/or grading and response definition; V, 
velocity of stretch; X, muscle reaction to stretch; Y**, joint angle; R1, joint angle at fast velocity passive stretch; 
R2, joint angle at slow velocity passive stretch; n.e., not extracted. Numbers in brackets are number of 
references. 
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…………….. in children with cerebral palsy 
                                           Quantification of spasticity specified? 
 
 
 Specified? Scoring Scale  
                                            (Ashworth-like scales - continued)      
                                           N  
                                           Y:S* 
                                           Y: S+D† 
(8) 
(0)  
(27) 
 
1,2,3,4,5  
0,1,2,3,4 
 
(9 + 9‡) 
(9)  
                                           N  
                                           Y:S* 
 
 
 
                                           Y: S+D† 
(8) 
(5) 
 
 
 
(47) 
0-4  
0-5 
0,1,2,3,4,5 
0,1,1+,2,3,4,5 
0,1,1+,2,3,4 
0,1,2,3,4,5 
(1) 
(2) 
(1) 
(1) 
(10+36§) 
(1)  
                                           N  
                                           Y:S* 
 
                                           Y: S+D† 
(0) 
(2) 
 
(1) 
(8) 
 
0,1,2,3,4,5 
0-5 
0,1,2,3,4 
0,1,2,3,4,5 
-1,0,1,2,3,4 
 
(1) 
(1) 
(1) 
(5+2‡) 
                                           N  
                                           Y:S* 
                                           Y: S+D† 
(1) 
(0) 
(4) 
 
(1) 
 
 
-1,0,1,2,3 
1,2,3,4,5 
0,1,2,3 
 
 
(3) 
(1) 
(1) 
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Table 3: Instruments used for the clinical assessment of spasticity……………. 
Group and instrument  Publication referred to Different 
velocities 
specified? 
Posture specified? 
     
Tardieu-like scales       
Tardieu scale (3) 34,36,49 Tardieu (1954, 1983) (2) 
none  (1) 
 
 
N 
Y 
(0) 
(3) 
N 
Y 
(1) 
(2) 
       
Modified Tardieu scale (10) 
6,29,36,41,42,47,71,90,99,126 
Boyd   (1999) (6) 
Tardieu (1954) (2) 
Held (1969) (2) 
 
N 
Y 
(9) 
(1) 
N 
Y 
(1) 
(2) 
Other clinical grading scales       
Spasticity Grading (2) 144,145   none  (2) N 
Y 
(2) 
(0) 
N 
Y 
(2) 
(0) 
Modified Composite 
Spasticity Index 
(1) 146  
 
none  (1) N 
Y 
(1) 
(0) 
N 
Y 
(0) 
(1) 
Duncan Ely test (3) 43-45 Bleck  (1987) (2) 
Gage (1992) (1) 
N 
Y 
(3) 
(0) 
N 
Y 
(0) 
(3) 
Nameless (4) 35,104,147,148 none  (4) N 
Y 
(4) 
(0) 
N 
Y 
(4) 
(0) 
* Number of references that specified scoring scale and/or grading scale, but did not define a corresponding 
response definition. 
† Number of references specified a scoring scale and/or grading scale with the corresponding response 
definition. 
 ‡ Not described in the reference, but reference is made to the original (or another) publication.  
N, no; Y, yes; S, scoring scale and/or grading; S + D, scoring scale an/or grading and response definition; V, 
velocity of stretch; X, muscle reaction to stretch; Y**, joint angle; R1, joint angle at fast velocity passive stretch; 
R2, joint angle at slow velocity passive stretch; n.e., not extracted. Numbers in brackets are number of 
references. 
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…………….. in children with cerebral palsy - continued 
                                            Quantification of spasticity specified? 
 
 
 Specified? Scoring Scale  
                                           (Tardieu-like scales - continued)   
                                           N  
                                           Y:S* 
                                           Y: S+D† 
(0) 
(0) 
(3) 
 
 
X at V?  
X and Y** at V? 
 
 
(1) 
(1) 
 X and Y** at V1,V2,V3 (1) 
                                           N  
                                           Y:S* 
                                           Y: S+D† 
(1) 
(0) 
(9) 
 
 
R1 
R1 and R2 
 
 
(3+5‡) 
(1) 
                                           (Other clinical grading scales - continued)   
                                           n.e. 
 
   
                                           n.e. 
 
   
                                           n.e. 
 
   
                                           n.e. 
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varies from grading muscle tone35, or grading the joint angle in the ROM at which 
an increase in muscle tone is experienced40, to a more complex combination of 
these or other different parameters38,144,147,148 (Appendix I). Because each of these 
‘Other Clinical Rating Scales’ was used only once or twice, we did not extract these 
data.  
 
 
Discussion 
 
In 119 references, 13 different instruments were used for the clinical assessment 
of spasticity in children with CP. This review shows that most of these instruments 
do not comply with the concept of spasticity as defined by Lance: they mostly grade 
muscle tone intensity only at one (often non-specified) velocity of passive stretch. 
The references in which these instruments were used seldom standardized the 
testing posture of the patient. For the quantification of spasticity, most 
instruments grade the intensity of the muscle tone and ROM. However, the scoring 
systems of most instruments are ambiguous because different grading and score 
ranges have been used.  
Comparison of research data on the treatment of spasticity is only possible if the 
exact scoring system has been defined. Only the TS measures the velocity-
dependent increase in muscle tone and compares the intensity and the angle of 
appearance of the increased muscle tone at three different movement velocities. 
Although the original publication of the NYU reports on the assessment of the 
muscle at slow and fast velocity stretches, the NYU grading does not comply with 
the concept of spasticity as its grading is restricted to the fast velocity stretch. The 
TS describes a very comprehensive method to assess patients, but it seems to be 
very time consuming. Its feasibility is, therefore, questioned, especially for use 
with children. This might explain the great variation in test protocols for the 
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clinical application of this scale in the included references. Simplification of the 
test protocol is, therefore, desirable.  
Although the TS takes the speed of the muscle stretch into account, no 
standardization of the three different velocities is described in the original 
publication28. Both the joint angle and the intensity of the muscle response are 
velocity dependent. Recently, Mackey et al.149measured the angular velocities with 
which the passive stretching of the elbow muscle is performed for assessment with 
the TS. The results showed great variances in the three angular velocities. To 
achieve a reliable assessment, it is, therefore, necessary to follow a standardized 
protocol.  
With the TS the intensity of the muscle tone is scored on a 5-point scale 
(Appendix 1), in which clonus is set to be the highest level of spasticity. However, 
as shown in Table 1, clonus is another excess symptom that is related to 
spasticity150, but not specific for the presence of spasticity. It also differs from 
spasticity in the muscles in which it can be evoked: clonus can only be evoked in 
specific muscles, whereas increased muscle tone can be evoked in all muscles.  
The TS compares the angle of appearance of the increased muscle tone at three 
different movement velocities. A measure derived from the TS, used in the 
literature126 as a clinical measure of spasticity, is the ‘dynamic component’6. This 
can be calculated as the difference between the joint angle of the passive range of 
joint movement at a very slow passive stretch (R2) and the joint angle of the catch 
at a fast velocity stretch (R1). However, the calculated difference adds together the 
variances of both joint angles, resulting in very wide inter-sessional variations, as 
has been demonstrated in a recent study151. Therefore, to evaluate the treatment of 
spasticity, it is probably better to compare the maximal ROM at a very slow 
passive stretch before and after treatment and the joint angle of the catch at a fast 
velocity passive stretch before and after treatment.  
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Conclusion  
 
According to the definition of spasticity, i.e. a velocity-dependent increase in 
muscle tone, the instruments that are most frequently used for the clinical 
assessment of spasticity in children with CP (the ‘Ashworth-like scales’) do not 
comply with the concept of spasticity. Only the original Tardieu Scale is a suitable 
instrument to measure spasticity. However, the original test protocol seems very 
time consuming, and lacks standardization of the muscle stretch velocities. 
Moreover, the rating of the intensity of the muscle response is not an exclusive 
measure of spasticity because it also includes clonus. Further research is needed to 
develop a clinical spasticity assessment instrument that complies with the concept 
of spasticity, with a detailed description of specific velocities of passive stretch, 
positioning of the patient, and grading of spasticity.  
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Appendix I: Clinical spasticity grading scales  
 
1. ASHWORTH-LIKE SCALES  
 
Original Ashworth Scale for grading spasticity23  
Grades the resistance encountered in a specific muscle group by means of passively 
moving a limb through its range of motion at a non-specified velocity.  
Score Description  
0 No increase in muscle tone  
1 Slight increase in muscle tone giving a catch and release when the limb was moved in flexion or 
extension 
2 More marked increase in muscle tone, but limb moves easily  
3 Considerable increase in tone, passive movement difficult  
4 Limb rigid in flexion or extension  
 
Modified Ashworth Scale - Bohannon scale for grading spasticity24  
Grades the resistance encountered in a specific muscle group by means of passively 
moving a limb through its range of motion at a non-specified velocity.  
Score Description  
0 No increase in muscle tone  
1 Slight increase in muscle tone, manifested by a catch and release, or by minimal resistance at the end of 
the ROM when the affected part(s) is (are) moved in flexion or extension  
1+ Slight increase in muscle tone, manifested by a catch, followed by a minimal resistance throughout the 
remainder (less than half) of the ROM  
2 More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved  
3 Considerable increase in muscle tone, passive movement difficult  
4 Affected part(s) rigid in flexion or extension  
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Appendix I: Clinical spasticity grading scales - continued 
 
Modified Ashworth Scale - Peacock scale for grading spasticity25  
Grades the resistance encountered in a specific muscle group by means of passively 
moving a limb through its range of motion at a non-specified velocity.  
Score Grade Description  
0 Hypotonic Less than normal muscle tone, floppy  
1 Normal No increase in muscle tone  
2 Mild Slight increase in muscle tone, ‘catch’ in limb movement or minimal resistance to 
movement through less than half of the range  
3 Moderate Marked increase in muscle tone through most of the range of motion but the passive 
movement of the affected part is easily performed  
4 Severe Considerable increase in muscle tone, passive movement difficult  
5 Extreme Affected part rigid in flexion or extension  
 
NYU Tone Scale26 
Muscle tone is graded by a combination of the resistance encountered in a specific 
muscle group to a rapid passive stretch, limitation of range of movement and 
function.  
Score Grade Description  
-1 Hypotonic Floppy, less than normal tone  
0 Normal Appropriate resistance to passive movement  
1 Mildly 
increased 
Minimal resistance to passive movement noted, but does not impair range or function 
2 Moderately 
increased  
Moderate resistance to passive movement noted, full range can be achieved but  
function is hampered by tone  
3 Severely 
increased 
Severe resistance to passive movement noted, full range cannot be reached  
or is difficult to reach, function is severely hampered 
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Appendix I: Clinical spasticity grading scales - continued 
 
2. TARDIEU-LIKE SCALES  
 
Tardieu Scale or Held Scale28  
Spasticity is clinically assessed by passively moving the joint at three specified 
velocities (V) and rating the intensity and duration of the muscle reaction to 
stretch (X) and the joint angle (Y) where this muscle reaction is first felt.  
Score Description  
Intensity and duration of reflex (X)  
0 No reflex  
1 Only visible contraction  
2 Contraction with a short catch  
3 Contraction lasting a few seconds or fatigable clonus after a few seconds  
4 Contraction lasting a few seconds OR infatigable clonus, not even after a few seconds  
Velocity of stretch (V)  
1 Slow  
2 Under gravity  
3 Rapid 
Angle in ROM (Y) Joint angle in degrees at which X was assessed at V  
 
Modified Tardieu Scale29  
Defines the moment of the ‘catch’ (e.g. Tardieu X=3 or X=4) in the range of motion 
(R1) at a fast passive stretch (Tardieu V3).  
R1 Joint angle at a fast stretch (Tardieu V3)  
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Appendix I: Clinical spasticity grading scales - continued 
 
3. OTHER CLINICAL GRADING SCALES  
 
Duncan Ely test39  
Grades buttock elevation in response to rapid passive flexion of the knee while the 
patient is in prone position.  
+ Buttock elevation 
- No buttock elevation  
 
Spasticity Grading (modified from Sindou and Jeanmonod37 by Lazareff et al.144)  
Four parameters are taken into account to evaluate the degree of muscle tone: (1) 
the degree to which abnormal posture can be reduced by passive mobilization; (2) 
passive range of motion of the joint; (3) muscle resistance in response to a non-
specified velocity stretch; and (4) the disability experienced by the patient.  
Score Grade Description  
0 Absent  
1 Mild No abnormal posture  
Normal passive movement  
No disability  
2 Moderate Abnormal posture, completely reduced by passive mobilization  
Full range of joint movement  
Higher muscular tone than in mild grade  
Moderate disability  
3 Marked Abnormal posture, incomplete reduced by passive mobilization  
Limited range of joint movement  
High resistance to muscle stretching  
Marked disability  
4 Severe Abnormal posture slightly reduced by passive mobilization  
Severe disability  
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Appendix I: Clinical spasticity grading scales - continued 
 
Modified Composite Spasticity Index (modified from Levin and Hui-chan38 by Jobin 
and Levin146)  
Evaluates ankle spasticity by grading the Achilles tendon jerk response and 
grading the resistance encountered in the ankle muscle by means of passively 
moving the ankle to dorsiflexion at a moderate speed. Both are added in a Modified 
Composite Spasticity Index.  
Score Grade Description  
Achilles tendon jerks  
0  No response  
1  - No description - 
2  - No description - 
3  - No description - 
4  Maximally hyperactive response  
Modified Ashworth Scale  
0  No response  
2  - No description - 
4  - No description - 
6  - No description - 
8  Maximally increased resistance  
Modified Composite Spasticity Index = Score Achilles tendon jerks + Score Modified Ashworth Scale (double weighted) 
0-4 Mild spasticity   
5-9 Moderate spasticity   
10-12 Severe spasticity   
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Appendix I: Clinical spasticity grading scales - continued 
 
Nameless40  
Grades spasticity on the basis of the range of resistance-free moment.  
Grade Description: muscle can be lengthened quickly through most of its range of 
motion… 
Mild spasticity  ... with the stretch reflex occurring in the last quarter of the range  
Moderate spasticity ...stretch occurs in mid-range  
Severe spasticity …stretch occurs in initial one quarter of the range 
 
Nameless148  
Grades elbow spasticity based on the amount of resistance and ease of joint 
movement at a non-specified velocity.  
Grade Description 
Mild  Mild resistance or a catch is felt during a rapid passive extension of the elbow; the movement could be 
accomplished easily; cases with involuntary elbow flexion on activity are also included in this grade 
Moderate  Moderate resistance is felt and the movement could be accomplished only with some difficulty  
Severe  Severe resistance is felt and the movement was either accomplished with great difficulty and pain or 
could be performed only partly  
 
Nameless35  
Grades the resistance encountered in a specific muscle group by means of passively 
moving a limb through its range of motion at a fast velocity.  
Score Description  
0 Mobilization without difficulty in the whole range of motion  
1 Stop, then free mobilization; slight elastic contraction of the muscle  
2 Stop, then mobilization against moderate resistance; moderate elastic contraction of the muscle 
3 Stop, then mobilization against severe resistance or strong elastic contraction of the muscle 
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Appendix I: Clinical spasticity grading scales - continued 
 
Nameless147  
Assesses whether spasticity is increased at rest or normal at rest but built up on 
activity.  
Grade Description 
Low  -No description- 
Normal  -No description- 
High  -No description- 
Very high  -No description- 
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Chapter 3 
 
Abstract 
 
Literature has shown the need for a new clinical spasticity instrument in 
children with cerebral palsy (CP). We adapted the Tardieu Scale to create the 
Spasticity Test (SPAT). First, the muscle is passively stretched with a slow velocity 
(≥ 3 seconds) to measure the maximum range of motion (ROM). Then, spasticity is 
assessed during a passive stretch with fast velocity (< 1 second) to measure the 
joint angle of the catch (AOC) and to grade the intensity of the muscle resistance. 
This study describes the feasibility and reliability of the SPAT in five leg muscles. 
Twenty children with CP (mean age 10 years 0 months, SD 2 years 8 months) were 
assessed by two examiners on three occasions using a repeated measures design, 
collecting all data on the same day. Intra-rater reliability was good for the 
hamstrings, soleus and gastrocnemius muscles, and when the spasticity scale was 
simplified, also for the adductor muscle, but not for the rectus femoris muscle. 
Inter-rater reliability was only good for the gastrocnemius muscle. When applied 
by one examiner, the SPAT was feasible and reliable for all of the investigated leg 
muscles, except for the rectus femoris muscle.  
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Introduction 
 
Spasticity is the phenomenon of a velocity-dependent increase in muscle tone in 
response to passive stretch1, encountered as resistance somewhere in the range of 
motion (ROM)2. When the angular velocity of the stretch increases, the intensity 
becomes stronger and appears sooner in the ROM3. This is studied by stretching 
the muscle with two different velocities, e.g. slow and fast4. It is especially 
important to test spasticity with a fast passive stretch. This makes it possible to 
detect the dominant phenomenon of spasticity: the 'catch', a sudden appearance of 
increased resistance in response to a fast passive stretch at a certain angle before 
the end ROM, which stops the movement immediately3,5. The angle at which the 
catch is first felt can be measured. Consequently, any measurement to assess 
spasticity should quantify the intensity of the encountered resistance and measure 
the angle of the catch (AOC) while passively stretching the muscle with at least a 
fast angular velocity. 
Spasticity is routinely assessed in children with cerebral palsy (CP) by means of 
clinical scales6, of which the Ashworth Scale (AS)7 and the Modified Ashworth 
Scale (MAS)8 are most frequently used4. However, these scales rate spasticity 
using an undefined velocity of stretch4. Moreover, both have been criticised to be 
invalid measures op spasticity9.  
The only clinical scales that measure spasticity with a fast angular velocity are 
the less frequently used Held Scale (HS)10 (better known as the Tardieu Scale [TS]) 
and the Modified Tardieu Scale (MTS)11.  
The TS assesses a muscle at three different velocities of passive stretch (e.g. 
slow, under gravity and fast), and measures the joint angles with goniometry and 
grades the intensity of the stretch reflex on a 5-point scale (Appendix I) at each 
velocity. However, although the TS measures spasticity with a fast velocity stretch, 
there are some limitations to its use. First, the intensity of the stretch reflex scale 
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implies that a clonus (a score of 3 or 4) is the most severe form of spasticity. 
However, clonus is a different symptom of the Upper Motor Neuron System4 and 
should be graded separately. Secondly, the TS has some practical disadvantages, 
such as the lack of standardisation of stretch velocities and joint starting positions 
and a  time-consuming testing protocol4.  
The MTS only uses the fast velocity stretch from the TS to record the AOC. 
However, according to its definition, the catch must be experienced somewhere 
before the end ROM. A prerequisite for its assessment should therefore be that 
ROM is included in the test, which is not so in the MTS. Moreover, the MTS does 
not measure the intensity of the encountered muscle resistance.   
In conclusion, there is a need for a new clinical spasticity scale which assesses 
the muscle at both slow and fast velocity stretch. This scale should be well 
standardised, unambiguous and not time-consuming. We simplified the TS to 
create the Spasticity Test (SPAT), and the purpose of this paper is to describe the 
feasibility and reliability of the SPAT in the clinical assessment of spasticity in 
children with CP.  
 
 
Methods 
 
Participants 
Included in the study were children, between 6 and 17 years of age, with a 
diagnosis of spastic CP. Exclusion criteria are presented in Table 1.  
Children were recruited from a special school for children with physical 
disabilities in the Netherlands. The Medical Ethics Committee of the VU 
University Medical Center approved the study. Full written informed consent was 
obtained from all parents and all children aged 12 years and older.  
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Table 1: Exclusion criteria 
Casting or botulinum toxin A injections within the previous 4 months;  
Orthopaedic surgery within the previous 12 months;  
Previous Selective Dorsal Rhizotomy or intrathecal baclofen treatment; 
Maximum passive ankle dorsiflexion (knee extended) of 15° plantarflexion; 
Maximum passive hip extension in prone position of 15° flexion; 
Disturbed behaviour that would make it difficult for the child to understand the tests or to cooperate during the study; 
Inability to relax during the measurements. 
 
Procedure 
The children were tested at school. According to the location of the motor 
disorder, the affected (unilateral), the most affected (asymmetric diplegia) or the 
right leg (symmetric diplegia) was tested. 
Data was collected during three trials, on the same day, by two examiners. Five 
leg muscles were assessed in each trial (presented in the order of testing): (medial) 
hamstrings, short adductors, soleus, gastrocnemius and rectus femoris muscles. 
Each muscle was tested in a standardised position (Appendix II). 
 
The Spasticity Test (SPAT) 
Spasticity is elicited by stretching the muscle at a high angular velocity (< 1 
second) and graded by the intensity of the muscle resistance and, when 
appropriate, the joint angle of the catch. Intensity is graded on a 4-point spasticity 
scale (0 = normal or increased muscle resistance over the whole ROM; 1 = increase 
in muscle resistance somewhere in the ROM without a catch; 2 = catch and release; 
3 = clear catch, blocking further movement). If the intensity score is 2 or 3, the 
joint angle of the catch (e.g. score 2: the limb is placed back in the position where 
the catch first appeared) is recorded with goniometry, and referred to as the Angle 
of Catch (AOC). If the score is 0 or 1, no AOC can be measured.   
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Prior to fast stretching the muscle is stretched with very slow velocity stretch (≥ 
3 seconds) to record the maximum ROM of each muscle with goniometry. A 
detailed protocol for the SPAT is presented in Appendix III.  
 
Examiners 
One examiner (a researcher, experienced in SPAT assessment) tested each 
patient twice in two subsequent trials. A second examiner (an experienced 
paediatric physical therapist, but inexperienced in SPAT assessment) tested each 
patient once in a third trial. The second examiner studied the written protocol with 
standardised guidelines beforehand, and one week prior to the study both 
examiners assessed three children in a practice session. Joint angle measurement 
(Appendix II) was always performed by an extra observer, trained in goniometry.  
Prior to each trial, the child watched a cartoon video for a minimum period of 15 
minutes while lying quietly on the research bench in order to enhance relaxation of 
the child.  
The examiners recorded the spasticity scores and the observer recorded the ROM 
and AOC values on separate scoring sheets, without discussion of results. Between 
the first and second trial, the child had a 1-hour break in his/her classroom. 
Between the second and third trial, the child had a 15-min break in the testing 
room.  
 
 
Statistical analysis 
 
All analysis were performed in SPSS (11.0) for Windows. Intra-rater reliability 
was assessed using the first two trials, and inter-rater reliability was assessed 
using the second and third trial.  
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The absolute agreement (AA) was calculated for the spasticity scale. For this 
study, an AA of 70% or higher was considered to be acceptable. The reliability of 
the ROM and AOC measurements was assessed by calculating the Intraclass 
Correlation Coefficient (ICC) (< 0.40 = poor; 0.40 - 0.59 = fair; 0.60 - 0.74 good; 0.75 
- 1.00 = excellent12) and the Standard Error of Measurement (SEM), expressed in 
degrees. From this, the smallest detectable difference (SDD) was calculated (1.96 * 
SEM * √ 2)13. The SDD is of meaningful interpretive value during the evaluation of 
therapeutic interventions: the change in an outcome has to be equal to or greater 
than de SDD to confirm statistically (p < 0.05) that the effect of an intervention is 
detectable in an individual patient.  
 
 
Results 
 
Ten boys and 10 girls were included in this study. The SPAT was mostly 
assessed in the right leg (n=14). Additional patient characteristics are presented in 
Table 2.   
 
Table 2: Patient characteristics 
SD = standard deviation; uni = unilateral; bi = bilateral; y = years; m = months; cm = centimeters; kg = kilogram 
Variable Number Mean   SD Range 
Location motor disorder (uni:bi) 12 : 8     
GMFCS level (I:II:III:IV) 14 : 3 : 0 : 3    
Age (y:m)   10:0   2:8 4:7 - 14:3  
Height (cm)    139  19 108 - 175 
Weight (kg)  35.2  13.8 15.0 - 59.0 
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Feasibility  
The SPAT takes approximately five to eight minutes to perform per limb. At the 
start of the first trial, six children (30%) said that they felt a little tense, so they 
were given additional explanation to make them feel at ease and help them to 
relax. This was successful, and when the third trial started, all the children felt 
comfortable and were relaxed.  
The SPAT was safely used in all children. Two children experienced a slight 
(unidentified) pain during specific joint testing (one in the ankle during hamstring 
testing, and the other one in the thigh during rectus femoris testing), but this did 
not effect the performance of the test. Another child experienced considerable 
(unidentified) pain in the knee while lying prone, and therefore the rectus femoris 
of this child was not tested.  
 
Reliability 
Table 3 presents the 4x4 contingency tables for the spasticity scale within the 
first and between the two examiner(s). The results show that the hamstrings, the 
adductors and especially the calf muscles, are most likely to be affected by 
spasticity, because the majority of these (80%-100%) had scores of 1, 2 and 3. 
Overall, grade 3 was most frequently rated (61.9% of all measurements).  
The means, standard deviations and ranges for all goniometric measurements 
(AOC and ROM), as well as the normal average ROMs14 for all muscles tested, are 
summarised in Table 4.  
Table 5 presents the intra-rater and inter-rater reliability obtained in this study, 
summarising the AA for the spasticity scale scores, and the ICC, SEM and SDD 
values for goniometric ROM and AOC testing. 
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Table 3: Frequency of intra-rater and inter-rater scores on the spasticity scale 
for the five muscle groups tested 
Intra-rater Examiner 1 (trial 1) 
  HS ADD RF SOL GC 
Spasticity scale 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 
E1 Grade 0 2 0 0 0 2 0 0 0 0 0 5 0 4 1 10 0 0 0 2 2 0 0 0 0 0 
(t2) Grade 1 0 0 0 1 1 2 0 0 2 4 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
 Grade 2 0 0 0 1 1 1 0 4 2 7 0 0 4 3 7 0 0 0 1 1 0 0 0 0 0 
 Grade 3 2 0 1 13 16 0 0 1 8 9 1 0 0 0 1 2 0 1 14 17 0 0 1 19 20 
 T 4 0 1 15 20 3 0 5 12 20 7 0 8 4 19 2 0 1 17 20 0 0 1 19 20 
Inter-rater Examiner 2 (trial 1) 
  HS ADD RF SOL GC 
Spasticity scale 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 0 1 2 3 T 
E1 Grade 0 1 0 0 1 2 0 0 0 0 0 6 1 3 0 10 0 1 0 1 2 0 0 0 0 0 
(t2) Grade 1 0 0 0 1 1 2 0 2 0 4 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 
 Grade 2 1 0 0 0 1 0 1 4 2 7 1 0 0 6 7 0 0 1 0 1 0 0 0 0 0 
 Grade 3 2 2 2 10 16 1 1 0 7 9 1 0 0 0 1 2 0 4 11 17 1 0 6 13 20 
 T 4 2 2 12 20 3 2 6 9 20 8 1 4 6 19 2 1 5 12 20 1 0 6 13 20 
HS = (medial) hamstring muscles; ADD = adductor muscle; RF = rectus femoris muscle; SOL = soleus muscle; GC 
= gastrocnemius muscle; E1= examiner 1; t2 = trial 2; T= total. Clarification to Table 3: In the first trial, 
examiner 1 rated 4 out of 20 measured hamstrings as grade 0, 0 as grade 1, 1 as grade 2 and 15 as grade 3. In 
the second trial, the same examiner rated 2 out of 20 measured hamstrings as grade 0, 1 as grade 1, 1 as 
grade 2 and 16 as grade 3. The absolute agreement (presented in Table 4) within both trials was (2+13)/20 = 
75% 
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Table 4: Normal average range of motion (ROM)14 and goniometric 
measurements (in degrees) of maximum ROM and angle of catch (AOC) for the 
five muscle groups tested 
    ROM      AOC   
   Examiner 1  Examiner 2   Examiner 1    Examiner 2 
   trial 1 trial 2 trial 1   trial 1  trial 2  trial 1 
Muscle 
tested 
n normal 
average 
ROM 
mean  
(SD) 
range 
mean  
(SD) 
range 
mean  
(SD) 
range 
 n* mean 
(SD) 
range 
n mean 
(SD) 
range 
n mean  
(SD) 
range 
HS 20 140 - 20† 63.8 
(12.0) 
33 - 85 
61.0 
(10.7) 
32 - 76 
55.9 
(13.6) 
38 - 84 
 17 86.8 
(13.1) 
65 - 116 
16 81.4 
(11.2) 
66 - 85 
15 73.07 
(15.8) 
49 - 96 
ADD 20 0 - 60‡ 59.55 
(11.5) 
40 - 80 
58.4 
(11.7) 
35 - 80 
58.6 
(11.5) 
35 - 75 
 16 32.8 
(12.4) 
15 - 52 
17 36.4 
(13.5) 
15 - 57 
14 33.2 
(10.2) 
20 - 52 
RF 19 135 – 0† 143.0 
(18.5) 
85 - 165 
140.2 
(20.9) 
81 - 162 
140.3 
(21.6) 
90 - 163 
 12 87.8 
(27.2) 
52 - 127 
8 96.1 
(27.9) 
66 - 146 
10 78.6 
(22.6) 
14 - 113 
SOL 20 (-50) - 20§ 17.5 
(9.9) 
0 - 5 
17.2 
(10.1) 
-4 - 38 
9.9  
(6.0) 
1 - 23 
 18 -5.2 
(9.70) 
-26 - 10 
18 -6.8 
(8.4) 
-20 - 12 
17 -5.0  
(7.0) 
-21 - 6 
GC 20 (-50) - 20§ 8.4  
(7.7) 
-4 - 30 
8.1  
(9.0) 
-6 - 29 
6.2  
(6.6) 
-4 - 20 
 20 -10.9 
(8.5) 
-29 - 3 
20 -9.3 
(8.1) 
-30 - 0 
19 -8.9  
(6.5) 
-25 - -1 
HS = (medial) hamstring muscles; ADD = adductor muscle; RF = rectus femoris muscle; SOL = soleus muscle; GC 
= gastrocnemius muscle. *number of muscle-measurements in which a catch was registered; †flexion-extension; 
‡neutral-abduction; §plantarflexion-dorsalflexion 
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Intra-rater reliability: ROM  
The intra-rater reliability of ROM testing was shown to be excellent (ICC range 
0.80 - 0.94) (Table 5), which is also reflected in a reasonably small amount of error 
(SEM values approximately 3° to 5°). All calculated SDDs were within an 
acceptable range, i.e. from 7.9° for the adductor and the gastrocnemius to 15.2° for 
the rectus femoris muscle.  
 
Intra-rater reliability: spasticity scale 
The results indicate an acceptable intra-rater agreement for the spasticity 
grading of the hamstrings, soleus and gastrocnemius muscles (70% - 95%), but poor 
for the adductor (60%) and rectus femoris muscles (47%). To observe whether one 
can distinguish the presence of a catch from the absence of a catch, we also 
converted the spasticity scale to a simplified 2-point spasticity scale, presented in 
Table 6. On this simplified spasticity scale, agreement increased, and was 
acceptable for all muscles, except for the rectus femoris muscle (100% for 
gastrocnemius, 85% for hamstrings and adductor, 80% for soleus and 68% for 
rectus femoris muscles).  
 
Intra-rater reliability: AOC  
The intra-rater reliability of AOC testing was shown to be good to excellent for 
the hamstrings, adductor and gastrocnemius muscles (ICC range 0.67 - 0.78), and 
fair for the soleus and rectus femoris muscles (ICC 0.54 and 0.42, respectively). 
The amount of error was smallest for gastrocnemius testing (SEM 4.8°), and 
greatest for rectus femoris testing (SEM 18.6°). The resulting SDD calculations 
were acceptable for the gastrocnemius (13.2°), and for hamstrings, adductor and 
soleus muscles (range 16.2° - 19.9°). The SDD of the rectus femoris exceeded 50°, 
which seems poor. 
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Table 5: Intra-rater and inter-rater reliability for the range of motion (ROM), the 
spasticity scale, and angle of catch (AOC) measurements for the five muscle 
groups tested 
 Intra-rater reliability  Inter-rater reliability 
    ROM        ROM  
Muscles tested   n ICC  SEM(°) SDD(°)    n ICC  SEM(°) SDD(°) 
HS   20 0.80 5.1  14.1      20 0.44  9.5  26.2  
ADD    20 0.94 2.9 7.9    20 0.86 4.4 12.1 
RF   19 0.92 5.5 15.2    19 0.81 9.2 25.5 
SOL    20 0.90 3.1 8.6    20 0.46 7.1 19.8 
GC    20 0.88 2.9 7.9    20 0.74 4.0 11.2 
 Spasticity  Scale  AOC  Spasticity  Scale    AOC  
              
 n AA  n ICC SEM(°) SDD(°)  n AA  n ICC SEM(°) SDD(°) 
HS 20 75%  15 0.69 5.8 19.9  20 55%  13 0.64 6.9 19.2 
ADD  20 60%  15 0.78 7.2 16.2  20 55%  12 0.53 9.7 27.0 
RF 19 47%  6 0.41 18.6 51.4  19 32%  6 -0.48 20.9 57.9 
SOL  20 70%  16 0.54 6.4 17.8  20 60%  16 0.74 4.1 11.4 
GC  20 95%  20 0.67 4.8 13.2  20 65%  19 0.77 3.6 9.9 
HS = (medial) hamstring muscles; ADD = adductor muscle; RF = rectus femoris muscle; SOL = soleus muscle; GC 
= gastrocnemius muscle; ICC = intraclass orrelation coefficient; SEM = standard error of measurement; SDD = 
smallest detectable difference; AA = absolute agreement  
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Table 6: The Spasticity Scale and the Simplified Spasticity Scale 
Spasticity Scale Simplified Spasticity Scale 
0 = normal or increased muscle resistance over the whole range of motion (ROM) 
1 = increase in muscle resistance somewhere in the ROM without a catch   
 
0 = no catch 
2 = catch and release 
3 = clear catch, blocking further movement 
 
1 = catch 
 
Inter-rater reliability: ROM 
The inter-rater reliability of the ROM testing was shown to be good to excellent 
for the adductors, rectus femoris and gastrocnemius (ICC range 0.74 - 0.86) and 
fair for the hamstrings and soleus muscles (ICC 0.44 and 0.46, respectively). The 
amount of error was greatest in the hamstrings and rectus femoris (despite its high 
ICC) (i.e. SEM values > 9°), and smallest for the adductor and gastrocnemius 
muscles (i.e. SEM values < 5°). The calculated SDD for the adductor and 
gastrocnemius are acceptable (12.1° and 11.2°, respectively), but seemed to be 
inadequate for the hamstrings, rectus femoris and soleus muscles (range 19.8° - 
26.2°).   
 
Inter-rater reliability: spasticity scale 
The results indicate poor inter-rater agreement (range 32% - 65%) for all 
muscles. However, if the spasticity grading is simplified (Table 6), agreement 
increases for all muscles, but only becomes good for the adductor, soleus and 
gastrocnemius muscles (i.e. 65% for hamstrings, 68% for rectus femoris, 75% for 
adductor, 85% for soleus, and 95% for gastrocnemius muscles). 
 
Inter-rater reliability: AOC 
The inter-rater reliability of AOC testing was shown to be good to excellent for 
the hamstrings, soleus and gastrocnemius muscles (ICC range 0.64 - 0.77), fair for 
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the adductor muscle (ICC 0.53), but very poorfor the rectus femoris (ICC -0.48). 
The amount of error was smallest for the gastrocnemius and soleus (SEM 3.6° and 
4.1°, respectively), and greatest for the rectus femoris (SEM 20.9°). The SDDs 
seems to be acceptable of the hamstrings, gastrocnemius and soleus (e.g. all below 
20°), but seem to be inadequate for the adductor and rectus femoris muscles (27° 
and 57.9°, respectively).  
 
 
Discussion and Conclusion 
 
We developed a new clinical instrument to assess spasticity in the lower limb 
muscles of children with CP: the Spasticity Test (SPAT). We investigated the 
feasibility and reliability of the SPAT in order to determine its usefulness in the 
clinical assessment of children with CP. 
The new instrument is named the SPAT (Spasticity Test) to avoid confusion with 
the Tardieu Scale (TS) and the Modified Tardieu Scale (MTS), from which it is 
simplified. The SPAT assesses the muscles with two different velocities. It has a 
detailed written test protocol (e.g. muscle-specific standardised guidelines 
concerning the stretching velocity, type and number of stretches, starting position 
for the limbs and testing position of the child15-17).  
The SPAT is easy to perform, and the bilateral examination can be completed 
within a maximum period of 15 minutes, which makes it feasible for use in clinical 
practice. 
The results show that when one experienced examiner performs the SPAT, the 
reliability is good for almost all the measured muscles, i.e. the hamstrings, soleus 
and gastrocnemius muscles, and also for the adductor muscle, provided that the 
spasticity scale is simplified from a 4 to a 2-point scale. Only the rectus femoris 
muscle could not be reliably tested with the SPAT, and this muscle should 
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therefore not be assessed with it. As in other studies, particularly those evaluating 
joint angles18,19, we found that the intra-rater reliability was considerably greater 
than the inter-rater reliability for almost all the measured muscles, thus repeated 
measurements should always be performed by the same examiner. When assessed 
by two examiners with different levels of experience, the SPAT is only reliable for 
the gastrocnemius. This is probably due to lack of experience in one of the 
examiners. Trained examiners can be expected to use the SPAT with a higher 
degree of reliability20. Before the SPAT can be used in a clinical practice with 
multiple examiners, this reliability research must be repeated with trained 
examiners, for whom a specific training programme must be developed.  
The SDDs in joint angles varied among the muscles tested. When tested by the 
same examiner, changes in excess of 8° - 14° in the range of motion (ROM) and in 
excess of 13° - 20° in the angle of the catch (AOC) would be required to 
demonstrate with confidence true changes in the soleus and gastrocnemius 
muscles and hamstrings. The interpretation of the SDD for each muscle is 
arbitrary. We based it on our clinical experience in which a difference in ROM of 
approximately 15° in the large muscles (the hamstrings and rectus femoris), and 
10° in the smaller muscles (the soleus and gastrocnemius) is found clinically 
relevant. These are therefore considered to be 'acceptable' SDD's.  
For AOC measurements, the SDD is more complicated to interpret. Treatment of 
spasticity is often based on the extent of the 'dynamic component'11 (absolute 
difference between ROM and AOC) of the tested muscle. The mean dynamic 
components in this study were 50° for rectus femoris muscle, 25° for the adductor 
muscles, and 20° for the other muscles. Except for the rectus femoris muscle, these 
could all be reliably tested with the SPAT.  
Other comparable studies evaluated the reliability of slow and fast joint angle 
measurements , and found poorer results. Kilgour et al.21 concluded that, for both 
velocities of the stretch, a change of more than 20° between sessions would be 
required to demonstrate a change in the ROM of the calf and hamstrings muscles. 
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Fosang et al.22 presented numerous intrarater SEM values for the gastrocnemius 
and the hamstrings muscle, the means of which (ROM: 4.8° and 6.4° and AOC: 5.5° 
and 8.5°, respectively) were all higher than the values found in our study. These 
studies used a less extensive protocol, and our better results might be explained by 
the detailed written protocol of the SPAT. Still, the variances found in our study 
were considerably higher for the AOC, compared to the ROM for all muscles. One 
explanation could be that particularly the fast velocity of stretch was not 
adequately standardised (see Appendix 2). Despite the written instructions on the 
fast velocity in the present study, some variation is still expected, as shown in an 
other study on biceps testing23.  
Angular velocity data was not measured, so we don't know how much the two 
velocities varied, and whether this influenced the reliability of the SPAT. We 
hypothise that better standardisation of the two velocities could increase reliability 
of the ROM and the AOC. Standardisation could be performed by use of a 
measurement device (for instance an electro-goniometer) that provides feedback on 
the angular velocity of the joint excursion.  
The reliability of the angular measurements could also have been influenced by 
the goniometry. To reduce measurement error, bony landmarks were marked for 
correct placement of the goniometer and assessment was performed by one trained 
observer according to a standardised protocol.  
The SPAT provides relevant clinical information in the evaluation of a single 
patient, as it is assumed that the level of intensity of the muscle resistance and the 
AOC reflect the level of spasticity. For example, when the gastrocnemius muscle of 
a patient is re-assessed after intervention by the same examiner and a clear catch 
is lowered in intensity from a score of 3 to a score of 0, or appears 15° later in the 
ROM, one can conclude that there is a decrease in spasticity. 
In conclusion, the SPAT is a new and feasible clinical instrument to measure 
spasticity. It has excellent intra-rater reliability for the hamstrings, soleus and 
gastrocnemius muscles, and, on condition that the spasticity scale is simplified, 
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good intra-rater reliability for the adductor muscles. Intra-rater reliability is poor 
for the rectus femoris muscle. Inter-rater reliability was poor for all muscles, 
except the gastrocnemius muscle. The results show that repeated SPAT 
measurements should be performed by the same trained examiner. To improve 
inter-rater reliability, we suggest that a special training programme should be 
developed, and that the velocity of the stretch should be further standardised by 
means of a measurement device. 
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Appendix I: Tardieu Scale or Held Scale  
 
Tardieu Scale or Held Scale10  
Intensity and duration of the reflex (X) Velocity of stretch (V) 
0 = no reflex V1: slow 
1 = only visible contraction V2: under gravity 
2 = contraction with a short catch V3: fast 
3 = contraction lasting a few seconds OR fatigable clonus after a few 
seconds 
 
4 = contraction lasting a few seconds OR infatigable clonus, not even after 
a few seconds 
Angle in ROM (Y*) 
Spasticity is clinically assessed by passively moving the joint at three specified velocities (V) and rating the 
intensity and duration of the muscle reaction to stretch (X) and the joint-angle (Y) where this muscle reaction is 
first felt. *The joint angle at slow velocity is also referred to as R2, the joint angle at fast velocity is also referred 
to as R1. 
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Appendix II: Protocol to measure range of motion and angle of 
the catch 
  
Protocol for patient and joint positioning to measure the range of motion 
(ROM) and the angle of the catch (AOC) with goniometry 
Muscle  Patient & joint positioning Maximal ROM and placement of goniometer-arms 
HS Supine: test leg: hip at 90° flexion, knee is 
extended from a maximally flexed position. 
Contralateral leg maintained in extension. 
Maximal ROM at moment at which the contralateral leg starts 
to move due to pelvic movement 
PA: laterally along the long axis of the femur 
DA: laterally along the long axis of the tibia 
ADD Supine: both hips at 60° flexion, knees at 90° 
flexion, feet flat. Both knees are abducted 
from the neutral position.  
Maximal ROM at moment of pelvic movement 
PA: vertically in the mid-position of both SIAS 
DA: on the upper thigh along the axis of the femur and the 
mid-patella 
RF Prone: test leg: knee is flexed from a 
maximal extended position. Contralateral leg 
maintained in extension. 
Maximal ROM at moment of pelvic movement*  
PA: laterally along the long axis of the femur 
DA: laterally along the long axis of the tibia  
SOL Supine: test leg: hip and knee flexed at 90°. 
Foot is dorsiflexed† from maximal plantar 
flexion. Contralateral leg maintained in 
extension. 
Maximal ROM at maximal dorsal flexion 
PA: laterally along the long axis of the tibia 
DA: proximal part of the lateral foot sole  
GC Supine: test leg: from the end ROM position 
of soleus dorsiflexion, the knee is slowly 
extended while foot remains dorsiflexed†. 
Contralateral leg maintained in extension. 
Maximal ROM at maximal dorsal flexion 
PA: laterally along the long axis of the shank 
DA: proximal part of the lateral foot sole 
HS = (medial) hamstring muscles; ADD = adductor muscle; RF = rectus femoris muscle; SOL = soleus muscle; GC 
= gastrocnemius muscle; PA = proximal arm; DA = distal arm; SIAS = Spina Iliaca Anterior Superior; *To hinder 
immediate elevation at beginning of movement the operator's assisting hand stabilises the pelvis by applying 
pressure to the buttock; †the hindfoot is positioned in neutral varus/valgus and the foot is held in supinated 
position. 
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Appendix III: The Spasticity Test (SPAT)  
 
General Protocol 
Child lies down on a research bench with head in midline and arms in anatomical 
neutral position. Shoes, socks and pants are removed.  
Specific starting positions of the joints are defined in Appendix II. The movement 
is initiated from a maximal possible joint position opposite to the direction of 
movement. 
Child is relaxed during testing. 
No pre-stretch is allowed prior to testing. 
 
ROM testing 
Stretch the muscle passively to its maximum ROM by applying a very slow stretch 
in the direction of the end position. The end position is defined as the point at 
which no further movement is possible, the examiner perceives extensive 
resistance to stretch, or the child complains of a feeling of discomfort.  
Very slow stretch is defined as excursion of the maximum ROM in three or more 
seconds (counting: one-hundred-and-one, one-hundred-and-two, one-hundred-and-
three). 
Soft bounced or jerked stretching of the hamstrings and adductors is allowed in the 
end position. Firm static stretching of the gastrocnemius and soleus is allowed in 
the end position.Normal static streching of the rectus femoris is allowed in the end 
position. 
The joint angle of maximum ROM of the 3rd repetitive stretch is measured with 
goniometry (see Appendix II). 
 
85 
Chapter 3 
Appendix III: The Spasticity Test (SPAT) - continued 
 
Spasticity testing: measurement of angle of catch (AOC) and grading on the 
spasticity scale  
Stretch the muscle passively towards its maximum ROM by applying a very fast 
stretch in the direction of the end position.  
Very fast stretch is defined as excursion towards the maximum ROM within one 
second (as fast as possible). 
After the 1st stretch with fast velocity, spasticity is graded on a 4-point scale. 
Subsequently, if the score is 2 or 3, the angle of the catch (AOC) is measured with 
goniometry (see Appendix II).  
 
Spasticity scale  
Grade Description 
0 normal or increased muscle resistance over the whole ROM 
1 increase in muscle resistance somewhere in the ROM without a catch   
2 catch and release 
3 clear catch, blocking further movement 
Ad. 0: normal muscle resistance: not flaccid, not increased 
increased muscle resistance over the full ROM: increased resistance to stretch over the full movement; the end 
ROM is achieved 
Ad. 1: increase in muscle resistance somewhere in the ROM without a catch: the resistance to stretch increases in 
part of movement; the end ROM is achieved 
Ad. 2: catch and release: a sudden increase in resistance before the end ROM blocking further movement, after 
which further movement is possible and the end ROM is achieved 
Ad. 3: clear catch, blocking further movement: a sudden increase in resistance before the end ROM blocking 
further movement, after which no further movement is possible  
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Abstract 
 
To evaluate the effect of multilevel botulinum toxin A and comprehensive 
rehabilitation on gait pattern, muscle length, and spasticity, a multicenter randomized 
trial was performed in 46 children with spastic cerebral palsy who walk with flexed 
knees. Their mean age was 8.0 years (range 4 to 11 years). They were randomly 
allocated to the intervention group (multilevel botulinum toxin A and comprehensive 
rehabilitation) or the control group (usual care). After 6 weeks, a significant treatment 
effect in the intervention group was observed on: improved knee extension during 
midstance and terminal swing (7° and 5°, P < 0.01, respectively); hip rotation during 
terminal swing (4°, P = 0.02); gait score (1.7, P < 0.01); decreased spasticity in 
hamstrings (11°, P < 0.01), gastrocnemius (6°, P = 0.01), and soleus (5°, P = 0.02); and 
increased muscle length in hamstrings (9°, P < 0.01) and gastrocnemius (5°, P < 0.01). 
The improved muscle length was maintained up to 24 weeks. This study demonstrated 
that multilevel botulinum toxin A and comprehensive rehabilitation improves knee 
extension during gait, increases muscle length, and decreases spasticity in injected 
muscles after 6 weeks in children who walk with flexed knees. Although the effect on 
muscle length was maintained after 24 weeks, the effect on gait and spasticity had 
disappeared.  
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Introduction 
 
Many children with cerebral palsy have a deviating gait pattern. One of the typical 
patterns that is often observed in cerebral palsy is characterized by flexion of the knee 
during midstance1. It has been demonstrated that the natural course of development in 
these children leads to a further deterioration in this flexion pattern2. Because this is 
generally accompanied by a deterioration in mobility3, treatment is indicated for these 
children at an early age.  
Although the exact cause of the flexion pattern is not known, it is acknowledged that 
it is attributable to imbalance of the flexor and extensor muscles. It is postulated that 
this muscle imbalance results from an underlying combination of decreased length of 
the flexor muscles, decreased strength of the extensor muscles, and abnormal 
involuntary increased activity of the flexor muscles during gait, such as spasticity4. 
Therefore, in order to improve or prevent further deterioration in the flexion pattern, 
treatment should focus on restoring these underlying deficits; this requires a 
comprehensive treatment approach, which should begin with physiotherapy, orthoses, 
and serial casting. If there is an insufficient response to improve the gait pattern, 
injection with botulinum toxin A is indicated.  
Botulinum toxin A decreases spasticity in the injected muscle and reduces the muscle 
tone for approximately 8 to 12 weeks5. When botulinum toxin A is indicated to improve 
the gait pattern in children who walk with a flexion pattern, multiple muscle groups 
should be treated in one session. This method is referred to as multilevel botulinum 
toxin A treatment. It is generally thought that the reduction in tone in the flexor 
muscles after multilevel botulinum toxin A injections creates basic conditions that are 
essential for the further improvement of muscle length and muscle strength in these 
children. Therefore, to optimize the success of multilevel botulinum toxin A injections, 
a comprehensive rehabilitation program seems to be crucial. Physiotherapy should be 
intensified during the pharmacologic period of botulinum toxin A6 and aim, in 
particular, at stretching the flexor muscles, strengthening the extensor muscles, and 
exercises to improve gait pattern. Serial castings7 should be applied to stretch 
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shortened muscles and thus increase muscle length, and new orthoses should be 
prescribed to prevent a relapse of muscle shortening and to improve knee extension 
during stance. Multilevel botulinum toxin A injections followed by such comprehensive 
rehabilitation may result in an improvement of the gait pattern of these children.  
This total treatment package has been standard clinical practice in recent years. A 
few randomized8-10 and nonrandomized studies7,11 have evaluated the effect of 
multilevel botulinum toxin A injections in children with cerebral palsy characterized by 
various gait patterns. However, little information is available about the effect of 
multilevel botulinum toxin A on the gait pattern of children who walk with flexed 
knees. These studies also failed to include a control group receiving usual care. It is 
important to determine the overall effectiveness of the best clinical practice in these 
children (multilevel botulinum toxin A plus physiotherapy, orthotics, and, if necessary, 
serial casting), as opposed to usual care.  
The aim of the present study was to measure the effect of lower extremity multilevel 
botulinum toxin A injections and comprehensive rehabilitation, compared with usual 
care in ambulatory children with cerebral palsy who walk with flexed knees during 
midstance. We hypothesized that multilevel botulinum toxin A injections plus 
comprehensive rehabilitation would decrease knee flexion during gait, decrease 
spasticity, and improve muscle length.  
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Methods 
 
Study patients 
From October 2001, children were screened for this multicenter trial in four Dutch 
departments of rehabilitation medicine. The screening included standardized medical 
history taking and a clinical examination, and frontal and sagittal gait video-
recordings with surface electromyography12. Inclusion was based on consensus between 
all four participating pediatric physiatrists, reached during a teleconsultation session 
in which the data collected during screening were discussed via a high-quality 
video/audio conference13. The inclusion and exclusion criteria are listed in Table 1.  
 
Study design and procedure 
In this study, the effect of multilevel botulinum toxin A and comprehensive 
rehabilitation was evaluated on the technical outcome measures: gait pattern, muscle 
length, and spasticity. Outcomes on mobility and energy cost are described elsewhere16. 
This study was approved by the Medical Ethics Committee of the VU University 
Medical Center in Amsterdam. Full written informed consent was obtained from all 
parents and 12-year-old children before enrolment. The children were randomly 
assigned to one of two groups. The intervention group received multilevel botulinum 
toxin A injections followed by intensive physiotherapy, orthoses, and, if necessary, 
serial casting. The control group continued with usual care (low-intensity 
physiotherapy, 1-2 sessions of 30-60 minutes a week; some used orthoses). The children 
in the control group were also indicated to receive multilevel botulinum toxin A 
injections after the control period.  
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Table 1: Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
Diagnosis of cerebral palsy Botulinum toxin A treatment in lower extremities  
Spastic hemiplegia or diplegia (according to Hagberg14 )    within 16 weeks before inclusion 
Age between 4 and 12 years Orthopedic surgery within 24 weeks before inclusion 
Spasticity in two or more lower extremity Contraindication for botulinum toxin A 
   muscle groups interfering with mobility Contraindication for general anesthesia 
Able to walk independently, with or without Orthopedic deformities which have a bad influence 
   walking aids    on walking: 
Gait characterized by persistent flexion of the      hip (sub)luxation with migration index15  > 50° 
  knee (≥10°) in midstance (barefoot or with        hip endorotation contracture > 15° 
  ankle-foot orthoses/shoes)       flexion contracture of knee > 15° 
Two or more muscle groups in one limb Severe fixed contractures: 
   requiring botulinum toxin A injection  age < 8 years 
Able to carry out instructions     ankle dorsiflexion with knee extended > −20° 
Adequate knowledge of the Dutch language     popliteal angle > 90° 
  age ≥ 8 years 
     ankle dorsiflexion with knee extended > −15° 
     popliteal angle > 80° 
 Presence of ataxia or dyskinesia 
 Other problems which have a negative influence  
    on walking 
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Intervention 
A consent treatment plan was formulated for each child before randomization, during 
the teleconsultation session. This plan included target muscle identification, 
calculation of the injection dosage, the need for serial casting, and the prescription of 
ankle-foot orthoses.  
 
Botulinum toxin A injections 
Possible target muscles were the psoas, medial/lateral hamstrings, hip adductors, 
rectus femoris, gastrocnemius, soleus, and tibialis posterior muscle. Muscle 
identification was based on the criteria listed in Table 2. The injections were 
administered under general anesthesia, in at least two sites per muscle belly, to a 
maximum of 50 U/site, with a dosage of 4-6 U/kg body weight botulinum toxin A 
(Botox; Allergan, Nieuwegein, the Netherlands) per muscle group. The maximum total 
dose was set at 25 U/kg body weight for children ≤5 years, and 30 U/kg body weight for 
children >6 years, with a maximum recommended dose of 600 U. A dilution of 50 U in 1 
mL 0.9% NaCl solution was used. Injection sites were determined by palpation of the 
muscle belly, and needle placement was verified either by stretching or electric 
stimulation of the muscle.  
 
Intensive physiotherapy 
Beginning 1 week after the multilevel botulinum toxin A injections, the children 
received treatment 3-5 times a week for 12 weeks from a physiotherapist, according to 
a standardized treatment protocol. Each session lasted for 45-60 minutes, and the 
treatment consisted of active and passive stretching of the flexor muscles, strength 
training of the extensor muscles, functional mobility training, and gait pattern 
training.  
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Orthoses 
To support full knee-extension in terminal stance, either stiff insoles or ankle-foot 
orthoses were prescribed.  
 
Serial casting 
If the passive ankle dorsiflexion with extended knee measured during screening was 
less than 0°, serial casting was initiated 1-3 weeks after the injection. Bilateral below-
knee walking casts were applied, and changed every week until ≥0° of dorsiflexion was 
achieved.  
The intervention group had one baseline assessment, and three follow-up 
assessments at 6, 12, and 24 weeks after multilevel botulinum toxin A injection. The 
control group had two assessments with a mean interval of 24.61 weeks (SD 5.7; range 
18-30).  
Gait analysis in the intervention group was performed only at baseline, and 6 and 24 
weeks after multilevel botulinum toxin A injection.  
 
 
Outcome measures 
 
Gait was analyzed from standardized videorecordings of gait in both frontal and 
sagittal planes while the child walked barefoot, with or without a walking aid. The 
children were instructed to walk at a comfortable walking speed along a level 10-meter 
walkway. The gait pattern was qualitatively evaluated according to the Edinburgh 
Visual Gait Analysis Interval Testing (GAIT) scale17, which is a biplane video-based 
scoring scale, developed to assess children with cerebral palsy. It measures 17 joint 
angles or movements of the trunk and the lower limbs during a representative stride. 
These 17 items are scored on a 3-point scale: 0 (normal kinematics), 1 (moderate 
deviation), and 2 (marked deviation). The scores are added together to obtain a GAIT 
total score, ranging from 0 to 34 points for each  
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lower limb. In addition to the GAIT total score, knee angle at midstance, ankle angle at 
midstance, knee angle at terminal swing, and hip rotation at terminal swing were 
measured. The measurement of joint angles from video-tapes with a digital screen 
goniometer was performed by one independent research student, who had no 
knowledge of the moment of assessment. The videotapes were analyzed randomly, and 
each limb was scored separately.  
 
Table 2: Target muscle identification for botulinum toxin A injections based on 
gait analysis and clinical examination in children with cerebral palsy who walk with 
flexed knees  
Muscle Criteria observed during gait analysis  Criteria observed during 
clinical examination 
Psoas  increased flexion of the hip during terminal stance, AND   
  anterior tilt of the pelvis during terminal stance   
 OR   
  increased flexion of the hip during terminal stance, AND   
  retraction of the pelvis during terminal stance   
Medial 
hamstrings* 
 increased flexion of the knee during midstance, AND &  spasticity in medial 
hamstring muscle 
  muscle activity† of the hamstrings during midstance   
 OR   
  increased flexion of the knee during midstance, AND   
  endo-adduction rotation of the hip during terminal swing, 
OR 
  
  increased flexion of the knee during terminal swing, OR   
  posterior tilt of the pelvis during terminal swing   
Rectus femoris  decreased progression to flexion of the knee joint during 
pre-swing and initial swing, AND 
&  spasticity in the rectus 
femoris muscle 
  muscle activity of the rectus femoris during pre-swing   
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Table 2: Target muscle identification for botulinum toxin A injections based on 
gait analysis and clinical examination in children with cerebral palsy who walk with 
flexed knees - continued 
Muscle Criteria observed during gait analysis  Criteria observed during 
clinical examination 
Biceps femoris equal to medial hamstrings &  biceps femoris muscle is 
responsible for decreasing the 
popliteal angle of ≤ 90° 
Adductor  adduction of the hip during swing and stance phase, AND &  spasticity in the adductor 
muscle 
  endorotation of the hip during swing and stance phase   
Gastrocnemius  muscle activity of the gastrocnemius during midstance &  decreased length‡ of the 
gastrocnemius muscle 
(maximum ankle dorsiflexion 
with knee extended ≥ 0°) 
Soleus  plantar flexion of the ankle during stance phase &  decreased length of the 
soleus muscle (maximum 
ankle dorsiflexion with knee 
90° flexed ≥ 0°) 
Tibialis posterior  varus/adduction/supination of the forefoot AND &  spasticity in the tibialis 
posterior muscle, AND 
  lateral sway of the knee during midstance or terminal stance   signs of overload (e.g. 
callus) on the lateral border of 
the foot 
All the criteria must be present to identify that muscle for botulinum toxin A injection. 
* Semitendinosus, semimembranosus with gracilis. 
† Muscle activity is measured by means of electromyography. 
‡ Muscle length is measured by means of goniometry (see Table 4).  
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The observer followed the recommended conditions to optimize reliable visual 
assessment, by including split-screen video-analysis with slow speed viewing and 
specific training in normative values of gait parameters18,19. Intra-observer 
reproducibility of the GAIT scale and additional kinematic measurements was 
established through repetitive scoring of 5% of all videos.  
Muscle length and spasticity were measured in hamstrings, adductors, rectus 
femoris, soleus, and gastrocnemius muscles. Muscle length was tested by assessing the 
range of motion at slow passive stretch (>3 seconds) while the child was relaxed. The 
range of motion of the third passive stretch was measured. Spasticity was then 
measured by assessing the joint angle at which a ‘catch’ (defined as a sudden increase 
in muscle tone blocking further movement) occurred in response to a single fast passive 
stretch (<1 second). Muscle length and spasticity measurement of all children were 
performed by the same experienced investigator, whereas the joint angles were 
measured with a standard goniometer by a second investigator. The protocol of the 
American Academy of Orthopedic Surgeons20 was followed for the positioning of the 
child and the goniometry for testing each specific muscle group.  
 
 
Statistical analysis 
 
Group characteristics were tested for differences with the Student t test or the chi-
square test. To study the effect of the treatment, the changes from baseline at Weeks 6, 
12, and 24 in the intervention group were compared with the effect of usual care in the 
control group. We studied the treatment effect at 6 weeks postinjection, because the 
pharmacologic effect of botulinum toxin A was likely to be maximal at this stage. 
Further analysis was performed at 12 weeks (muscle length and spasticity only) and 24 
weeks to assess the duration of the effect.  
In the intervention group, the limbs that had been injected with botulinum toxin A 
were analyzed, and in the control group we analyzed the limbs that would be injected 
with botulinum toxin A after the control period. Although all outcomes were assessed 
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for both limbs separately, we chose to report the results of the right and left limbs 
together, because no significant differences were evident between right and left.  
All differences in effect between the intervention and the control group were analyzed 
in a linear mixed model analysis21,22 (SPSS 11.5), which estimated the treatment effect 
on the different outcome measures. A three-level model (children, limb, and 
observation) was used to adjust for dependency of repeated observations and left and 
right limbs in each subject. The factor ‘center’ (center of inclusion and assessment) was 
taken into account in all statistical analyses.  
The intraclass correlation coefficient was used to describe the intra-observer 
reproducibility of the GAIT total score and kinematic parameters. All analyses were 
performed by a statistician (D.K.) and the principal investigator (V.S.). The level of 
statistical significance was set at P < 0.05, and all P values were two-sided.  
 
 
Results 
 
During an intake period of 19 months, 58 children were screened and 47 were included 
in the study. The selection and randomization procedures are presented as a graph in 
Figure 1. In the control group, one child dropped out after the first baseline assessment 
at the request of the parents. This child was excluded from all analyses. The groups did 
not differ with regard to the personal characteristics summarized in Table 3. In the 
intervention group, 42 limbs were treated with botulinum toxin A. The most frequently 
targeted muscles were medial hamstrings, psoas, and gastrocnemius, in varying 
combinations: 9 limbs (21%) were injected in the medial hamstrings and 
gastrocnemius; 18 (43%) were injected in the psoas and  
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Figure 1: Schematic design of selection and randomization 
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medial hamstrings; 9 (19%) were injected in the psoas, medial hamstrings, and 
gastrocnemius. Other muscles that were injected (alone or in combination) were lateral 
hamstrings, rectus femoris, soleus, adductors, and tibialis posterior. All children 
received multilevel injections in at least one of their limbs. A mean dose of 18.01 U/kg 
body weight (SD 4.74) was injected, ranging from 5.63 to 27.14 U/kg.  
 
Baseline Differences 
The groups did not differ with regard to the personal characteristics summarized in 
Table 3. The difference between the two groups in terms of age and weight was 
assessed with the Student t test; the difference in sex, diagnosis, and gross motor 
function classification system level was assessed with chi-square tests.  
 
Table 3: Characteristics of all participating children  
Group Age (yr)  
mean ± SD 
Weight (kg) 
 mean ± SD 
Sex (n) 
males: 
Diagnosis 
(n) 
GMFCS level 
(n) 
ml-BTX-A, (U)   mean 
± SD 
  [range]  [range] females uni : bi I :II :III :IV  [range] 
Intervention 8.13 ± 2.25 26.76 ± 7.63 16 : 7 3 : 20 9 : 3 : 10 : 1 442.83 ± 132.84 
(n = 23) [4.15 to 11.45] [15.00 to 45.00]    [180 to 710] 
Control 7.88 ± 2.25 25.59 ± 8.27 16 : 7 1 : 22 9 : 4 : 7 : 3  
(n = 23) [4.45 to 11.00] [13.00 to 44.00]     
Abbreviations: bi: Bilateral; GMFCS: Gross motor function classification system23; ml-BTX-A: Multilevel botulinum toxin 
A; U: Units; uni: Unilateral 
 
No significant differences were found between the intervention and the control group 
at baseline with regard to the gait parameters, except for the knee angle at midstance 
(P < 0.01), which was significantly worse in the control group (Fig 2). No significant 
differences in muscle length or the level of spasticity were observed at baseline 
between the two groups (Fig 3). The estimated mean differences in change between the 
intervention and the control group with regard to gait parameters, muscle length, and 
spasticity are presented in Table 4.   
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Figure 2: Estimated mean values in knee, hip, and ankle angles and Edinburgh 
Visual Gait Analysis Interval Testing (GAIT) scale total score during gait in 
intervention and control group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#A significant difference at baseline; *A significant difference in change from baseline between the two groups. 
Dashed line demarks the moment of botulinum toxin A injections in the intervention group. On the horizontal axis: 
weeks are before/after botulinum toxin A injections in intervention group. On the vertical axis: negative values 
indicate flexion on knee angles, plantar flexion on ankle angle, and internal rotation on hip rotation. Positive values 
indicate dorsal flexion on ankle angle.  
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Gait parameters 
GAIT indicated substantial to good intra-observer reliability with an intraclass 
correlation coefficient of 0.88. Kinematic parameters exhibited substantial to good 
intra-observer reliability with an intraclass correlation coefficient of 0.90 for knee  
angle at midstance, 0.88 for ankle angle at midstance, 0.77 for knee angle at terminal 
swing, and 0.74 for hip rotation at terminal swing.  
After 6 weeks there was a significant treatment effect (Table 4) on the knee angle at 
midstance (7.0°, P < 0.01), knee angle at terminal swing (5.2°, P < 0.01), hip rotation at 
terminal swing (3.6°, P = 0.02), and GAIT total score (−1.7 point, P < 0.01). Secondary 
analysis indicated that 17 of the 23 children (74%) in the intervention group improved 
more than 5° in knee extension of at least one limb, as opposed to 7 of the 23 in the 
control group (30%) (P = 0.004). Two children (9%) in the intervention group, as 
opposed to 6 in the control group (26%), deteriorated more than 5° in knee flexion.  
Figure 2 reveals that the significant differences in effect after 6 weeks mainly result 
from improvement in the intervention group, whereas the control group manifested no 
change. No significant treatment effect was observed on the ankle angle at midstance. 
Improvement in gait pattern was not maintained at 24 weeks after the injections.  
 
Muscle length 
At 6 weeks after the injections, there was a significant treatment effect on the muscle 
lengths of the hamstrings (P < 0.01) and gastrocnemius (P > 0.01), which was 
maintained at 12 weeks (P = 0.02 and P = 0.03 respectively) and 24 weeks (P < 0.01 
and P < 0.01 respectively). Furthermore, a significant treatment effect on the muscle 
length of the soleus was present at 12 weeks (P = 0.03). Figure 3 indicates that the 
significant differences in effect mainly result from muscle length improvement in the 
intervention group, whereas in the control group there was no change or a slight 
deterioration. There was no significant treatment effect on the rectus femoris and the 
adductor muscle, although there was a tendency for improvement in adductor muscle;  
this did not reach significance (P = 0.05) at 6 weeks (Table 4).  
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Figure 3: Estimated mean values in 
muscle length and spasticity of five 
leg muscles in intervention and 
control groups 
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he 
Muscle length was measured by assessing the 
range of motion during a slow passive stretch. 
Spasticity was measured by assessing the angle of 
occurrence of the catch during a fast passive 
stretch. *A significant difference in change from 
baseline between the two groups. Dashed line 
demarks the moment of botulinum toxin A 
injections in the intervention group. On the 
horizontal axis: weeks are before/after botulinum 
toxin A injections in the intervention group. On t
vertical axis: negative values indicate plantar 
flexion in the soleus and gastrocnemius muscle, 
whereas positive values indicate dorsal flexion.  
Chapter 4 
104 
Table 4: Effect (estimated mean differences in change between intervention and 
control group) on gait parameters, muscle length, and spasticity  
 Week Effect  (95% CI) P  Value 
 Gait parameters    
 Knee angle midstance (°) 6 7.03 (3.76 to 10.30) <0.01 
 24 3.62 (−1.01 to 8.24) 0.12 
 Knee angle terminal swing (°) 6 5.15 (1.91 to 8.38) <0.01 
 24 4.44 (−0.14 to 9.01) 0.06 
 Hip rotation terminal swing (°) 6 3.63 (0.58 to 6.67) 0.02 
 24 4.18 (−0.12 to 8.48) 0.06 
 Ankle angle midstance (°) 6 2.08 (−1.63 to 5.80) 0.27 
 24 2.40 (−2.85 to 7.62) 0.37 
 GAIT 6 −1.74 (−2.76 to −0.72) <0.01 
 24 −1.02 (−2.47 to 0.43) 0.17 
 Muscle length    
 Hamstrings (°) 6 −8.87 (−12.87 to −4.88) <0.01 
 12 −9.68 (−14.24 to −5.12) <0.01 
 24 −10.10 (−16.12 to −4.08) <0.01 
 Rectus femoris (°)            6 4.26 (−0.63 to 9.15) 0.09 
 12 3.71 (−1.83 to 9.29) 0.19 
 24 6.19 (−1.16 to 13.54) 0.10 
 Adductors (°) 6 3.10 (−0.05 to 6.25) 0.05 
 12 1.34 (−2.25 to 4.94) 0.46 
 24 2.94 (−1.80 to 7.69) 0.22 
 Soleus (°) 6 2.28 (−0.79 to 5.36) 0.14 
 12 3.82 (0.30 to 7.33) 0.03 
 24 0.94 (−3.71 to 5.59) 0.69 
 Gastrocnemius (°) 6 4.76 (2.04 to 7.47) <0.01 
 12 3.57 (0.47 to 6.67) 0.02 
 24 4.66 (0.57 to 8.75) 0.03 
 
 
 
Multilevel BTX-A and comprehensive rehabilitation on gait 
105 
Table 4: Effect (estimated mean differences in change between intervention and 
control group) on gait parameters, muscle length, and spasticity - continued 
 Week Effect  (95% CI) P  Value 
Spasticity    
 Hamstrings (°) 6 -11.40 (-17.37 to -5.43) <0.01 
 12 -11.68 (-18.50 to -4.87) <0.01 
 24 -5.70 (-14.70 to 3.30) 0.21 
 Rectus femoris (°)            6 11.50 (-0.25 to 23.26) 0.06 
 12 14.02 (0.59 to 27.45) 0.04 
 24 21.98 (4.23 to 39.72) 0.02 
 Adductors (°) 6 2.62 (-1.37 to 6.62) 0.20 
 12 2.92 (-1.63 to 7.48) 0.21 
 24 3.41 (-2.61 to 9.42) 0.27 
 Soleus (°) 6 5.45 (0.69 to 10.21) 0.02 
 12 8.88 (3.45 to 14.31) <0.01 
 24 3.81 (-3.37 to 10.99) 0.30 
 Gastrocnemius (°) 6 5.69 (1.40 to 9.98) 0.01 
 12 10.03 (5.12 to 14.93) <0.01 
 24 6.31 (-0.18 to 12.80) 0.06 
Positive values indicate increased extension on knee angles; increased external rotation on hip rotation; increased 
dorsal flexion on ankle angle; increased muscle length and decreased spasticity on rectus femoris, adductors, soleus, 
and gastrocnemius. Negative values indicate improved gait pattern on GAIT, increased muscle length and decreased 
spasticity on hamstrings.  
Abbreviations CI: Confidence interval; GAIT: Gait Analysis Interval Testing scale total score 
 
Spasticity 
At 6 weeks there was a significant treatment effect on spasticity in the hamstrings (P 
> 0.01), soleus (P = 0.02), and gastrocnemius (P = 0.01) muscles, which was maintained 
at 12 weeks after the injections (all P > 0.01), but not at 24 weeks after the injections. 
There was a significant treatment effect on spasticity in the rectus femoris muscle at 
12 (P = 0.04) and at 24 weeks (P = 0.02). Figure 3 reveals that these significant 
differences in effect mainly result from a decline in spasticity in the intervention group, 
whereas the control group manifested no change or a slight increase, except in the 
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rectus femoris muscle, which was the result of an increase in spasticity in the control 
group (Fig 3). No significant treatment effect was observed on the adductor muscle.  
 
 
Discussion 
 
This randomized clinical trial evaluated the effect of treatment with multilevel 
botulinum toxin A and comprehensive rehabilitation on gait pattern, muscle length, 
and spasticity in children with cerebral palsy who walked with flexion of the knee in 
midstance. The study demonstrated that multilevel botulinum toxin A injections in the 
hamstring muscle, in some combination with the psoas and gastrocnemius muscle, 
followed by intensive rehabilitation, significantly improved the knee extension during 
midstance and terminal swing and hip rotation during terminal swing. It also 
improved the overall quality of the gait pattern towards a more ‘normal’ gait. The 
efficacy of the treatment in reducing muscle shortening and spasticity was also 
demonstrated.  
An improvement in gait kinematics and the quality of the gait pattern assessed 
according to the GAIT scale was documented at 6 weeks after the injections. At the 
commencement of this study, the children in the intervention group had a mean knee 
flexion of 20°, and this was prevented from deterioration. It is known from  
the literature that that flexed-knee gait has a substantial effect on gait energy 
expenditure24, and that knee angles beyond 20° flexion considerably impair the ability 
to walk25. So it is clinically important to prevent these children from any deterioration. 
The mean improvement of 7° in knee extension during midstance in barefoot walking 
that was found in this study is similar to the results found after 2 weeks in other 
uncontrolled studies in which children received hamstrings injections to improve knee 
extension26-28. Moreover, significantly more children in the intervention group had an 
increase in knee extension compared with the control group. Therefore, we believe that 
the results of the present study indicate a clinically meaningful improvement in flexed 
knee gait.  
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We found no evidence of maintained effect on gait after 24 weeks, contrary to the 
reports of Cosgrove et al.27, who reported an effect that was maintained up to 26 weeks; 
however, they did not include a control group. In the present study, gait analysis was 
only performed at 6 and 24 weeks. However, it is likely that the effect wears off 
somewhere in between, and that the assessment at 24 weeks was too late to 
demonstrate sustained improvements. The effect of ankle-foot orthoses on walking was 
not measured in the present study.  
Although our randomization procedure yielded no differences in patient 
characteristics, and no differences were evident between the two groups in muscle 
length and level of spasticity, in the control group there was significantly more knee 
flexion at baseline. Because we do not know the exact influence of this, the results of 
this study apply at least to children with ranges of knee flexion that are comparable 
with those in the intervention group.  
In the present study, muscle shortening was not included in the exclusion criteria, 
although it has been suggested by many authors that this is a contraindication for 
botulinum toxin A treatment. This, despite the fact that desired improvements are only 
to be expected in muscles that have a reduced range of motion at baseline (thus muscle 
shortening), and not in muscles that have a full range of motion. At baseline, the 
patients in the present study manifested moderate muscle shortening in the 
hamstrings (mean 60.58°) and mild shortening in the gastrocnemius (mean 1.37°) and 
soleus muscles (mean 10.29°), but full length in the rectus femoris (mean 136.57°) and 
adductor muscles (mean 45.90°). As expected, the results of this study did produce the 
desired significant improvement in the length of hamstrings and gastrocnemius 
muscles on all assessments, and also in the soleus at 12 weeks, but not in the rectus 
femoris or adductors. Additionally, the muscles that were the main target of botulinum 
toxin A injection in this study were the hamstrings and gastrocnemius muscles, and 
these were found to improve shortly after the injections. Because children with muscle 
shortening were excluded from the other studies, it is not easy to compare our results 
with those of other studies. However, the study demonstrated that an improvement in 
muscle lengths can be maintained up to 24 weeks after treatment in shortened 
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muscles, and therefore mild to moderate muscle shortening does not seem to be a 
contraindication but, in fact, an indication for treatment.  
A reduction in spasticity was observed in the muscles that were most frequently the 
target for botulinum toxin A injections (i.e., the hamstrings and gastrocnemius) at 6 
weeks after the injections and lasting up to 12 weeks. This finding could be expected 
owing to the pharmacologic mechanism of botulinum toxin A, which blocks signal 
transmission at the neuromuscular junction by preventing the release of acetylcholine. 
After approximately 3 months the neuromuscular junction is restored, as a result of 
sprouting at the nerve end, so the lack of significant findings at 24 weeks supports this 
temporary effect on spasticity.  
Although the soleus was not a target muscle in the patient group, its spasticity also 
decreased significantly. Because the gastrocnemius and soleus muscles are 
anatomically near to each other, the reduced spasticity may be due to diffusion of 
botulinum toxin A. This diffusion to adjacent muscles has also been reported in studies 
in which hand29 or neck30 muscles have been treated with botulinum toxin A.  
The results of other randomized studies lack agreement on the effect that botulinum 
toxin A has with regard to decreasing spasticity9,31,32. However, although most previous 
studies used the (Modified) Ashworth Scale to assess spasticity, many researchers have 
recently stated that the Ashworth is not a valid measure of spasticity33-35, and that it 
does not acknowledge the velocity dependency of spasticity36 defined by Lance37. We 
therefore added a velocity component, by measuring the joint angle in response to a 
slow passive muscle stretch (range of motion), followed by the joint angle at which an 
increase in muscle tone is encountered in a fast passive muscle stretch, comparable to 
the modified Tardieu Scale38. This method has been demonstrated to be valid in clinical 
practice for the measurement of spasticity39, making it possible to detect subtle 
intervention effects, as also reported in comparable studies38,40.  
There were varying intervals between the measurements in the control group. These 
varying intervals were unavoidable because we had to find a balance between what 
was scientifically desirable, practically achievable, and clinically necessary: if 
treatment was planned during the holidays, or if a child complained of pain, the 
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physician decided to provide the multilevel botulinum toxin A treatment earlier. An 
interval of 18 weeks was therefore set as a minimum in the control group. As a 
consequence, the mean duration between the first and the last assessment differed 
between the two groups, from 24 weeks in the control group to 28 weeks in the 
intervention group. Using the linear mixed model analysis, we adjusted for this time 
discrepancy by extrapolating the changes during the assessment period in the control 
group. It is unlikely that this has influenced our results, because stable baseline values 
were found in the control group for all outcome measures.  
In this multicenter study, multiple assessors performed the measurements. To 
standardize the treatment and the assessment methods, training sessions were 
organized before the study. The study was only partially blinded. One single assessor, 
who was blinded for the moment of assessment, scored the gait-analysis from videos. 
The intra-rater reliability of the GAIT scale in the present study was good, similar to 
that reported in a recent study41, and the intra-rater reliability of the kinematic 
parameters was substantial to good. We used an observational assessment based on 
videotapes, rather than the more objective three-dimensional gait analysis, because the 
latter method was not available in all of the participating rehabilitation centers. In a 
recent study42 video-based scoring of sagittal knee position during midstance was 
compared with three-dimensional gait analysis and demonstrated to be highly 
correlating, indicating high validity.  
The other assessments were not blinded. It is unlikely that this lack of blinding had a 
negative influence on our results, because the assessors were not aware of the results 
of previous assessments.  
Many randomized and nonrandomized studies have evaluated the effect of botulinum 
toxin A treatment for the lower extremities in children with cerebral palsy, but only a 
few included children with flexed knee gait, despite the risk of deterioration these 
children have to face when they grow up. Because of the underlying muscle imbalance, 
a comprehensive treatment program is required to improve the flexion pattern. The 
effect of the total program was chosen as the focus of this study, rather than the 
contribution of each individual component (multilevel botulinum toxin A, 
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physiotherapy, orthoses, and serial casting). Therefore we do not know how much of 
the effect is specifically contributable to the multilevel botulinum toxin A injections 
alone, or to the intensive physical therapy, orthosis, or serial casting. The unknown 
contribution of each of the components and the optimal combination of elements in the 
treatment program are subjects for future research.  
The main focus of this study was on the technical outcomes of gait pattern, muscle 
length, and spasticity. However, the long-term goal of the multilevel botulinum toxin A 
and rehabilitation treatment is aimed at improvement on the level of mobility. These 
results are described in another paper, and it was found that the treatment also has an 
improved effect on mobility. However, the treatment effects on mobility appear later 
(12 weeks after injection) than the effect on gait pattern (6 weeks after injection) 
(results will be presented elsewhere16).  
 
 
Conclusion 
 
In this multicenter randomized clinical trial, multilevel botulinum toxin A injections 
and comprehensive rehabilitation (as opposed to usual care) resulted in a significant 
improvement in knee extension during gait, muscle length, and spasticity in the 
injected muscles of children with cerebral palsy whose gait is characterized by a flexed 
knee pattern. Muscle shortening should not be a contraindication, because the 
treatment was specifically effective in achieving a significant improvement in muscle 
length. Although the effect on muscle length was still present after 24 weeks, the effect 
on gait had disappeared.  
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Abstract 
 
Objective: To evaluate the combined effect on mobility of treatment with 
multilevel botulinum toxin type A (BTX-A) and comprehensive rehabilitation in 
children with cerebral palsy (CP). Design: Randomized clinical trial using a 
multiple baseline design. The intervention group was treated 6 weeks after 
randomization. The control group was treated after a longer period of 18 to 30 
weeks. Repeated measurements in both groups were continued throughout the 
process, before and up to 48 weeks after treatment. Setting: Four departments of 
rehabilitation medicine in The Netherlands. Participants: Forty-six children with 
spastic CP (mean age ± standard deviation, 8.0±2.1y). Intervention: The 
intervention group (n=23) was treated with multilevel BTX-A and comprehensive 
rehabilitation. Control group subjects (n=23) continued with their usual physical 
therapy (PT) for 18 to 30 weeks, and then also received multilevel BTX-A and 
comprehensive rehabilitation. Main Outcome Measures: The primary outcome 
measure was the Gross Motor Function Measure (GMFM-66); the secondary 
measures were problem score and energy cost. Results: The treatment effect during 
the first 24 weeks of follow-up in the intervention group was compared with the 
effect of usual PT in the control group. Treatment with multilevel BTX-A and 
comprehensive rehabilitation provided a significantly greater improvement at 12 
and 24 weeks in both the GMFM-66 (2.1 points, P=.02; and 3.5 points, P<.01, 
respectively) and problem score (1.8 and 1.7 points, P<.001, respectively) compared 
with usual PT. No difference was found in energy cost. Before-after analysis of the 
total group (n=46) showed a significant long-term improvement (48wk) on all 
outcome measures. Conclusions: Treatment with multilevel BTX-A and 
comprehensive rehabilitation significantly improves mobility as measured by the 
GMFM-66 and problem score in children with CP.  
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Introduction 
 
Most children with cerebral palsy (CP) have a deviating gait pattern. One of the 
typical patterns is characterized by flexion of the knee during midstance1. These 
children walk either with a crouch pattern2 or with a jump knee pattern2 without 
ever reaching full extension during the midstance. This is often caused by muscle 
imbalance resulting from a combination of spasticity of flexor muscles, weakness of 
extensor muscles, and/or coactivation of both flexor and extensor muscles, which 
may lead to fixed muscle contractures during development. The natural course of 
development in these children is a further deterioration in the flexion pattern3, 
which is generally accompanied by a deterioration in mobility4. Therefore, 
treatment at an early stage is indicated to improve knee extension in gait. A 
comprehensive rehabilitation approach is needed, aimed at both decreasing 
spasticity and improving muscle strength and length.  
Since 19935, injection with botulinum toxin type A (BTX-A) has been used for 
spasticity management in the lower-leg muscles of children with CP. BTX-A is 
injected into the muscle, where it produces a local, dose-dependent, and reversible 
paresis. To improve mobility in children who walk with a flexion pattern, multiple 
muscle groups should be treated in 1 session (multilevel BTX-A). To optimize the 
spasticity reduction induced by BTX-A injections, it has been suggested that the 
muscles should be actively and passively stretched after treatment, based on a 
comprehensive rehabilitation plan of serial casting and optimal orthotics6. 
Additionally, intensive physical therapy (PT) is indicated to improve muscle 
strength and length7. All these treatment options (casting, orthoses, intensive PT) 
can be summarized by the denominator of ‘comprehensive rehabilitation.’  
Although many randomized studies have evaluated the effect of a single-level 
BTX-A injection in the gastrocnemius muscle to improve equinus gait8-11 so far 
there have been only 3 randomized12-14 and 2 nonrandomized6,15 studies that 
exclusively evaluated the effect of multilevel BTX-A injections. Of these studies, 
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only 1 used a control group that received the usual PT13. Moreover, evaluation of 
the primary outcome in these studies6,12,15 was mostly at the level of impairment 
(range of motion, spasticity, gait kinematics), while the main goal of multilevel 
BTX-A treatment is at the level of activity, in particular in the domain of 
mobility16. Improvement in mobility, in particular, is a more long-term treatment 
goal. Therefore, our purpose in this randomized study was to measure the effect on 
mobility of lower-extremity multilevel BTX-A treatment and comprehensive 
rehabilitation on children with CP who walk with flexed knees in midstance up to 
1 year after treatment.  
 
 
Methods 
 
Study population 
Between October 2001 and March 2003, 58 children from 4 Dutch departments of 
rehabilitation medicine were screened for participation in this trial. The screening 
included a standardized medical history and clinical examination, and frontal and 
sagittal plane gait video-recordings with surface electromyography17. Inclusion was 
based on the consensus of 4 participating pediatric physiatrists during a 
teleconsultation session in which the data collected were discussed via high quality 
audiovisual conferencing18. The inclusion and exclusion criteria are listed in 
appendix I. 
Forty-seven of the 58 children were found to be eligible and were enrolled. One 
child, however, withdrew after the first baseline assessment (at the parent’s 
request) and was considered a drop-out. The remaining 46 children participated 
and were analyzed in the study (fig 1). Table 1 summarizes the patients’ personal 
and treatment characteristics.  
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Figure 1: Schematic design of study and study assessments 
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Legend to Figure 1: The duration of baseline for children in th†e control group varied from 18 to 30 weeks. 
NOTE. Negative values for number of weeks before intervention; positive values for number of weeks after 
intervention. Thick black line in the intervention group analysis charts demarks multilevel BTX-A injections and 
comprehensive rehabilitation. *One child in the intervention group and 3 in the control group withdrew from the 
study after week 24 follow-up. They subsequently underwent myotenotomy of the gastrocnemius muscle, 
orthopedic surgery, or selective dorsal rhizotomy, on recommendation of the pediatric physiatrist (JGB).  
 
Table 1: Personal and treatment characteristics of all participating children and 
a subgroup of children completing energy cost measurements  
 Group Energy Cost Subgroup 
Characteristics Intervention 
(n=23) 
Control  
(n=23) 
Intervention 
(n=11) 
Control  
(n=10) 
Sex (boys/girls) 16/7 16/7 6/5 7/3 
Diagnosis (unilateral/bilateral) 3/20 1/22 1/10 0/10 
GMFCS level (I/II/III/IV) 9/3/10/1 9/4/7/3 6/0/5/ND 3/3/4/ND 
Mean age ± SD (y) 8.1±2.3 7.1±2.3 8.3±2.1 7.2±1.1 
    Range 4.2-11.5 4.5-11.0 4.5-10.1 5.7-10.6 
Mean weight ± SD (kg) 26.76±7.63 25.59±8.27 27.00±1.87 24.33±9.88 
    Range 15.00-45.00 13.00-44.00 17.00-45.00 13.00-44.00 
Mean dosage BTX-A ± SD (U) 442.83±132.84 460.00±101.23 471.36±92.74 449.00±98.06 
    Range 180-710 250-600 340-625 330-570 
No. of limbs treated 42 40 20 18 
Target muscle groups,* no. of limbs 
(hst+ps+gc/hst+ps/hst+gc/other) 8/18/9/7 10/14/13/7 4/7/6/3 5/2/9/2 
Orthoses (insoles/AFO) 5/17 2/21 3/7 2/8 
Casting (yes/no) 6/18 11/12 3/7 6/4 
Abbreviations: AFO, ankle-foot orthosis; gc, gastrocnemius; GMFCS, Gross Motor Function Classification System; 
hst, hamstrings; ND, no data; ps, psoas; SD, standard deviation. 
* Most frequently targeted muscles were hamstrings, gastrocnemius, and psoas in varying combinations. Other 
muscles injected were (alone or in combination) rectus femoris, soleus, adductors, and tibialis posterior. 
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Study design and procedure 
The children were randomly assigned to 1 of 2 groups: intervention and control 
(fig 1). An independent statistician (DLK) performed the randomization, using 
computer-generated random blocks of 4 (all permutations of AABB), stratified per 
center. The selection, randomization, and measurement procedures are shown in 
figure 1.  
 
Intervention group 
Children in the intervention group (n=23) were treated with multilevel BTX-A 
injections and comprehensive rehabilitation. This group had 2 assessments during 
a 6-week baseline period and 4 follow-up measurements, at 6, 12, 24, and 48 weeks 
after treatment.  
 
Control group 
Children in the control group (n=23) continued with their usual PT (low 
intensity, 1−2 sessions of 30−60min a week, some used orthoses) for a period of 18 
to 30 weeks. They were assessed every 6 weeks. After this baseline period, the 
controls were also treated with multilevel BTX-A injections and comprehensive 
rehabilitation, with a follow-up at 6, 12, 24, and 48 weeks after treatment.  
 
Multilevel BTX-A injections and comprehensive rehabilitation 
During the teleconsultation, a consent treatment plan was formulated for each 
child regardless of his/her group randomization; the plan included target muscle 
identification, calculation of injection dose, need for serial casting, and prescription 
of ankle-foot orthoses (AFOs). Possible target muscles were the psoas, mediolateral 
hamstrings, hip adductors, rectus femoris, gastrocnemius, soleus, and tibialis 
posterior. The principles of multilevel surgery were applied in the selection of 
target muscles, based on the result of gait analysis and clinical examination19. The 
injections were given with the subjects under general anesthesia, in at least 2 sites 
per muscle belly, to a maximum of 50U per site, with a dosage of 4 to 6U/kg of body 
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weight of BTX-A (Botox) per muscle group. A maximum total dose was set at 
25U/kg of body weight for children 5 years or younger, and 30U/kg of body weight 
for children 6 or more years old, with a maximum recommended dose of 600U. We 
used a dilution of 50U in 1mL of 0.9% NaCl solution. Injection sites were 
determined by palpation of the muscle belly, and needle placement was verified by 
either stretching or electric stimulation of the muscle.  
Beginning 1 week after the multilevel BTX-A injections, each child was treated 3 
to 5 times a week for 12 weeks by a physiotherapist, according to a standardized 
treatment protocol. Each session lasted 45 to 60 minutes, and the treatment 
consisted of stretching the flexor muscles, training to strengthen the extensor 
muscles, and functional mobility training. If the passive ankle dorsiflexion with 
extended knee measured during screening was less than 0°, serial casting was 
initiated 1 to 3 weeks after the injection. Bilateral below-knee walking casts were 
applied and changed every week until 0° or more of dorsiflexion was achieved. Stiff 
insoles or AFOs were prescribed to support full knee-extension in terminal stance.  
 
Outcome measures 
The primary outcome measure was the Gross Motor Function Measure (GMFM), 
a standardized observational instrument that requires a child to demonstrate 
various motor skills, as outlined in the GMFM administration and scoring 
guidelines. Consequently, it reports a child’s actual ability level. In this study, we 
used the 66-item version of the GMFM (GMFM-66), an internationally recognized 
valid and reliable objective outcome measure, based on interval scaling20.  
Our first secondary outcome measure was the gross energy cost of walking. 
Energy cost21 (in J·kg−1·m−1) was determined by measuring oxygen uptake and 
carbon dioxide production with a portable gas analyzing systema during a 6-minute 
walk at a comfortable self-selected speed. Oxygen uptake was converted to joules 
and expressed relative to walking speed (in m/min) and body mass (in kilograms)21. 
Mean steady-state values during the last 60 seconds were used for analysis. This 
test was performed in a subgroup (n=24) in 1 center only.  
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Another secondary outcome measure was a parent self-reported problem score, 
which recorded the 3 main problems related to lower-extremity mobility tasks 
experienced by their child. We used a semi-structured interview method and a 
standardized set of examples. Each problem was rated by the parent in terms of 
difficulty of performance on an 11-point scale (0 [no problem] to 10 [major 
problem]).  
The GMFM-66 and energy costs were assessed during all baseline and follow-up 
measurements in both groups. At baseline, the problem score was assessed once in 
the intervention group and twice in the control group and at all follow-up visits. 
The children were assessed and treated in their own recruitment center. It was not 
possible to blind the observers for treatment group—the groups were transparent 
because of their different number of assessments. All observers were certified to 
administer the GMFM-66 and were fully trained to perform all the assessments. 
Moreover, to reduce testing bias in the subjective prediction of change in one of the 
outcome measures, the observers never reviewed any previous test values.  
Based on the GMFM-66, this study had a power of 71% (47 subjects were initially 
enrolled) to detect a mean change of 1.6 points between the groups, with a 2.2-
point standard deviation (SD) on GMFM-66 scores. This mean change of 1.6 points 
on the GMFM-66 could be considered a clinically meaningful change of motor 
function22.  
Approval for the study was obtained from the Medical Ethics Committee of the 
VU University Medical Center in Amsterdam and full written informed consent 
was obtained from all parents and children 12 years of age or older before 
enrolment.  
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Statistical analysis 
 
Group characteristics were tested for differences with the Student t test 
(continuous data) or the chi-square test (dichotomous or ordinal data). We used 2 
types of analysis to study the treatment effect. The strongest level of evidence was 
given by the trial analysis, in which the effect in the intervention group (−6wk 
before to 24wk after treatment) was compared with the usual PT effect in the 
control group (−30wk to −1wk before treatment). Additionally, using secondary 
before-after analysis, the long-term effect at 48 weeks after treatment was 
compared with before-treatment (−6 and −1wk) values. For these analyses, the full 
follow-up term of the total population (intervention group plus control group) was 
used. To identify characteristics of the children who might have responded 
differently to treatment, subgroup analysis were performed for the level of 
functioning classified with the Gross Motor Function Classification System 
(GMFCS)23 and age (<7y, ≥7y), also in the total population.  
All differences in effect were analyzed in a linear mixed-model analysis24,b which 
estimated the treatment effect on the different outcome measures while adjusting 
for dependency of repeated observations in each subject. The factor ‘center’ was 
considered in all statistical analyses. An independent statistician (DLK) and the 
principal investigator (VAS) performed all analyses. The level of statistical 
significance was set at P less than .05, which was adjusted in the subgroup 
analysis through Bonferroni adjustment. All P values were 2-sided.  
 
 
Results 
 
The mean baseline period from the first baseline assessment until the time of 
treatment ± SD was 5.8±1.0 weeks in the intervention group (range, 4−8wk) and 
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23.6±6.8 weeks in the control group (range, 10−35wk). The groups did not differ 
with regard to personal characteristics (see table 1).  
Each patient was treated with multilevel BTX-A in at least 1 limb. A mean dose 
of 18.01±4.74U/kg of body weight was injected, ranging from 5.63 to 27.14U/kg of 
body weight.  
 
Trial analysis 
For all outcome measures the estimated mean difference between the 2 groups in 
change from initial baseline and the 95% confidence intervals (CIs) are shown in 
table 2 (see Trial Analysis).  
A significant treatment effect on the GMFM-66 was found 12 and 24 weeks after 
treatment in the intervention group (fig 2A). On the energy cost test, 2 children 
with GMFCS level IV (control group) did not reach a steady state of oxygen uptake 
during walking. Another child was afraid of the mask, which made testing 
impossible (control group). These 3 were excluded from the analysis. Group 
characteristics of the remaining 21 children are presented in table 1. No significant 
treatment effect was found in energy cost (see fig 2B). On the problem score, the 
parents reported a total of 40 different problems involving balance (unaided 
standing, unaided walking, getting on or off a bicycle), falling or tripping, walking 
(walking longer distances, walking indoors or outdoors, walking with bare feet, 
climbing stairs, walking on uneven surfaces, walking in a supermarket), transfers 
(getting in or out of a car, rising from the ground unaided), running, and playing 
(jumping a rope, kicking a ball). A significant treatment effect on problem score 
was found in the intervention group 12 and 24 weeks after treatment (see fig 2C).  
 
Before-after analysis: long-term effect 
The last values assessed in both groups before treatment (mean of −6 and −1 week 
for the GMFM-66 and energy cost, −1 week for the problem score, respectively) 
were used as baseline values to compare the long-term effect (48 wk) for the total 
group (n=46). These are presented in table 2 (see Baseline Values). No significant  
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Table 2: Three types of results: last baseline values for the intervention group 
(n=23) and control group (n=23); trial analysis of estimated mean difference 
between the 2 groups in change from initial baseline; and before-after analysis 
for estimated mean long-term change from baseline for the total group (n=46)  
 Baseline Values* Trial Analysis  Before-After Analysis  
Outcome Intervention 
Group 
Control 
Group 
Estimated Mean 
Difference in Change† 
P‡ Estimated Mean 
Long-Term Change 
P‡ 
GMFM-66 (0-100)       
 Baseline 67.91 ± 15.39 65.90 ± 11.37     
 Week +6§   −0.77 (−3.07 to 1.52) .50 −0.83 (−1.93 to 0.26) .13 
 Week +12   2.07 (0.31 to 3.83) .02 1.43 (0.69 to 2.17) <.001 
 Week +24   3.48 (1.34 to 5.61) .002 2.07 (0.96 to 3.18) <.001 
 Week +48     2.26 (1.29 to 3.22) <.001 
Energy cost (J·kg−1·m−1)║       
 Baseline 11.61 ± 6.57 10.77 ± 3.13     
 Week +6   −0.88 (−2.75 to 0.99) .35 0.26 (−0.46 to 0.98) .46 
 Week +12   0.50 (−1.37 to 2.38) .59 −0.07 (−1.40 to 1.26) .91 
 Week +24   0.31 (−1.58 to 2.21) .74 −0.90 (−1.59 to −0.20) .01 
 Week +48     −1.78 (−2.64 to −0.92) <.001 
Problem score (0-10)       
 Baseline 7.81 ± 1.66 8.25 ± 1.51     
 Week +6   −0.70 (−1.44 to 0.04) .07 −0.85 (−1.53 to −0.17) .02 
 Week +12   −1.78 (−2.62 to −0.93) <.001 −1.83 (−2.54 to −1.11) <.001 
 Week +24   −1.65 (−2.81 to −0.48) <.001 −1.90 (−2.54 to −1.27) <.001 
 Week +48     −1.40 (−2.04 to −0.76) <.001 
NOTE. Values are mean ± SD or mean (95% CI). For GMFM-66 a positive value indicates improvement; for energy 
cost and problem score a negative value indicates improvement. * Mean of -6 and -1 week for the GMFM-66 and 
energy cost, and -1 week for the problem score, respectively. 
† Corrected for baseline differences. ‡ P values with linear mixed-model analysis, models are adjusted for center. 
§ The positive values indicate the number of weeks after intervention.║Energy cost only presented for subgroup; 
in the before-after analysis 1 additional patient was left out of the analysis. 
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differences were found. The results of these before-after analyses are also 
presented in table 2 (see Before-after Analysis), showing estimated mean changes 
from this baseline for the total group and 95% CIs at 48 weeks after treatment. 
Significant improvements were found in all outcome measures, GMFM-66, energy 
cost, and problem score, at 48 weeks after treatment.  
  
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Estimated marginal means and standard 
errors of (A) GMFM-66, (B) energy cost (only presented for 
subgroup), and (C) problem scores on different study visits 
(6-wk intervals): trial analysis for intervention group (n=23) 
and control group (n=23). NOTE. Energy cost is in J·kg−1·m−1. 
Numbers on the x axis represent, for the intervention and 
control group, respectively: 1 (week −6, week −30); 2 (week 
−1, week −24); 3 (week +6, week −18); 4 (week +12, week 
−12); 5 (no assessment, week −6); and 6 (week +24, week 
−1). A dashed line demarks the multilevel BTX-A injections 
and comprehensive rehabilitation in the intervention group. 
*Significant difference in change between the intervention 
group and the control group, corrected for baseline 
differences (P<.05).  
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 Before-after analysis: subgroup effect 
Subgroup analysis showed that the energy cost in children with GMFCS level III 
was improved significantly more 48 weeks after treatment, compared with children 
with GMFCS levels I and II (see fig 3B). For the other outcome measures, no 
significant differences in effects were found for different GMFCS levels (see figs 
3A, C) or age subgroups (results not presented).  
Figure 3. Estimated marginal means and standard 
errors of (A) GMFM-66, (B) energy cost (only presented 
for subgroup), and (C) problem scores on different study 
visits (6-wk intervals): before-after analysis in the total 
group (n=46) for subgroups based on GMFCS. NOTE. 
Energy cost is in J·kg−1·m−1. Numbers on the x axis 
represent: 1 (week −6); 2 (week −1); 3 (week +6); 4 (w
+12); 5 (no assessment); 6 (week +24); 7 to 9 (no 
assessment); and 10 (week +48). A dashed line demarks 
multilevel BTX-A injections and comprehensive 
rehabilitation in the total group (n=46). *Significant 
difference in change between the GMFCS levels, 
corrected for baseline differences (P<.05).  
eek 
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Discussion 
 
In this randomized clinical trial, we evaluated the effect of treatment with 
multilevel BTX-A and comprehensive rehabilitation on the mobility of children 
with CP who were walking with flexion of the knee in midstance.  
In the trial analysis, we found that multilevel BTX-A given in combination with 
comprehensive rehabilitation significantly improved gross motor function. In 
addition, parents of the patients reported a significant improvement in the 
perceived difficulty of individually selected mobility tasks. We found no evidence, 
however, of a treatment effect on the energy cost of walking.  
The improvement on the GMFM-66 (3.5 points) found at 24 weeks after 
treatment was a small, but significant, treatment effect. In the literature, the 
reported change over 1 year in children more than 5 years of age who received 
usual care was less than 1 point on the GMFM-6620. Recently, it was shown that a 
change score of 1.6 points is clinically meaningful, and a change score of 3.7 points 
discriminates moderate or no improvement from a great improvement22. Relative 
to these changes, we believe that our results indicate a clinically meaningful 
improvement in gross motor function. The secondary before-after analysis also 
indicates that long-term effects (>1y) on gross motor function can be expected, but 
this needs to be confirmed in a randomized controlled trial.  
One other randomized study13 also evaluated multilevel BTX-A with the GMFM 
and found no significant difference between the multilevel BTX-A group and the 
group continuing with regular (nonintensive) PT. This study had a crossover 
design that evaluated the effects over a period of 6 months. Because we showed 
that an effect 1 year after treatment can still be expected, a 6-month period might 
have been too short. Other randomized studies8-11 failed to show any significant 
treatment effect of single level BTX-A injections without intensified PT on the 
GMFM in children walking with equinus. Our results might suggest that the 
combined effect of multilevel BTX-A treatment and comprehensive rehabilitation 
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could be more effective in improving gross motor function than multilevel BTX-A 
alone. This is speculative, however, and can only be confirmed in a randomized 
trial that compares multilevel BTX-A alone to multilevel BTX-A and 
comprehensive rehabilitation.  
Some authors14,25 advise that multilevel BTX-A injections should only be given to 
children up to 7 years old. The results of our subgroup analysis, however, showed 
no difference in treatment effects between children of a minimum age of 7 and 
younger children.  
Although the children in this study were selected on the basis of an energy-
inefficient gait pattern of knee flexion26, we found no treatment effect on energy 
cost in the trial analysis. The small number of patients available for energy cost 
analysis might have influenced this. Nevertheless, the estimated mean changes at 
these different follow-ups were all less than 10%, which also does not seem 
clinically relevant. Secondary before-after analysis showed an improvement of 
more than 10% at 48 weeks, which was significant. Without the use of a control 
group, however, the study power of this analysis was 56%, which therefore limits 
the interpretation of these findings. In the long-term, children who used walking 
aids (GMFCS level III) improved significantly more than did children walking 
without aids (GMFCS levels I and II). As shown in figure 2B, this may be because 
children with GMFCS III, with a baseline energy cost twice as high as children 
with GMFCS level I, have more scope to improve. Children in the latter group 
seem to be nonresponsive to change in energy cost because their energy cost is 
already low, although it is higher than that of healthy children.  
A significant treatment effect was seen on the problem score at 12 and 24 weeks. 
Compared with other reports, where the clinically relevant change was set at 10% 
of the total range of the scale9, our results indicate a clinically relevant change. 
Problems frequently mentioned by parents were (1) falling and tripping during 
walking, (2) limited duration of walking, and (3) problems with balance. Although 
the problem score is self-developed and not validated, it may reveal benefits 
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associated with the parents’ subjective experience of improvement in a child’s 
mobility.  
We also found a long-term improvement on the problem score at 48 weeks after 
treatment. All children continued with their usual PT after the period of intensive 
PT (12wk), with the same intensity as before the multilevel BTX-A injections; only 
1 child was re-treated with a BTX-A injection and only in the rectus femoris muscle 
(at 30wk after treatment, without comprehensive rehabilitation), and none had 
serial casting again. Therefore, the long-term effects found in this study on all 
outcome measures might suggest that combined treatment of multilevel BTX-A 
and comprehensive rehabilitation can result in an overall long-term improvement 
in mobility, even 1 year after treatment. This should be confirmed in a randomized 
controlled study, however.  
 
Study limitations 
General shortcomings of this study were the use of multiple assessors 
(multicenter trial), the lack of assessor blinding, and the varying duration of 
baseline in the control group. To standardize the treatment and assessment 
methods, training sessions were organized before the study. All assessors also 
attended the GMFM course and passed its criterion test. A varying baseline for the 
control group was necessary because we had to strike a balance between what was 
scientifically desirable, practically obtainable, and clinically needed: if treatment 
was planned during the holidays, or a child complained of pain, the physician 
decided to schedule multilevel BTX-A treatment earlier. A period of 18 weeks was 
therefore set as a minimum in the control group. Using the linear mixed-model 
analysis, we adjusted for any missing visits during the study24. It is not clear 
whether the varying baseline influenced our results. Although all control children 
were scheduled to receive multilevel BTX-A treatment and comprehensive 
rehabilitation, we found stable baseline values for all outcome measures. If the 
baseline period had been 30 weeks for all children (including the ones who 
complained of pain), it would seem reasonable to expect stable values as well, or 
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even slightly deteriorating baseline values rather than improved ones, leading to 
similar or even greater treatment effects.  
We selected children with a flexion gait pattern for treatment. This pattern is 
caused by an imbalance of flexor and extensor muscle activity, which necessitated 
the application of a comprehensive treatment program. We chose the effect of the 
total program as the subject for this study, rather than the contribution of each 
component (multilevel BTX-A, intensive PT, serial casting and orthoses); therefore, 
we do not know, for example, how much of the effect is specifically contributable to 
the multilevel BTX-A injections alone, or to the intensive PT. Because the optimal 
combination of these factors is not known, the contribution of each of the 
components of the treatment program must be assessed in future research.  
The main focus of this study was on the level of mobility, because this is the main 
and final goal of the BTX-A and rehabilitation treatment. Effect of the treatment 
on technical outcome measures was outside the scope of this study. We are 
currently preparing a second report that will discuss the effect of multilevel BTX-A 
and comprehensive rehabilitation on video-based gait analysis, range of motion as 
a measure of muscle length, and spasticity.  
 
 
Conclusions 
 
Combined treatment with multilevel BTX-A and comprehensive rehabilitation is 
an effective treatment modality that leads to clinically relevant improvements in 
gross motor function and self-reported mobility tasks in children who walk with 
flexion of the knees. We found no accompanying change in energy cost of walking.  
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Appendix I: Inclusion and Exclusion Criteria  
 
Inclusion criteria Exclusion criteria 
Diagnosis of CP 
Spastic hemiplegia or diplegia (according to Hagberg27) 
Age between 4 and 12y 
Spasticity* in 2 or more lower-extremity muscle groups 
interfering with mobility 
GMFCS levels I to IV 
Gait characterized by persistent flexion of the knee 
(≥10°) in mid-stance (barefoot or with AFOs/shoes) 
Two or more muscle groups in 1 limb needing BTX-A 
injection 
Ability to carry out instructions 
Adequate knowledge of the Dutch language 
BTX-A treatment in lower extremities within 16 
weeks before inclusion 
Orthopedic surgery 24 weeks before inclusion 
Contraindication for BTX-A 
Contraindication for general anesthesia 
Orthopedic deformities that have a bad influence on 
walking 
     - (Sub)luxation of the hip with an MI >50° 
     - Hip endorotation contracture >15° 
     - Flexion contracture of knee >15° 
Severe fixed contractures: 
 Age <8y 
     - Ankle plantarflexion with knee extended >20°† 
     - Popliteal angle >90° 
 Age ≥8y 
     - Ankle plantarflexion with knee extended >15°† 
     - Popliteal angle >80° 
Presence of ataxia or dyskinesia 
Other problems that have a negative influence on 
walking 
Abbreviations: AFOs, ankle-foot orthoses, GMFCS, Gross Motor Function Classification System; MI, migration 
index28. 
* Spasticity was defined during clinical examination as the occurrence of a ‘catch’ (sudden increase in muscle 
tone) somewhere before the end of the range of motion in response to a fast passive stretch (in hamstrings, 
adductor, rectus femoris, gastrocnemius, and soleus muscles). 
† From neutral. 
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Abstract 
 
This study evaluates whether the in literature reported potential predictors can 
predict the outcome of multilevel BTX-A injections in children who walk with a 
flexed knee. Forty-six children with spastic CP, aged between 4 and 12 years, 
participated in this study. Multiple linear regression analysis was applied to study 
the associations between 11 predictors and 2 different outcome measures (the 
Gross Motor Function Measure [GMFM66] and knee angle at midstance) at 6, 12, 
24 and 48 weeks of follow-up. Each model was adjusted for the outcome score or 
value at baseline. 
Only age was found positively associated with change in the GMFM66 at 12 
weeks follow-up, and only ankle angle at midstance was found positively associated 
with change in knee angle at midstance at 48 weeks follow-up. Of these, only the 
former association was found to be clinically relevant. Furthermore, the baseline 
GMFM66 score was negatively associated with change in GMFM66 at 6 weeks but 
not at the other follow-up measurements. The baseline knee angle at midstance 
was negatively associated with change in knee angle at midstance at 6 and 48 
weeks follow-up, but not at 24 weeks.  
This study shows that the majority of potential predictors do not predict the 
outcome of multilevel BTX-A injections and comprehensive rehabilitation in 
children who walk with a flexed knee pattern. The only relevant significant 
predictor for favourable responses in this patient group, with regard to gross motor 
function, is older age.  
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Introduction  
 
In children with cerebral palsy (CP), gait and mobility problems are very 
common1, 2. In recent years, several studies have shown the ameliorating effect of 
botulinum toxin A (BTX-A) injections in gait and mobility after injection of the M. 
Triceps Surae in children walking in equinus3-5. Our study group recently found in 
a randomised clinical trial that, in children who walk with a flexed knee pattern, 
multilevel BTX-A injections (different muscles acting over different joints injected 
in one session) combined with comprehensive rehabilitation leads to a significant 
improvement in knee extension at midstance after 6 weeks (increase of 7°, 
p<0.01)6, and to a significant improvement in gross motor function, measured with 
the Gross Motor Function Measure (GMFM66), after 12 weeks (increase of 
2.1points, p=0.02), which continued until 24 weeks (increase of 3.5points, p<0.01)7.  
However, not all treated children are found to be response to BTX-A treatment8. 
Various factors are suggested to be predictive of a good response. For patients with 
equinus gait, these are often described as: young age, mild to moderate severity of 
motor involvement (classificed according to the Gross Motor Function 
Classification System [GMFCS]9) and the absence of fixed contractures (e.g. no 
limited range of motion [ROM])10, 11. Although the scientific evidence for these 
potential predictors is only limited, clinicians often use these as indication criteria, 
to serve as a guiding principle for the choice of treatment11-13. As a consequence, 
children who do not meet these criteria (e.g. older children, with less severe 
involvement, and fixed contracture) might therefore not be selected for treatment. 
Recently, two studies focused on the evaluation of predictors of a good response 
on BTX-A treatment in children with CP14, 15. Besides the earlier suggested factors 
(age, severity of motor involvement, ROM), they also evaluated gender, spasticity 
(rated on the Ashworth Scale16), localisation of the motor disorder, level of motor 
function (measured with the GMFM17). It was found that differt factors were 
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related to different types of outcome: spasticity, level of motor function, and 
ambulation status were related to the parent’s experienced improvement14; age 
was related to the outcome on the GMFM15; and localisation was related to 
outcome on selective motor control15 and gait pattern15. This might indicate that 
none of these factors can be regarded as a true predictor. Furthermore, it is 
noteworthy that severity of motor involvement and ROM were not found to be 
predictive for any of the outcome measures14, 15, despite their suggested 
potentiality10.  
The former two studies only included children walking with equinus. Since these 
children may differ in various characteristics from children walking with flexed 
knee gait, it is possible that different factors might be predictive of a good response 
on multilevel BTX-A treatment. However, no study has yet identified possible 
predictors in children who walk with a flexed knee pattern who were treated with 
multilevel BTX-A injections to improve gross motor function and gait pattern.  
The aim of the present study was therefore to describe the number of responders 
to multilevel BTX-A treatment and to evaluate whether the in literature suggested 
factors are predictive of a favourable outcome on gross motor function and knee 
angle at midstance after multilevel BTX-A treatment, in children walking with 
flexed knee gait.  
 
Methods 
 
Participants  
From October 2001 to March 2003, 58 children were screened for this multicenter 
trial in four Dutch departments of rehabilitation medicine, and 46 children were 
included in the study. The main inclusion criteria were: aged between 4 and 12 
years, ability to walk with/without a walking aid (GMFCS9 I-IV), gait 
characterized by persistent flexion of the knee (≥10°) in midstance. Children with 
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severe contractures were excluded (see Scholtes et al.6, 7 for exact inclusion and 
exclusion criteria).   
 
Design 
All were participants in a randomised clinical trial to evaluate the effect of 
multilevel BTX-A and comprehensive rehabilitation in children with CP. All 46 
children were treated with multilevel BTX-A injections (BOTOX®, Allergan, 
Nieuwegein, the Netherlands) under general anesthesia, followed by 
comprehensive rehabilitation (standarized physical therapy; serial casting; and/or 
new orthosis) (see Scholtes et al.6, 7 for a more detailed description of the study).   
The study protocol was approved by the Medical Ethics Committee of the VU 
University Medical Center in Amsterdam. Full written informed consent was 
obtained from all parents, and also from 12 year-old children, prior to enrolment.  
 
 
Measurements  
 
Outcome measures 
The two outcome measures were gross motor function (measured with the 
GMFM17) and the knee angle at midstance during gait. The GMFM was assessed 
by trained and certified examiners at 6 weeks before treatment and at 6, 12, 24 
and 48 weeks after treatment (barefoot, without a walking aid). We used the 66 
item version of the GMFM (GMFM66), which is a standardized observational 
instrument based on interval scaling17, that requires the child to demonstrate 
various motor skills as outlined in the GMFM administration and scoring 
guidelines.  
2-D gait analysis was performed with the child walking barefoot (with or without 
a walking aid) on a 10 metre pathway at 6 weeks before treatment and at 6, 24 and 
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48 weeks after treatment. The videorecordings were randomly assessed by a 
blinded research assistant, from which the sagittal knee angles at midstance (in 
degrees) were measured using a digital screen goniometer. The mean (right and 
left) knee angle at midstance was used as the outcome measure. 
 
Predictors 
All variables that have been described as potential predictors in literature were 
included (see Table 1). The variables were derived from medical history (personal 
and disease characteristics), physical examination (motor impairments) gait 
analysis (motor impairments), and GMFM66 assessment (motor function) that was 
taken from each patient at baseline.  
 
 
Statistics 
 
All analysis were performed in SPSS (11.5) for Windows. To describe the number 
of responders to  the treatment on the two different outcome measures, three 
categories of responders were used: ‘good’ (GMFM: ≥ +1.6 points18; knee angle: ≥ 
+5° [towards extension]), ‘non’ (GMFM: >+1.6 and < +1.6 points; knee angle: > +5° 
and <+5°) and ‘bad’ (GMFM: ≤ +1.6 points; knee angle: ≤ +5° [towards flexion]). For 
this purpose, the individual changes in the GMFM66 and the knee angle at 
midstance were calculated for each patient by subtracting the baseline value from 
the value at each follow-up measurement. For both outcomes, a positive change 
indicates a favourable response.  
Linear regression analysis was then used to identify the potential predictors for 
outcome on the GMFM66 and knee angle at midstance. First, each of the potential 
predictors presented in Table 1 was included in the model, one by one, for each 
outcome measure. All models were adjusted for their corresponding score at 
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baseline (i.e. GMFM66 score, or knee angle at midstance). Then, only the potential 
predictors that showed a univariate association with p < 0.10 were selected and 
entered simultaneously in a final linear (multivariate) regression analysis. 
Separate models were built for the different follow-up assessments: 6 weeks, 12 
weeks, 24 weeks, and 48 weeks. 
 
 
Results  
 
Study population and baseline characteristics 
Four children withdrew from the study after the 24th week of follow-up, and 
underwent myotenotomy of the gastrocnemius muscle, orthopedic surgery or 
selective dorsal rhizotomy on the recommendation of the pediatric physiatrist (JB). 
Therefore, at week 48, only 42 children were assessed. The personal and treatment 
characteristics of the children are summarised in Table 1. 
 
The mean ROM of the hamstrings (64.1°) and gastrocnemius (1.6°) muscle 
indicate that these muscles are shortened in this study population, compared to 
the normal ROM19. There was spasticity in the hamstrings and the gastrocnemius 
muscles. The children walked with a mean knee flexion at midstance of 24.2° (SD 
12.4), and with a mean ankle flexion at midstance of -5.6˚ (SD 22.5), which 
indicates mild plantar flexion. The high standard deviation of the ankle flexion at 
midstance indicates that there were also children who walked with ankle 
dorsiflexion.  
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Table 1: Characteristics of the study population (n = 46) 
Characteristics  Predictors 
Medical history: personal and disease characteristics   
Gender (boy: girl)  32:14  
Age, year 8.0 (2.1)  
Weight, kg 26.2 (7.9)  
Severity of motor involvement according to the GMFCS (I: II: III: IV)  18:7:17:4 * 
Localisation of the motor disorder (unilateral: bilateral) 4:42  
 
 
Treatment   
Dosage BTX-A, U/kg 18.0 (4.7)  
Serial casting, n 17  
Orthoses  n 45 
 
 
Baseline values: motor impairments and motor function   
Range of motion (ROM)† °        hamstrings   64.1 (13.5)  
                                                    gastrocnemius   1.6 (8.2)  
Spasticity† °                                hamstrings  78.0 (17.4)  
                                                    gastrocnemius  -16.6 (12.3)  
Gait kinematics‡ °                      knee angle at midstance  -24.2 (12.4)  
                                                    ankle angle at midstance   -5.6 (22.5)  
Functional muscle strength§       squat test (unable:able)  12:32  
Level of motor function              GMFM66  66.8 (13.4)  
Data are mean (SD); BTX-A = botulinum toxin type A. *Dummies were used for levels I to IV, the reference 
category was GMFCS I; †ROM and spasticity were assessed with the (relaxed) child lying on an examination 
couch, with head in midline and arms in an anatomically neutral position. Spasticity was defined as the 
occurrence of a ‘catch’ (sudden increase in muscle tone) somewhere before the end of the range of motion in 
response to a fast passive stretch. ‡Means of right and left leg. §Measured with the squat-test: the child stands 
in front of the observer, hands may be held for balance, with both feet a shoulder width apart; the child is asked 
to squat down towards the floor and subsequently stand up again (sitting or touching the floor with buttocks is 
not allowed) 8 times, or until the child is fatigued (score: unable [<8x] or able [≥ 8x]). 
144 
Predictors of multilevel BTX-A and comprehensive rehabilation 
 
Good, non and bad responders 
Table 2 describes the different categories of responders on the GMFM66 and the 
knee angle at midstance and their mean change at the different follow-up 
measurements. The GMFM66 was not assessed in one child at 6 weeks after 
treatment, and gait-analysis was not performed for one child at 48 weeks after 
treatment. The results show that on both outcome measures,  
 
Table 2: Descriptives of good, non and bad responders on GMFM66 and knee 
angle at midstance at different follow-up measurements after treatment (in 
numbers and percentages) 
  GMFM66  knee angle at midstance (°) 
  n (%) mean ∆ (SD) range ∆ 
 
 n (%) mean ∆ (SD) range ∆ 
 
Week 6 good 10 (22)  3.0 (1.3) 1.6 : 5.6  26 (57) 11.7 (5.7) 5.0 : 25.0 
 non 23 (50)  0.1 (0.8) -1.59 :  1.35  18 (39)   0.9 (3.1) -4.0 : 4.5 
 bad 12 (28) -5.7 (3.4) -11.33 : -1.83   2 (3) -17.0 (2.1) -18.5 : -15.5 
Week 12 good 21 (46)  3.5 (1.7) 1.6 : 8.0  n.a. n.a. n.a. 
 non 22 (48)  0.1 (1.0) -1.6 : 1.6  n.a. n.a. n.a. 
 bad   3 (6) -3.4 (1.7) -5.3 : -2.2  n.a. n.a. n.a. 
Week 24 good 22 (48)  4.9 (3.5) 1.6 : 14.5  15 (33)  10.0 (4.5) 5.0 : 21.5 
 non 21 (46) -0.1 (1.0) -1.6 : 1.2  21 (47)   0.6 (2.2) -2.5 : 4.5 
 bad  3 (7) -3.3 (1.5) -5.0 : -2.2   9 (20)  -8.2 (4.2) -18.5 : -5.5 
Week 48 good 23 (55)   4.5 (2.8) 1.8 : 14.5   8 (19) 12.2 (4.9) 5.0 : 20.5 
 non 16 (38) 0.1 (1.0) -1.6 : 1.6  30 (71)   0.0 (3.0) -4.5 : 4.5 
 bad  3 (7) -2.2 (0.7) -3.0 : -1.6   4 (10) -16.8 (5.8) -24.0 : -12.0 
∆=change from baseline; n.a. = no assessment 
 
145 
Chapter 6 
there were children who improved, but also children who remained stable, or who 
even deteriorated. The greatest good response on the knee angle at midstance was 
found at 6 weeks after treatment (good responders: 57%). The effect decreased to 
19% in good responders after 48 weeks. In contrast, only 22% of the children were 
good responders on the GMFM66 after 6 weeks; this increased to 46% after 12 
weeks, and continued to increase up to 55% after 48 weeks. Remarkable is the 
overall large group of non-responders on both outcomes, which varied around 50% 
at most follow-up measurements.  
 
Predictors of GMFM66 
Table 3 shows the results of the final (multiple) regression analysis. At 12 weeks 
after treatment, only age was positively associated with change in GMFM66 
(regression coefficient 0.38), indication that the treatment had a better effect on 
older children: one year increase in age results in 0.38 point increase in GMFM66. 
The baseline score showed a significant negative association (regression coefficient 
-0.10) with the short term (6 weeks) change in GMFM66, indicating that children 
with a lower level of motor function showed more improvement on the GMFM66. 
No significant predictors were found for 24 and 48 weeks after treatment. The 
multiple regression analysis explained 21% and 19% of the variance of change in 
GMFM66 score at 6 and 12 weeks, respectively. 
 
Predictors of knee angle at midstance  
Table 3 also shows the results of the final (multiple) regression analysis. The 
baseline knee angle at midstance showed a significant negative association with 
the change in the angle at midstance at 6 weeks (regression coefficient -0.26) and 
at 48 weeks (regression coefficient 
-0.32), indicating that children with more knee flexion at baseline showed more 
improvement on the knee angle at midstance. At 48 weeks, only the ankle angle at 
midstance was positively associated in such a way that the treatment had a better 
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effect in children who walk with more ankle (dorsi)flexion at midstance: an 
increase of 1° in ankle (dorsi)flexion resulted in 0.21° increase in knee angle at 
midstance. The multiple regression analysis at week 48 explained 36% of the 
variance of change in the knee angle at midstance. 
 
Table 3: Results of (multiple) regression analysis* on change in GMFM66: 
(multiple) regression coefficients (B) and 95% confidence interval for each 
predictor at different follow-up measurements 
Dependent variable  Follow up B Predictor 95% CI p-value R2
∆ GMFM66  week 6  5.53 Intercept 0.34 : 10.72 0.037 21.2% 
  -0.10 GMFM66 score at baseline -0.17 : -0.02 0.013  
  0.12 ROM gastrocnemius -0.01 : 0.24 0.063  
       
 week 12 -2.71 Intercept -6.61 : 1.18  0.167 19.2% 
  0.02 GMFM66 score at baseline -0.04 : 0.07 0.510  
  0.38 Age 0.02 : 0.74 0.041  
  0.07 ROM gastrocnemius -0.01 : 0.16 0.097  
       
 week 24 -2.89 Intercept -8.45 : 2.67  0.300 7.1% 
  0.07 GMFM66 score at baseline -0.01 : 0.16 0.073  
       
 week 48 -1.59 Intercept -6.61 : 3.43 0.526 6.2% 
   0.06 GMFM66 score at baseline -0.01 : 0.13  0.111  
B=regression parameter; CI = Confidence Interval; ∆ = change from baseline; R2 = R-square (the proportion of 
explained total variance explained by the final model) 
* only those predictors that were correlated significantly (p < 0. 05) or showed a trend for correlation (p<0.10) 
with the mean change in GMFM66 (corrected for GMFM66 score at baseline) are included in the model 
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Table 4: Results of (multiple) regression analysis* on change in sagittal knee 
angle at midstance: (multiple) regression coefficients (B) and 95% confidence 
interval for each predictor at different follow-up measurement points 
Dependent variable  Follow up B Predictor 95% CI p-value R2
∆ knee angle at midstance  week 6  0.04 Intercept -5.27: 5.36 0.987 13.5% 
  -0.26 knee angle at midstance at baseline -0.45 : -0.06 0.012  
       
 week 24 -0.27 Intercept -5.21 : 4.67 0.913 2.4% 
  -0.09 knee angle at midstance at baseline -0.27 : 0.09 0.307  
       
 week 48 -5.50 Intercept -10.82 : -0.18 0.043 36.1% 
  -0.32 knee angle at midstance at baseline -0.52 : -0.12 0.003  
   0.21 ankle angle at midstance at baseline  0.00 : 0.43 0.050  
  -6.71 GMFCS 2 -13.70 : 0.29 0.060  
  1.60 GMFCS 3 -3.83 : 7.03 0.554  
  -4.14 GMFCS 4 -13.50 : 5.21 0.375  
B=regression parameter; CI = Confidence Interval; ∆ = change from baseline; R2 = R-square (the proportion of 
explained total variance explained by the final model) 
* only those predictors that were correlated significantly (p < 0. 05) or showed a trend for correlation (p<0.10) 
with the mean change in GMFM66 (corrected for GMFM66 score at baseline) are included in the model 
 
 
Discussion 
 
In an earlier randomised clinical trial we found that multilevel BTX-A injections 
and comprehensive rehabilitation in 46 children who walk with a flexed gait 
pattern had a positive overall effect on gross motor function7 (with significant 
improvements at 12 and 24 weeks) and on knee angle at midstance6 (with 
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significant improvements at 6 weeks). In the present study we found that only 
around 50% of these children were good responders at the corresponding follow-up 
points. To improve selection of the patients who are most likely to benefit from this 
intervention, we aimed to identify predictors for a good response. We evaluated all 
potential predictors (see Table 1) that have been suggested in the literature14, 15. 
We only found age and ankle angle at midstance were found to be predictive of a 
favourable response on gross motor function and knee angle at midstance, 
respectively. 
Age was associated in such a way that the treatment had a better medium term 
(12 weeks) effect on older children, increasing with 0.38 points on the GMFM66 per 
year of the child’s age. This finding is of clinical relevance, because a childs natural 
course of gross motor function stabalizes at the age of approximately 8 years9, it 
supports the effectiveness of the treatment in the older age group. Fazzi et al.14, 
found that children of 4 years of age or younger improved significantly more on the 
GMFM66 than children over 4 years of age. In that study, young children (mean 
5.4 years, ± SD 3 years) were included. Although these results seem to contradict 
the findings in our study, we had excluded very young children (< 4years). We 
found no association between age and change in knee extension at midstance. This 
supports the findings of Fazzi et al.15, who also only reported an age effect on gross 
motor function, and not on gait pattern. 
Ankle angle at midstance was associated in such a way that the best longterm 
(48 weeks) effect was found in children with larger ankle dorsal flexion. However, 
the 0.21° increase in the knee angle at midstance, which results from a 1° increase 
in ankle (dorsi)flexion, is not clinically relevant, and should be interpreted with 
caution. 
Furthermore, we found that initially (at 6 weeks) children with a higher baseline 
GMFM66 score improve less on the GMFM66 than children with a lower score. 
However, at 24 weeks they tend to improve more (without reaching significance; 
p=0.07), indicating that the effect was reversed. Perhaps, the higher level of motor 
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function eventually makes it easier to apply newly learned motor skills in the 
home situation. This long term effect seems to contradict with the findings of 
Fattal Falavski et al.14, who reported that children with lower scores on the GMFM 
improved most at 4 months after treatment. However, this was assessed according 
to the subjective experience of the parent. 
As expected, the children with more knee flexion at baseline in the present study 
showed more improvement in knee angle at midstance than children with less 
knee flexion.  
 
The predictive power of the different models was weak, explaining less than 20 - 
40% of the total variance. This means that the improvements in gross motor 
function or knee angle at midstance are not strongly influenced by their baseline 
values and identified predictors (age and ankle angle at midstance, respectively). 
Moreover, the severity of motor involvement, the localisation of the motor disorder, 
the ROM, and the severity of spasticity, which have also been suggested as 
potential predictors in other studies13-15, were not predictive for any outcome at any 
of the different follow up points. This shows that it remains difficult to predict the 
effect of treatment with BTX A in children with CP. One limitation in this respect 
is that only 4 children in the present study had a unilateral spastic motor disorder, 
so the 'localisation of the motor disorder’ was, in fact, not expected to correlate with 
the outcome. 
in this study we also evaluated two other suggested potential predictors: gait 
kinematics and muscle strength13, neither of which were found to be predictive. 
However, it is questionable whether (functional) muscle strength was accurately 
measured with the squat test. It would probably have been better to measure to 
maximum number of squats (e.g. the repetition maximum). 
Another limitation of this study is the relative small study group (n = 46). This 
might hamper adequate study power, although no more than 3 factors were 
included simultaneously in the multiple regression analysis, and none of the 
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remaining factors showed even a trend for association. So, even with a larger study 
group, the potentially of these factors to be an actual predictor is doubtful.  
Despite the group descriptive analysis on responder-type, for which three 
categories were developed, we did not use logistic multilevel regression, as this 
would have lead to loss of information and in turn, loss of study power20.  
 It is conceivable that other prognostic predictors might play an important role, 
such as degree of selective motor control12 and level of balance or co-ordination. 
Therefore, more studies are needed to determine whether these patients’ 
characteristics are prognostic for the desired effect in this specific patient group. 
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Chapter 7 
General discussion 
 
In the previous chapters of this thesis, the results of a randomised controlled 
trial (RCT), the BOLIEN study, were presented. In this trial, an intervention of 
multilevel botulinum toxin type A (BTX-A) injections and comprehensive 
rehabilitation was compared to usual care in children with spastic cerebral palsy 
(CP) who walk with a flexed knee gait. The main aim of the study was to assess the 
the effectiveness of this intervention on mobility. The outcomes with regard to gait 
pattern, muscle length and spasticity were also measured, and determinants of the 
outcomes were studied. To asses spasticity, we developed the Spasticity Test 
(SPAT), a clinical instrument adapted from the original Tardieu Scale. 
 
In this final chapter, the General Discussion, several methodological 
considerations and aspects of outcome assessment are discussed and the 
effectiveness of the multilevel BTX-A injections and comprehensive rehabilitation 
is evaluated. Furthermore, the clinical implications are also considered, and 
recommendations are made for future research.  
  
 
Methodological considerations 
 
We performed an RCT in which we evaluated the effects of multilevel BTX-A 
treatment and comprehensive rehabilitation or usual care in two comparable 
groups. However, our results may have been influenced by the heterogeneity of our 
study population, by the lack of blinded assessment, and by the complexity of the 
treatment. 
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Heterogeneity 
Randomisation was successful with respect to the personal characteristics of our 
heterogeneous study group (see Table 1, Chapter 5). However, despite 
randomisation, the children in the control group had more knee flexion at baseline 
than the children in the intervention group (see Figure 2, Chapter 4). The amount 
of knee flexion at baseline was shown to be predictive of the amount of 
improvement in knee flexion after the BTX-A treatment (Chapter 6), in such a way 
that the children who had relatively greater knee flexion at the start of the 
intervention improved more in knee flexion after the treatment than the children 
with relatively less knee flexion. This implies that the control group is expected to 
improve even more after treatment. Therefore, our results with regard to the 
outcome on knee flexion might even be under-estimated, because the analyses were 
controlled for this baseline difference. The amount of knee flexion at baseline was 
not found to be predictive of the outcome on gross motor function (Chapter 6). We 
did not investigate whether or not knee flexion was a predictor of the effect on 
other outcomes (i.e. spasticity, muscle length, parent-percieved mobility, energy 
cost).  
 
Blinding 
The children in our study were assessed by multiple observers, who were 
employed in the centre of recruitment, and therefore their independency with 
respect to the participating children might be discussed. The observers were not 
blinded for treatment group, so the lack of blinding might have biased our results. 
However, this is only thought to be of marginal influence because the observers 
were experienced, fully trained and certified to assess the primary outcome, the 
score on the Gross Motor Function Measure-661 (GMFM-66). Moreover, the 
observers did not refer to any previous test values. However, the possible 
dependency of the observers, which was hampered by the limited staff available for 
the organization of the study, is thought to be of more substantial influence. Such 
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problems with regard to independency and blinding of the observers might be 
prevented in future research by obtaining financial support for additional research 
staff, such as independent research assistants.  
 
Treatment  
In the BOLIEN study, we formulated clear guidelines with regard to the BTX-A 
injections (e.g. individual target muscle selection; maximal dosage regimen; 
injection technique) and serial casting (e.g. method and maximum duration). 
Furthermore, we developed a physical therapy protocol, containing guidelines for 
the training program (e.g. intensity and treatment focus). In  all these guidelines 
the heterogeneity of the patients was taken into account, offering individually 
tailored treatments according to the child’s specific needs. Because all children 
with CP have their own specific needs, the exact content of the treatment cannot 
be described. Strict standardization of an intervention, in which a homogeneous 
group of patients receive the same experimental treatment, will ideally make it 
possible to assess the efficacy of this intervention under optimal circumstances. 
However, this does not provide an answer to  questions about the effectiveness of 
the intervention, which closely reflects routine clinical practice, and is relevant for 
rehabilitation purposes.  
With regard to the choice of treatment in the BOLIEN study, we were specifically 
interested in the effectiveness of multilevel BTX-A and comprehensive 
rehabilitation as a combined treatment package, because this was considered to be 
the best clinical practice for the patients in the participating rehabilitation centers. 
This treatment package aims to improve the underlying muscle imbalance caused 
by spasticity, and also to improve muscle weakness and muscle length, which is 
thought to be the main prerequisite to achieve an improvement in mobility. This 
treatment rationale has been explained in more detail in the Introduction part 
(Chapter 1). The combined treatment package was compared to usual care, which 
consisted of low-frequency physical therapy. Therefore, from the results of this 
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study we cannot assess the effectiveness of each individual component of the 
treatment package within the total treatment effect. In order to assess the effect of 
multilevel BTX-A injections in addition to comprehensive rehabilitation, a 
randomised controlled trial (RCT) should be performed, in which the control group 
should only receive the comprehensive rehabilitation (intensive physical therapy, 
orthoses and serial casting).  
 
 
Outcome assessment 
 
Assessing spasticity 
A specific outcome of interest in this thesis was the clinical assessment of 
spasticity (Chapters 2 and 3). We explained in Chapter 2 that many different 
instruments that have been developed are used to assess spasticity in children 
with CP. A lack of consensus on the most appropriate instrument is illustrative of 
the ongoing discussion on how to measure ‘spasticity’. This discussion seems to be 
directly related to the, mainly semantic, discussion on the about the definition of 
spasticity.  
In our study, spasticity was defined, according to Lance2, as ‘a motor disorder 
characterised by a velocity dependent increase in tonic stretch reflexes (‘muscle 
tone’) with exaggerated tendon jerks, resulting from hyperexcitability of the 
stretch reflex, as one component of the upper motor neuron syndrome (UMNS)’. 
The clinical symptom of spasticity in this definition is a velocity-dependent 
increase in muscle tone. However, the term ‘spasticity’ is also often used to indicate 
all or several symptoms of the UMNS (see Table 1, Chapter 2). To illustrate the 
ongoing debate, a European interdisciplinary research group has recently proposed 
a new, more general, definition, in which spasticity is defined as ‘intermittent or 
sustained involuntary activation of muscles’. Thus, in a addition to a velocity-
159 
Chapter 7 
dependent increase in muscle tone, this definition also includes all other symptoms 
of  abnormal muscle activity, such as non-velocity-dependent increased muscle tone 
(e.g. hypertonia) and clonus. By doing so, the term ‘spasticity’ becomes a synonym 
for the excess symptoms (signs of abnormal involuntary muscle activation)  of the 
UMNS3. We believe that this leads to considerable confusion4. Moreover, it is clear 
that these symptoms can exist independent of each other, and do not necessarily 
share a common pathophysiology (Chapter 2).  
We therefore wish to emphasise that the formulation a clear and unambiguous 
definition of spasticity is the first step in reaching consensus on the appropriate 
method of clinical spasticity assessment, and that the definition should describe 
what one attempts to assess. Although it is not our intention to propose a new 
definition of spasticity, we feel that further clinical confusion may well be avoided 
if the clinical evaluation and definition of spasticity is restricted to a ‘velocity-
dependent increased resistance to passive stretch’ when passively manipulating a 
muscle. This velocity-dependency has been validated in many studies5-8, by 
showing that stretching a muscle at a sufficiently high velocity is essential in order 
to elicit a stretch reflex at a certain angle in the range of motion (ROM), and the 
faster the stretch, the earlier and stronger the reflex component of the increased 
muscle tone will be. It is especially important to assess spasticity with a fast 
passive stretch, in order to detect the dominant phenomenon of spasticity: the 
'catch'. The catch is defined as a sudden appearance of increased resistance in 
response to a fast passive stretch at a certain angle (‘angle of the catch’ [AOC]) 
before the end ROM, which stops the movement immediately5,9. Any clinical 
assessment of spasticity should verify this velocity-dependency, by comparing and 
grading the intensity of the muscle tone elicited at a very slow and a very fast 
passive muscle stretch, and measuring the AOC in relation to the ROM of that 
muscle. Both angular velocities should be well defined and standardised.  
The outcome of the review described in Chapter 2 of this thesis showed that the 
most frequently used Ashworth and Modified Ashworth Scales are inadequate for 
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the measurement of spasticity, because they assess resistance to passive stretch, at 
only at one (undefined) velocity, thereby not demonstrating the velocity-dependent 
character. Moreover, these methods often lack an adequate description of the 
testing procedure, which hampers correct interpretation of the results and limits 
their use for clinicians and researchers.  
Based on these grounds, we developed a clinical spasticity assessment scale, 
based on the original Tardieu Scale10: the Spasticity Test (SPAT). This scale has a 
well defined assessment protocol, and assesses the muscle during two passive 
stretches. We tested the feasibility and reliability of the SPAT, and concluded that 
an experienced examiner can use the SPAT to make a reliable assessment of the 
hamstrings and calf muscles, but for adductor-testing a simplified version of the 
SPAT is recommended. Unfortunately, the SPAT is not reliable for the 
measurement of the rectus femoris, but as present, no clinical alternative can be 
suggested. When an assessment is made by two examiners with different levels of 
experience, the SPAT is only reliable for the gastrocnemius muscle. A possible 
explanation for this low (inter-rater) reliability is the test’s presumed  
susceptibility to practise effects11, but this should be studied in future research. 
Another explanation is that the applied velocities varied between the observers, 
despite the standardisation in the written guidelines. Measurement of the angular 
velocities and assessment of reliability in a clinical setting is therefore the main 
challenge for future studies.  
 
Assessing mobility  
The main outcome of interest in this study was the assessment of mobility. For 
this purpose, the GMFM-661 was used. At the moment, this is one of the most 
appropriate measures for this purpose in patients with CP, because it has been 
validated in this patient group for the measurement of changes of gross motor 
function over time. The GMFM66 is a capacity measure: it assess abilities in a 
controlled evaluative setting, but it gives no information about the actual 
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performance in daily life12. A child’s ‘capacity’ indicates the highest probable level 
of what the child can do in a controlled environment, whereas a child’s 
‘performance’ describes what the child does in the everyday setting. Relating this 
to the results of the BOLIEN study, we know that multilevel BTX-A and 
comprehensive rehabilitation improved the children’s capacity in standing, 
walking, jumping or running, but does this also mean that they walk more indoors 
or outdoors, or that they climb stairs or run more frequently? This question cannot 
be answered from the results of this study because we did not measure 
performance. The known ceiling-effect of the Pediatric Evaluation Disability 
Inventory13 (PEDI) in children over 7.5 years of age and/or with a higher level of 
motor function, limited its usefulness as an outcome measure for that purpose in 
our study. Nevertheless, changes on our secondary outcome measure, the Problem 
Score (Chapter 5), which was rated on an internationally accepted Visual Analogue 
Scoring (VAS) scale, suggests that these children also improved in mobility 
performance. Although the Problem Score is subjective, and its reliability has not 
yet been studied, the reported problems are parent-perceived and based on the 
performance of daily tasks, which varied from walking certain distances and 
climbing stairs, to playing outdoors. 
 
 
Effectiveness of multilevel BTX-A and 
comprehensive rehabilitation 
 
In the BOLIEN study, the effect of the intervention on mobility was statistically 
significant, as measured with the GMFM-66. The improvements at the different 
follow-up points were rather small (e.g. range 2.1 - 3.5 points), but nevertheless 
they are clinically relevant14. These effects were observed over a period between 12 
and 48 weeks after BTX-A treatment. Over this entire period, 50% of the study 
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participants had improved. We feel that a 50% improvement is rewarding, and this 
is also supported by the considerable improvements (proportional changes up to 
25%) on the secondary problem score. Although theoretically both outcomes may 
differ in the information they provide with regard to mobility (i.e. capacity and 
performance, as was explained earlier), the latter outcome suggests that the 
intervention also improved mobility of the children in daily life, as perceived by the 
parents, and this is therefore an important finding. It is noteworthy that no 
treatment effect (positive nor negative) was found on the energy cost of walking 
during the first 24 weeks of follow-up. These findings are in accordance with the 
results reported in the literature15. This might indicate that an improved gait 
pattern or improved mobility does not necessarily lead to an improvement in 
energy cost, although this is generally assumed.  However, further analyses did 
show a positive treatment effect on energy cost for the whole group at the 48-week 
follow-up (no control group). Moreover, it was shown that only the more severely 
affected children (GMFCS level III) seemed to improve at this point (Chapter 5). 
Therefore, it is possible that the lack of effect during the first 24 weeks is 
influenced by the low number of children, in particular the more severely affected 
children.  
Nevertheless, according to the GMFM-66, 50% of the study participants were 
still classified as ‘non responders’. Surprisingly, additional analysis showed that of 
all the patient characteristics that were thought to be predictive of this outcome, 
only age appeared to be so. We found that the children who were relatively older at 
the start of the intervention benefited more from the treatment than the children 
who were relatively younger (Chapter 6). This effect was only present at the 12-
week follow-up. This age-effect is not in agreement with the effect reported in 
another study16, but in that study a different outcome measure was used. It is 
conceivable that other prognostic predictors, which were not (accurately) evaluated 
in our study, might play an important role, such as degree of selective motor 
control17, muscle strength18, and also level of balance or co-ordination. It is 
163 
Chapter 7 
important to gain insight into these characteristics of responders and non-
responders. Therefore, new studies are needed to determine whether these patient 
characteristics are prognostic for the desired effect in this specific patient group.  
In addition to the improvement in mobility, treatment with multilevel BTX-A 
and comprehensive rehabilitation in the BOLIEN study also resulted in changes in 
gait pattern, muscle length and spasticity. The significant improvement in these 
impairment outcomes was demonstrated immediately at the first 6-week follow-up 
(Chapter 4), unlike the improvements in mobility, which were demonstrated 
somewhat later at 12-week follow-up (Chapter 5). The (clinically more relevant) 
changes in mobility continued up to 24 weeks, whereas the improvement in the 
level of impairment had mainly relapsed at that point. This long-term effectiveness 
on mobility is clinically important. It shows that, even though the pharmacological 
effect of BTX-A had worn off and the intensified physical therapy was 
discontinued, there was still a potential for further improvement in mobility. It 
seems plausible that the initial improvements in spasticity and muscle length 
restored the underlying muscle balance, at least to some extent. Increased muscle 
strength is also thought to add to this restored muscle balance, but muscle 
strength was not assessed as an outcome measure in this study. The restored 
muscle balance possibly led to an improvement in gait pattern and offered a 
starting point for improvement in (existing) motor skills during therapy, which 
through practise become more routine in daily life, leading to an improvement in 
mobility. However, the inter-relationships between these different impairment and 
mobility outcomes, and their apparent difference in timing of the recorded effect 
(e.g. the point in time when a significant change was measured) have not been 
addressed been addressed in our study. The relationship between impairment and 
activity is known to be complex, and the heterogeneity in clinical presentation of 
the various impairments in children with CP further complicates this evaluation. 
Nonetheless, gaining more knowledge about the relationship between impairments 
and activity in these children may help us to provide a more profound scientific 
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base for the fine-tuning of our treatment, in order to achieve more effective results. 
For example: if muscle weakness is found to influence the flexed knee gait pattern 
to a greater extent than spasticity, physicians might want to focus more on muscle-
strengthening exercises than on the reduction of spasticity. 
 
 
Final conclusions, implications and 
recommendations 
 
This thesis showed that a combined treatment package of multilevel BTX-A and 
comprehensive rehabilitation is effective in children with CP who walk with a 
flexed knee gait. There was an immediate positive effect on spasticity, muscle 
length and gait pattern, and a longer-lasting improvement in mobility (for at least 
six months, and probably even for one year). In children aged 4 to 12, the older 
children are more likely to benefit in terms of improvement in mobility, but all 
children will benefit equally in terms improvement in gait pattern. 
This thesis also provided useful insight into issues regarding the clinical 
assessment of spasticity. In order to assess spasticity clinically, and to assess the 
velocity-dependent increased resistance to passive stretch, the muscle response 
should be measured at two different velocities of muscle stretch.  
 
 
Clinical Implications  
 
The (relevant) positive effect on the GMFM-66 in children who walk with a flexed 
knee gait shows that improvement in mobility is possible after multilevel BTX-A 
and comprehensive rehabilitation treatment. At present, however, the 
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fundamental, active components of this combined treatment package are not clear. 
Implementation of the total combined treatment approach is therefore 
recommended in the daily rehabilitation of children with CP who walking with 
flexion of the knees during midstance, when their need is to improve, or maintain, 
their level of mobility. For structural implementation, we recommend the use of 
the clinical guidelines described in Chapters 4 and 5 on patient selection, BTX-A 
dosage, target muscle selection, the prescription of orthosis, serial casting, and the 
physical therapy program. The guidelines for the maximum dosage of BTX-A are 
consistent with the recently developed European consensus on best practice for 
BTX-A treatment of CP19, and with the Dutch concept guidelines for the treatment 
of children with spastic CP20. Is should be noted that successful implementation 
consequently requires a multidisciplinary team approach, consisting of a 
rehabilitation physician, a physical therapist, and an orthotist. Furthermore, 
prerequisites for selections should be good motivation of the children and their 
parents/caregivers and their intention to comply with the treatment program, in 
particular with the intensive physical therapy program. Moreover, because the 
improvement in mobility is not an immediate effect, their motivation may need to 
be continuously stimulation throughout the treatment period.  
Furthermore, we recommend the use of the SPAT as a clinical measurement of 
spasticity in both clinical practice and research. However, we do suggest that the 
observers should receive adequate training before starting the actual assessments, 
and that the detailed standardised procedure is adhered to. This is especially 
important for research purposes. However, because of its low interrater reliability, 
we recommend that, when the SPAT is used for research purposes, all the 
assessments of a patient are performed by the same observer.  
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Recommendations for future research  
 
• Further RCTs should be performed to study the contribution of each of the 
individual components of the combined treatment package to the total 
treatment effect. In particular, the effect of the combined multilevel BTX-A and 
comprehensive rehabilitation,  compared to the effect of comprehensive 
rehabilitation alone, should be investigated. In these studies, muscle strength 
and degree of selective motor control should also be included as an outcome 
measure.  
• Further research should be carried out to study the relationships between the 
changes in gait pattern, spasticity, muscle strength and muscle length (level of 
impairment) on one hand,  and the changes in mobility (level of activity level) 
on the other hand.  
• More research is needed to identify possible predictors (e.g. muscle strength, 
selective motor control, co-ordination) of a favourable effect of multilevel BTX-A 
and comprehensive rehabilitation, especially on mobility.  
• More attention should be paid to optimisation of the different components of 
the comprehensive rehabilitation. With regard to physical therapy, future 
studies should address the aspects of optimal duration, frequency, intensity 
and form (e.g. strength training, endurance training, co-ordination training, 
flexibility training, gait training).  
• Future research should further investigate the validity and reliability of the 
SPAT. At present, plans have been made for continuing research to standardise 
the two velocities of stretch, and to develop a training program for assessors to 
improve the SPAT’s reliability. Furthermore, the construct validity, the 
responsiveness (sensitivity to change), and the minimal clinically important 
change should be investigated.  
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• Future research should also focus on the development and validation of 
instruments to assess mobility performance in children with CP. They should 
have good feasibility for use in clinical and research settings, and be applicable 
for children of all ages. For this purpose, subjective instruments based on child 
or parent self-assessment, such as the problem score, should be refined and 
further tested. More objective measures, such as a activity monitoring, could 
also be of value, in particular in the research setting. An activity monitor is a 
portable device that provides an objective evaluation of the amount of daily 
activity, such as running, walking, standing, sitting, lying down, etc. This 
measure has been already validated for use in non-cerebral palsied paediatric 
populations21,22, so future research should aim to validate this instrument for 
use in the cerebral palsied population.  
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 Summary  
 
 Most children with spastic cerebral palsy (CP) have a deviating gait pattern, and 
one of the typical patterns is a flexed knee gait. Children who walk with a flexed 
knee gait are specifically at risk of deteriorating in mobility. To prevent this 
(potential) deterioration, treatment is indicated at an early stage. It is postulated 
that the cause of this gait pattern is attributable to a combination of abnormal 
involuntary muscle activity (such as spasticity), muscle weakness and/or reduced 
muscle length. In this, spasticity is defined as ‘a motor disorder characterized by a 
velocity-dependent increase in tonic stretch reflexes (muscle tone) with 
exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as 
one component of the upper motor neuron syndrome’. This is clinically recognisable 
as a velocity-dependent increase in muscle tone in response to muscle stretch, 
demonstrated at a certain angle in the range of motion (ROM).  
The presence and severity of spasticity and other impaired muscle functions vary 
per patient. Nonetheless, characteristic for all patients with CP is that the 
impairments are not equally spread throughout their muscles. This results in a 
muscle imbalance, for instance in an agonist-antagonist couple (such as flexor-
extensor) there is generally more spasticity and/or shortening in one muscle than 
in the other. Treatment of this muscle imbalance is considered to be the main 
prerequisite for a potential improvement in mobility. The treatment rationale is 
therefore to aim at decreasing the muscle activity in spastic (usually flexor) 
muscles, stretching the shortened (usually flexor) muscles, and strengthening the 
weakened (usually extensor) muscles at the same time. To decrease spasticity, 
botulinum toxin type A (BTX-A) can be injected in the muscle, and a 
comprehensive rehabilitation treatment, consisting of intensive physical therapy, 
orthosis and serial casting, can be used to train the weaker extensor muscles, 
stretch the shorter flexor muscles and increase mobility.  
In this thesis it was hypothized that treatment with multilevel BTX-A and 
comprehensive rehabilitation will improve spasticity, muscle length and the flexed 
knee gait pattern, which in turn is hypothized to improve activities in the domain 
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of mobility. Multilevel BTX-A treatment refers to the injection of multiple muscles 
(around the hip, knee and ankle) within one treatment session, and is particularly 
indicated for children with a gait which is characterized by flexion of the knee in 
midstance. For the evaluation of spasticity, an appropriate measurement 
instrument was needed. Since the characteristics of patients with CP differ widely, 
it is likely that certain patients will benefit more than others from multilevel BTX-
A and comprehensive rehabilitation.  
This thesis therefore evaluates: 
1. the available instruments for the clinical assessment of spasticity in children 
with CP, and their compliance with the velocity-dependent concept of 
spasticity (Chapter 2) 
2. the reliability of a new instrument for the clinical assessment of  spasticity in 
children with CP (Chapter 3) 
3. the effects of multilevel BTX-A and comprehensive rehabilitation on 
spasticity, muscle length and gait pattern in children with CP who walk with 
a flexed knee gait (Chapter 4) 
4. the effect of multilevel BTX-A and comprehensive rehabilitation on mobility 
in children with CP who walk with a flexed knee gait (Chapter 5) 
5. the predictors of multilevel BTX-A and comprehensive rehabilitation on gait 
pattern and mobility in children with CP who walk with a flexed knee gait 
(Chapter 6)  
 
The most widely accepted definition of spasticity was formulated by Lance in 
1980. In this definition, he defined spasticity as the clinical symptom of a velocity-
dependent increase in muscle tone at passive stretch. Elaborating on this 
definition to include a clinical assessment of spasticity implies grading the 
intensity of the muscle tone and comparing it at different passive velocity 
stretches. Although ignored in Lance's definition, the patient’s testing posture and 
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 the initial length from which the muscle is stretched are both of significant 
influence on spasticity.  
Chapter 2 presents the results of a critical review of the various clinical 
instruments that are used to evaluate spasticity in children with CP. The purpose 
of this study was to evaluate whether these clinical instruments assess spasticity 
in accordance with the velocity-dependency as defined by Lance, and whether these 
assessments are properly standardized. The various clinical instruments were 
identified through systematic literature searches, and evaluated on: 1) whether the 
assessment was made at different standardized velocities of passive stretch, 2) 
whether a standardized testing posture was defined, and 3) how spasticity was 
quantified. 
Thirteen clinical spasticity assessment instruments were identified and 
evaluated. Most of these instruments, including the mostly frequently used 
Ashworth Scale (AS) and the Modified Ashworth Scale (MAS), do not comply with 
the concept of spasticity, as defined by Lance. They grade muscle tone only at one 
(often non-specified) velocity of passive stretch. Only the Tardieu Scale (TS) 
measures the velocity-dependent increase in muscle tone and compares the 
intensity and the angle of appearance of the increased muscle tone at (three) 
different velocities. However, these velocities have not been fully standardized. 
With respect to the standardised posture, the TS assesses patients in two 
positions: sitting and lying. With respect to quantification, the TS produces 
separate scores for both tone intensity and ROM at different velocities. However, 
these are used ambiguously by different users.  
In conclusion, only the original TS is a suitable instrument for the assessment of 
spasticity, since it grades muscle tone intensity and ROM at three different 
velocities. However, the original testing protocol has a comprehensive and time-
consuming clinical scoring system.  
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Although the velocity-dependent characteristic of spasticity can only be studied 
by stretching the muscle at two different velocities, e.g. slow and fast, it is 
especially important to test spasticity with a fast passive stretch. This makes it 
possible to detect the dominant phenomenon of spasticity: the 'catch', a sudden 
appearance of increased resistance in response to a fast passive stretch at a certain 
angle before the end ROM, which stops the movement immediately. Based on this 
rationale, a new spasticity assessment instrument was developed, the Spasticity 
Test (SPAT), which was based on the TS.  
Chapter 3 describes the feasibility and reliability of the SPAT in five leg 
muscles. With this instrument, the muscle is first passively stretched at a slow 
velocity (≥ 3 seconds) to measure the maximum ROM. Spasticity is then assessed 
during a passive stretch at a fast velocity (< 1 second) to measure the joint angle of 
the catch (AOC) and to grade the intensity of the muscle resistance on a 4-point 
(0,1,2,3) spasticity scale. The SPAT has a standardized testing protocol describing 
the patient and observer position for each muscle tested, as well as describing the 
ROM and AOC measurement, using hand-held goniometry.  
Twenty children with a diagnosis of spastic paresis were included in this study. 
They were all tested three times on one day by two different observers. In each 
session, the ROMs of five leg muscles were assessed (hamstrings, short adductors, 
soleus, gastrocnemius and rectus femoris muscles), after which spasticity was 
assessed with the spasticity scale and the AOCs. In all the tests the goniometry 
was performed by a third observer. Reliability was expressed in  absolute 
agreement (AA) (only for the spasticity scale), and in Intraclass Correlation 
Coefficients (ICCs) and Standard Errors of Measurement (SEMs).  
The SPAT was easy to administer, and the assessment was performed in 5 to 8 
minutes. The intra-rater reliability was good for the hamstrings, soleus and 
gastrocnemius muscles (ROM: SEM range 2.9˚ - 5.1˚, spasticity scale: AA 70% - 
95%, AOC: SEM 4.8˚ - 6.4˚ ). When the spasticity scale was simplified to a 2-point 
(0,1) scale rating the absence or presence of a catch, the intra-rater reliability was 
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 also good for the adductor muscle, but not for the rectus femoris muscle. The inter-
rater reliability was only good for the gastrocnemius muscle (ROM: SEM 4.0°, 
spasticity scale: AA 65%, AOC: SEM 3.6˚). These results show that repeated SPAT 
measurements should be performed by the same trained examiner. In conclusion, 
when applied by one examiner, the new SPAT is a feasible and reliable clinical 
instrument to measure spasticity for all of the leg muscles studied, except for the 
rectus femoris muscle. To improve inter-rater reliability, we suggest that a special 
training programme for examiners should be developed, and that the velocity of 
the stretch should be further standardized by means of a measurement device. 
 
Chapters 4 and 5 present the results of a multi-centre randomized controlled 
trial on the effect of multilevel BTX-A injections and comprehensive rehabilitation 
in children with CP who walk with a flexion pattern. Forty-six children were 
included in this study. The inclusion criteria were: diagnosis of CP; ability to walk 
(with or without a walking aid or an ankle-foot orthoses); gait characterized by 
persistent flexion of the knee in midstance; age between 4 and 12 years; spasticity 
in two or more leg muscles interfering with mobility; with an indication for 
multilevel BTX-A. The children were randomly assigned to the intervention or the 
control group. The intervention group was treated with multilevel BTX-A 
injections and comprehensive rehabilitation. The comprehensive rehabilitation 
consisted of a 12-week period of intensive physical therapy according to a 
standardized protocol, orthoses and, if necessary (i.e. if the ROM of the 
gastrocnemius muscle was less than 0˚ dorsiflexion), serial casting. Children in the 
intervention group were assessed twice during a 6-week baseline period, and there 
were 4 follow-up measurements at 6, 12, 24 and 48 weeks after the injections. The 
control group continued to receive usual care (low intensity physical therapy, some 
used orthoses) for a period of 18 to 30 weeks. They were assessed every 6 weeks. 
After this baseline period, the children in the control group were also treated with 
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multilevel BTX-A and comprehensive rehabilitation, with a follow up at 6, 12, 24 
and 48 weeks after treatment.  
 
Chapter 4 first evaluates the effect of multilevel BTX-A and comprehensive 
rehabilitation on gait pattern, muscle length and spasticity, as opposed to usual 
care. For the purpose of this study, the effect in the intervention group (n=23)  up 
to 24 weeks after treatment was compared with the effect of usual care in the 
control group (n=23).  
The gait pattern was evaluated with the Edinburgh Visual Gait Analysis 
Interval Testing (GAIT) scale. Knee angle at midstance, ankle angle at midstance,  
knee angle at terminal stance, and hip rotation at terminal swing were also 
measured. Muscle length and spasticity were assessed with two components of the 
SPAT; the ROM during a slow passive stretch (> 3 sec) and the AOC during a fast 
(<1 sec) passive stretch, respectively.  
After 6 weeks there was a significant improvement in the quality of the gait 
pattern (1.7 points improvement on the GAIT score, p < 0.01) and in the gait 
kinematics during midstance (7˚ improved knee extension, p < 0.01) and terminal 
swing (5° improved knee extension, p < 0.01, and 4˚ improved hip rotation, p = 
0.02). The 7˚ improvement in knee extension at midstance, in particular, was found 
to be clinically relevant. No effect was found at 24 weeks, but it is likely that this 
second assessment was too late to demonstrate sustained improvement, because no 
gait assessment was performed at 12 weeks. A significant effect in muscle length 
was found at 6 weeks: muscle length improved in the hamstrings (9°, p < 0.01) and 
in the gastrocnemius muscles (5°, p < 0.01), and both improvements were 
maintained up to 24 week after treatment. These changes were found to be 
clinically relevant. No change was found in the length of the rectus femoris and 
adductor muscles, but since these muscle lengths were both normal at baseline this 
was to be expected. A reduction in spasticity was found at 6 and 12 weeks in the 
injected hamstrings (11°, p < 0.01) and gastrocnemius muscles (6°, p = 0.01). This 
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 could be expected because of the pharmacological mechanism of BTX-A, which is 
known to be only temporary. An additional effect was found in the uninjected 
soleus muscles (5°, p = 0.02), which could be due to diffusion of BTX-A from the 
injected gastrocnemius muscle.  
Based on the results of this study, multilevel BTX-A and comprehensive 
rehabilitation (as opposed to usual care) is effective in improving gait pattern, 
increasing the muscle length of shortened muscles and decreasing spasticity in 
injected muscles in children who walk with flexed knees. Of these effects, only the 
effect on muscle length was still present after 24 weeks.  
 
Subsequently, Chapter 5 evaluates the effectiveness of multilevel BTX-A 
injections and comprehensive rehabilitation on mobility. For the purpose of this 
study, the effect in the intervention group (n=23) up to 24 weeks after treatment 
was compared with the effect of  usual care in the control group (n=23) (e.g. trial 
analysis). The uncontrolled long-term effect at 48 weeks after treatment was also 
evaluated within the total group (n=46) (e.g. before-after analysis). Finally, sub-
group analysis for the level of Gross Motor Function Classification System 
(GMFCS) and age were performed to detect differences in treatment effect between 
the groups.   
The primary outcome for mobility was the Gross Motor Function Measure-66 
(GMFM66). The secondary outcomes were the energy cost of walking (measured in 
a sub-group of 21 children) and a parent self-reported problem score (0-10 scale).  
The trial analysis showed a significant treatment effect on mobility (GMFM66) in 
favour of the intervention group at 12 and 24 weeks (2.1, p=0.02 and 3.5 points, p 
<0.01 respectively). This was also found on the problem score (-1.8 and -1.7 points, 
p <0.01 respectively). The effect on both outcomes were considered to be clinically 
relevant. No treatment effect was found on energy cost. The before-after analysis 
also showed long-term (i.e. 48 weeks after treatment) effects on these outcomes 
(GMFM-66 2.3 points, p < 0.01; PS -1.4 points, p < 0.01), and there was also a long-
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term significant effect on energy cost (-1.8 J/kg/m, p <0.01).  However, these long-
term findings should be confirmed in a randomized controlled study. With respect 
to the effect on energy cost 48 weeks after treatment, it was found that children 
who used walking aids (GMFCS level III) improved significantly more than 
children walking without aids (GMFCS levels I and II). A possible explanation for 
this is that children in the latter group seem to be non-responsive to change in 
energy cost because their energy cost is already low, although it is higher than that 
of healthy children.  
Based on the results of this study, multilevel BTX-A and comprehensive 
rehabilitation (as opposed to usual care) is an effective method of treatment that 
leads to clinically relevant improvements in mobility, in terms of  GMFM-66 score 
and parent-perceived mobility problems, in children who walk with flexed knees. 
Conversely, it does not effect the energy cost of walking.  
 
Patients with spastic CP are very heterogeneous with respect to the severity of 
impaired muscle functions, localisation of the motor disorder, and the severity of 
motor involvement. Therefore, it is likely that certain patients will benefit more 
than others from multilevel BTX-A and comprehensive rehabilitation. Chapter 6 
describes a study in which an attempt was made to identify predictors for a 
favourable outcome of multilevel BTX-A injections and comprehensive 
rehabilitation on gross motor function (measured with the Gross Motor Function 
Measure (GMFM66)) and gait pattern (assessed  according to the knee angle at 
midstance) in children who walk with a flexed knee gait. For this purpose, we used 
follow-up data (6, 12, 24 and 48 weeks after treatment) from the total group (n=46) 
in the randomized controlled trial as described in chapters 4 and 5. All in the 
literature suggested factors were considered to be possible predictors of outcome: 
age, gender, severity of motor involvement, localisation of the motor disorder, level 
of motor function, muscle strength, ROM, spasticity, and gait kinematics.  
179 
 Of all the potential predictors, only age and ankle angle at midstance were found 
to be predictive of an improvement in gross motor function and gait pattern, 
respectively. Age was associated in such a way that the treatment had a better 
medium-term (12 weeks) effect on older children, increasing with 0.4 points on the 
GMFM66 per year of the child’s age (on condition that other factors remain 
unchanged). This finding was considered to be clinically relevant. Ankle angle at 
midstance was associated with gait pattern in such a way that the best long-term 
(48 weeks) effect was found in children with increased ankle dorsal flexion. 
However, the 0.21° increase towards knee extension, which results from a 1° 
increase in ankle dorsiflexion, was not clinically relevant. The predictive power of 
the different models was weak, explaining less than 20-40% of the total variance. 
Moreover, none of the potential predictors gender, severity of motor involvement, 
localisation of the motor disorder, ROM, and spasticity  
were found predictive for any outcome at any of the different follow-up points.  
Based on these results, the only relevant significant predictor for a favourable 
response of multilevel BTX-A injections and comprehensive rehabilitation in this 
patient group, with regard to gross motor function, is older age.  
 
In Chapter 7 provides the general discussion. Several methodological 
considerations and aspects of outcome assessment were discussed and the 
effectiveness of the multilevel BTX-A injections and comprehensive rehabilitation 
was evaluated. It was concluded that a combined treatment package of multilevel 
BTX-A and comprehensive rehabilitation is effective in obtaining improvements in 
mobility in children with CP who walk with a flexed knee gait. With regard to the 
clinical assessment of spasticity, it was concluded that the velocity-dependent 
increased resistance to passive stretch should always be assessed by measuring the 
muscle response at two different velocities of muscle stretch. Furthermore, chapter 
7 discussed the clinical implications, and formulated recommendations for future 
research.   
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 Samenvatting 
 
 Veel kinderen met een spastische cerebrale parese (CP) hebben een afwijkend 
looppatroon. Eén van de meest typerende looppatronen is het zogenaamde ‘flexie-
patroon’. Het is bekend dat kinderen die lopen met een flexie-patroon tijdens hun 
ontwikkeling een verhoogd risico hebben op een achteruitgang in hun 
mobiliteit.Vroegtijdige behandeling is daarom essentieel om deze (dreigende) 
achteruitgang te voorkomen. De oorzaak van het flexie-patroon is vermoedelijk een 
combinatie van abnormale onwillekeurige spier-aktiviviteit zoals spasticiteit, in 
combinatie met spierzwakte en/of afgenomen spierlengte. Het begrip spasticiteit 
wordt hier gedefinieerd als ‘een motorische stoornis, gekenmerkt door een 
snelheidsafhankelijke toename in tonische rek reflexen (spiertonus) met verhoogde 
peesreflexen, als gevolg van overprikkelbaarheid van de rekreflex, als een 
onderdeel van een centraal motorische parese’. Spasticiteit in een spier is klinisch 
te herkennen als een snelheidsafhandelijke toename in spiertonus wanneer deze 
spier passief gerekt wordt. Deze verhoogde spiertonus treedt op bij een bepaalde 
hoek in de range of motion (ROM) van die spier.  
De aanwezigheid en ernst van spasticiteit, als ook die van andere 
spierfunctiestoornissen, varieert per patiënt. Hierdoor heeft elke patiënt een uniek 
klinisch beeld. Wel is het zo dat alle patiënten met CP kenmerkt worden door het 
feit dat de spierfunctiestoornissen nooit gelijk verdeeld zijn over de verschillende 
spieren, wat leidt tot een dysbalans in de spieren. Bijvoorbeeld, in een agonist-
antagonist koppel (zoals een flexor-extensor koppel) is de spasticiteit en/of 
spierverkorting in de ene spier vaak groter dan in de andere spier. Behandeling 
van deze spier-dysbalans wordt als het belangrijkste uitgangspunt genomen voor 
een mogelijke verbetering in mobiliteit van de patiënt. De opzet van de 
behandeling is daarom gericht op het verbeteren van de spierbalans, door 
gelijktijdig de overmatige spieraktiviteit van de spastische spieren (meestal de 
flexoren) te verminderen, de verkorte spieren (meestal de extensoren) op te rekken, 
en de zwakke spieren te versterken (meestal de extensoren). Eén van de 
mogelijkheden om spasticiteit te verminderen, is door botuline toxine type A (BTX-
182 
Samenvatting 
A) te injecteren in die spier. Wanneer meerdere spieren, werkend over meerdere 
gewrichten (rondom heup, knie en enkel), tijdens één behandelsessie geïnjecteerd 
worden, spreek men van multilevel BTX-A. Na injectie volgt een 
revalidatieprogramma, gericht op het verbeteren van de mobiliteit. Dit bestaat uit 
het (1) aanmeten van ortheses (‘spalken’), (2) een periode van redressiegips-
behandeling, en (3) een periode van intensieve fysiotherapie waarin door middel 
van rekken de verkorte flexoren worden verlengd, en door middel van training de 
zwakke extensoren worden versterkt.  
In dit proefschrift werd verwacht dat behandeling met multilevel BTX-A injecties 
en revalidatie een positief effect heeft op spasticiteit (afname), spierlengte 
(toename) en looppatroon (verbetering), waardoor een verbetering van mobiliteit 
wordt verwacht. Deze behandeling is vooral geïndiceerd bij kinderen lopend met 
een flexie-patroon, en daarom zijn zij de focus van dit proefschrift. In dit 
proefschrift wordt het volgende geëvalueerd: 
(1) Wat zijn de klinische nstrumenten voor het meten van spasticiteit bij 
kinderen met CP, en wordt hiermee het snelheidsafhankelijke karakter 
van spasticiteit vastgelegd? (Hoofdstuk 2) 
(2) Wat is de betrouwbaarheid van een nieuw meetinstrument om klinisch 
spasticiteit te meten bij kinderen met CP? (Hoofdstuk 3) 
(3) Wat is het effect van multilevel BTX-A injecties en revalidatie op 
spasticiteit, spierlengte en looppatroon bij kinderen met CP lopend met 
een flexie-patroon? (Hoofdstuk 4) 
(4) Wat is het effect van multilevel BTX-A injecties en revalidatie op 
mobiliteit bij kinderen met CP lopend met een flexie-patroon? (Hoofdstuk 
5) 
(5) Zijn er factoren die het effect voorspellen van multilevel BTX-A injecties 
en revalidatie op looppatroon en mobiliteit bij kinderen met CP lopend 
met een flexie-patroon? (Hoofdstuk 6) 
 
183 
 De meest gebruikte definitie van spasticiteit werd geformuleerd door Lance in 
1980, waarin spasticiteit gedefinieerd werd als een klinisch symptoom, 
gekenmerkt door een snelheidsafhankelijke toename van spiertonus bij passieve 
rek van die spier. Wanneer we volgens deze definitie spasticiteit willen meten, 
moeten we de intensiteit van de spiertonus zowel scoren als vergelijken bij 
verschillende snelheden van passieve rek. Belangrijk hierbij is dat zowel de lengte 
van waaruit de spier gerekt wordt als de uitgangshouding van de patiënt van 
substantiële invloed zijn op de ernst van de spasticiteit, ook al wordt dit niet zo 
duidelijk benoemd in de definitie van Lance.  
Hoofdstuk 2 beschrijft de resultaten van een kritische review over de 
verschillende klinische meetinstrumenten die gebruikt worden om spasticiteit te 
meten bij kinderen met CP. Het doel van deze studie was om te evalueren of deze 
meetinstrumenten het snelheidsafhankelijke concept van spasticiteit meten, zoals 
gedefinieerd door Lance, en of deze meetinstrumenten voldoende zijn 
gestandaardiseerd. De verschillende meetinstrumenten zijn eerst verzameld met 
een systematische zoekstrategie in de literatuur, en vervolgens geëvalueerd op: (1) 
of de afname geschiedde onder verschillende snelheden van passieve rek, (2) of de 
uitgangspositie van de patiënt was gedefinieerd, en (3) op welke manier spasticiteit 
werd gekwantificeerd.  
Dertien verschillende klinische meetinstrumenten voor spasticiteit werden 
geïdentificeerd en geëvalueerd. Het merendeel van deze instrumenten, waaronder 
de meest gebruikte Ashworth Schaal (AS) en de gemodificeerde Ashworth Schaal 
(MAS), voldoen niet aan het concept spasticiteit, zoals gedefinieerd door Lance. 
Deze schalen evalueren spasticiteit slechts bij één (veelal ongespecificeerde) 
snelheid van passieve rek. Alleen de Tardieu Schaal (TS) evalueert spasticiteit 
door de intensiteit van de spiertonus én de hoek waarbij deze optreedt in de ROM 
te vergelijken bij drie verschillende snelheden van passieve rek. Desondanks zijn 
de verschillende snelheden in de TS niet duidelijk gestandaardiseerd. Bovendien 
wordt deze test uitgevoerd bij twee verschillende uitgangshoudingen van de 
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patiënt: in een zittende en in een liggende positie. Met betrekking tot de 
kwantificatie beschrijft de TS het gebruik van verschillende scores voor intensiteit 
en ROM bij de drie verschillende snelheiden: deze worden echter door de 
gebruikers inconsequent gebruikt.  
De conclusie van deze studie is dat de TS weliswaar een geschikt instrument is 
om klinisch spasticiteit te meten, aangezien het de spiertonus en ROM evalueert 
bij drie verschillende snelheden, maar helaas een heel uitgebreid en tijdsinstensief 
klinisch scoringssysteem heeft.  
 
Ondanks dat de snelheidsafhankelijke eigenschap van spasticiteit alleen 
bestudeerd kan worden door de spier met verschillende snelheden te rekken, dat 
wil zeggen langzaam en snel, is met name de snelle rek van belang bij het meten 
van spasticiteit. Hierdoor kan men namelijk het meest prominente fenomeen van 
spasticiteit opsporen: de ‘catch’. Dit is een plotselinge toename van verhoogde 
weerstand in reactie op een snelle rek van een spier, welke optreedt op een 
bepaalde hoek vóór het eind van de ROM, en welke verdere beweging direct stopt. 
Dit fenomeen is genomen als basis bij het ontwikkelen van een nieuw 
meetinstrument, de Spasticiteit Test (SPAT), welke is gebaseerd op de Tardieu 
Schaal.  
Hoofdstuk 3 beschrijft de toepasbaarheid en de betrouwbaarheid van de SPAT 
in vijf beenspieren. Met dit instrument wordt de spier eerst passief gerekt met een 
langzame snelheid (> 3 seconden) om de ROM te meten. Vervolgens wordt 
spasticiteit opgewekt door de spier heel snel te rekken (in < 1 seconde). Hierbij 
wordt eerst de hoek gemeten waarbij de catch optreedt (angle of the catch, AOC). 
Vervolgens wordt de intensiteit van deze spierreactie gescoord op een 4-punts 
spasticiteitschaal (0,1,2,3). De SPAT heeft een gestandaardiseerd meetprotocol: de 
uitgangsposities van patiënt en uitvoerder zijn per spier beschreven, daarnaast is 
ook de ROM en AOC bepaling met gebruik van hand-held-goniometrie beschreven.  
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 Twintig kinderen met de diagnose spastische parese zijn geïncludeerd in deze 
studie. Allen zijn drie keer op dezelfde dag gemeten door twee verschillende 
uitvoerders. De goniometrie werd in alle drie sessies uitgevoerd door een derde 
uitvoerder. In elke sessie werden eerst de ROMs van vijf beenspieren (hamstrings, 
adductoren, soleus, gastrocnemius, rectus femoris) gemeten. Vervolgens werd de 
spasticiteit gemeten met de AOCs en de spasticiteitschaal. Betrouwbaarheid werd 
uitgedrukt in Absolute Agreement (AA) (alleen voor de spasticiteitschaal), en de 
Intraclass Correlatie Coëfficiënten (ICCs) en de Standard Error of Measurement 
(SEMs). 
De SPAT was gemakkelijk uit te voeren, elke test duurde 5 tot 8 minuten. De 
intra-beoordelaar betrouwbaarheid was goed voor de hamstrings, soleus en 
gastrocnemius (ROM: SEM range 2.9˚ - 5.1˚, spasticiteitschaal: AA 70% - 95%, 
AOC: SEM 4.8˚ - 6.4˚ ). Voor de adductoren, maar niet voor de rectus femoris, was 
de intra-beoordelaar betrouwbaarheid wel goed wanneer de spasticiteitschaal 
vereenvoudigd werd naar een 2-punts schaal (0,1). Op deze eenvoudige schaal 
wordt het wel of niet optreden van een catch gescoord. De inter-beoordelaar 
betrouwbaarheid was alleen goed voor de gastrocnemius (ROM: SEM 4.0°, 
spasticiteitschaal: AA 65%, AOC: SEM 3.6˚). Deze resultaten geven aan dat 
herhaalde SPAT metingen altijd uitgevoerd moeten worden door één (getrainde) 
uitvoerder. Concluderend: mits uitgevoerd door één uitvoerder, is de SPAT een 
gemakkelijk uitvoerbaar en betrouwbaar klinisch meetinstrument om spasticiteit 
te meten in alle bestudeerde beenspieren, behalve de rectus femoris. Om de inter-
beoordelaar betrouwbaarheid te verbeteren, stellen we voor dat er een speciaal 
trainingsprogramma moet worden ontwikkeld voor uitvoerders, en dat de snelheid 
waarmee de spier wordt gerekt verder gestandaardiseerd moet worden door middel 
van meetapparatuur.  
 
Hoofdstuk 4 en 5 beschrijven de resultaten van een multicenter, 
gerandomiseerde studie naar het effect van multilevel BTX-A injecties en 
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intensieve revalidatie bij kinderen met CP die lopen in het flexie-patroon. 
Zesenveertig kinderen zijn geïncludeerd in deze studie. De inclusie criteria waren: 
diagnose CP; zelfstandige loopvaardigheid (met of zonder loophulpmiddel en/of 
orthese); looppatroon gekenmerkt door persisterende flexie in de knie tijdens de 
midstance; leeftijd tussen 4 en 12 jaar oud; spasticiteit in twee of meer 
beenspieren, welke de mobiliteit beperkt en waarvoor multilevel BTX/A 
behandeling geïndiceerd is. De kinderen werden gerandomiseerd naar een 
interventie of controle groep. De interventiegroep werd behandeld met multilevel 
BTX-A injecties en intensieve revalidatie. De intensieve revalidatie bestond uit een 
periode van 12 weken intensieve fysiotherapie volgens een standaard protocol, 
ortheses, en -indien nodig (d.w.z. wanneer de ROM van de gastrocnemius minder 
dan 0° dorsaalflexie haalt)-, een periode van redressiegips behandeling. Kinderen 
in de interventiegroep werden twee keer gemeten tijden een 6-weken durende 
baseline periode. Vervolgens waren er nog 4 follow-up metingen op 6, 12, 24 en 48 
weken na de injecties. De kinderen in de controle groep ontvingen voor een periode 
van 18 tot 30 weken dezelfde behandeling zoals ze dat op dat moment gewend 
waren (‘usual care’). Deze bestond uit lage intensiteit fysiotherapie. Sommige 
kinderen droegen ortheses. De kinderen in de controle groep werden tijdens deze 
periode elke 6 weken gemeten. Na deze baseline periode, werden ook deze kinderen 
behandeld met multilevel BTX-A en intensieve revalidatie, en vervolgens gemeten 
tijdens follow-up op 6, 12, 24 en 48 weken na injecties.  
 
In hoofdstuk 4 worden eerst de effecten van multilevel BTX-A injecties en 
intensieve revalidatie vergeleken met usual care, geëvalueerd op looppatroon, 
spierlengte en spasticiteit. Hiervoor is het effect van de interventie groep (n=23) tot 
24 weken na injectie vergeleken met het effect van usual care in de controle groep 
(n=23). 
Het looppatroon werd beoordeeld met de Edinburgh Visual Gait Analysis 
Interval Testing (GAIT) schaal. Tevens werden de knie hoek tijdens midstance, de 
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 enkel hoek tijdens midstance, de knie hoek tijdens terminal stance, en heup rotatie 
tijdens terminal swing gemeten. Spierlengte en spasticiteit werden gemeten met 
twee elementen van de SPAT, respectievelijk de ROM tijdens een langzame 
passieve rek (> 3 seconden) en de angle of the catch (AOC) tijdens een snelle 
passieve rek (< 1 seconde).  
Na 6 weken was er een significante verbetering in de kwaliteit van het 
looppatroon (1.7 punten toename op de GAIT score, p < 0.01), en in de kinematica 
tijdens de midstance (7° verbetering naar knie extensie, p < 0.01) en terminal 
swing (5° verbetering naar knie extensie, p < 0.01, en 4° verbetering van de heup 
rotatie, p = 0.02). Vooral de 7° verbetering naar knie extensie in de midstance werd 
klinisch relevant geacht. Er werd geen effect gevonden in het looppatroon op 24 
weken na injectie. Het is mogelijk dat dit tweede tijdstip te laat gekozen was om 
een blijvende verbetering aan te tonen, daar er geen loopanalyse was afgenomen op 
12 weken. Op spierlengte werd een significante verbetering aangetoond op 6 weken 
na injectie in de hamstrings (9°, p < 0.01) en in de gastrocnemius (5°, p < 0.01). In 
beide spieren hield het effect aan tot 24 weken na injectie. Deze verbeteringen 
werden klinische relevant geacht. De spierlengte van de rectus femoris en 
adductoren veranderde niet, maar omdat deze al op normale lengte waren voor 
injectie, werd een verandering hierin ook niet verwacht. Op 6 en 12 weken na 
injectie was de spasticiteit in de geïnjecteerde hamstrings en gastrocnemius 
afgenomen (resp. 11° en 6°, p < 0.01). Volgens de farmacologische werking van de 
BTX-A was dit te verwachten, aangezien bekend is dat het effect slechts tijdelijk 
aanhoudt. Er werd ook een significant effect gevonden in de niet-geïnjecteerde 
soleus (5°, p = 0.02). Dit zou verklaard kunnen worden door het optreden van 
diffusie van BTX-A van de geïnjecteerde gastrocnemius.  
Uit de resultaten van deze studie werd geconcludeerd dat multilevel BTX-A en 
intensieve revalidatie (in vergelijking met usual care) effectief is in het verbeteren 
van het looppatroon, het verbeteren van de spierlengte in verkorte spieren, en het  
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verbeteren van de spasticiteit in met BTX-A geïnjecteerde beenspieren in kinderen 
met CP die lopen met knie-flexie. Alleen het effect op spierlengte was blijvend tot 
24 weken na de injectie.  
 
In Hoofdstuk 5 is de effectiviteit van multilevel BTX-A injecties en intensieve 
revalidatie geëvalueerd op de mobiliteit. Hiervoor is eerst het effect van de 
interventiegroep (n=23) tot 24 weken na injectie vergeleken met het effect van 
usual care in de controlegroep (n=23) in de ‘trial analyse’. Vervolgens is het lange 
termijn effect van de hele groep (n=46) op 48 weken na injectie geëvalueerd in de 
‘voor-na-analyse’. Ten slotte zijn er ‘sub-groep analyses’ uitgevoerd voor het niveau 
van functioneren volgens de Gross Motor Function Classification System (GMFCS) 
en voor leeftijd om eventuele verschillen in behandeleffect tussen deze groepen op 
te sporen.  
De primaire uitkomstmaat voor mobiliteit was de Gross Motor Function 
Measure-66 (GMFM66). De secundaire uitkomstmaat was het energieverbruik 
tijdens het lopen (gemeten in een sub-groep van 21 kinderen) en een door ouders 
ingevulde probleem score (0-10 schaal).  
De trial analyses toonden een significant behandeleffect in het voordeel van de 
interventiegroep op mobiliteit (GMFM66) op 12 en 24 weken na injectie (resp. 2.1, 
p=0.02 en 3.5 punten, p <0.01). Eenzelfde effect werd gevonden op de 
probleemscore (resp. -1.8 en -1.7 punten, p <0.01). De effecten op beide 
uitkomstmaten werden klinisch relevant geacht. Er werd geen effect gevonden op 
het energieverbruik tijdens lopen. De voor-na-analyses lieten op de GMFM66 en 
probleemscore ook een lange-termijn verbetering zien (resp. 2.3, p < 0.01; en -1.4 
punten, p < 0.01). Ook op energieverbruik tijdens lopen werd een significante 
verbetering gezien (-1.8 J/kg/m, p < 0.01). Deze lange-termijn verbeteringen 
moeten echter bevestigd worden in een gerandomiseerde studie. Wat betreft het 
effect op het energieverbruik tijdens lopen, werd aangetoond dat kinderen die 
lopen met een loophulpmiddel (GMFCS niveau III) significant meer verbeteren dan 
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 kinderen die lopen zonder loophulpmiddel (GMFCS niveaus I en II). Een mogelijke 
verklaring hiervoor is dat de kinderen uit de laatste groep (GMFCS niveaus I en 
II) niet responsief zijn voor veranderingen in hun energieverbruik, aangezien hun 
energieverbruik al laag is, ondanks dat het nog steeds hoger is dan dat van 
gezonde kinderen. 
Uit de resultaten van deze studie werd geconcludeerd dat multilevel BTX-A en 
intensieve revalidatie (in vergelijking met usual care) een effectieve 
behandelmethode is in kinderen met CP die lopen met knie-flexie. Het leidt tot 
klinisch relevante verbeteringen in de mobiliteit, zoals aangetoond op de GMFM66 
en de door ouders ervaren problemen in mobiliteit. Echter, het heeft geen effect op 
het energieverbruik tijdens lopen.  
 
Kinderen met spastische CP zijn erg heterogeen met betrekking tot de ernst van 
hun spierfunctiestoornissen, lokalisatie van de motorische beperking, en de ernst 
van de aandoening op het motorisch functioneren. Het lijkt daarom aannemelijk 
dat bepaalde patiënten beter zullen reageren op multilevel BTX-A injecties en 
intensieve revalidatie dan andere. In Hoofdstuk 6 wordt een studie beschreven 
waarin een poging is gedaan om predictoren te identificeren die een gunstig 
resultaat voorspellen van behandeling met multilevel BTX-A injecties en 
intensieve revalidatie bij kinderen die lopen met een flexie-patroon op het grof 
motorisch functioneren (gemeten met de Gross Motor Function Measure [GMFM-
66]) en het looppatroon (gemeten met de knie hoek tijdens de midstance). Voor 
deze studie zijn de follow-up data (6, 12, 24 en 48 weken na injectie) gebruikt van 
de kinderen (n=46) die deelnamen aan de in de hoofdstukken 4 en 5 beschreven 
gerandomiseerde studie. In de literatuur zijn de volgende factoren beschreven, 
welke voorspellend zouden zijn voor een gunstig effect: leeftijd, geslacht, ernst van 
de aandoening op motorisch functioneren, lokalisatie van de motorische beperking, 
spierkracht, ROM, spasticiteit en gangbeeld parameters.  
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Van al deze factoren werden alleen leeftijd en enkel hoek tijdens de midstance 
voorspellend gevonden voor een verbetering in respectievelijk het grof motorisch 
functioneren en looppatroon. Leeftijd was dusdanig geassocieerd met het grof 
motorisch functioneren, dat oudere kinderen op middellange termijn (12 weken) 
beter reageerden op de behandeling dan jonge kinderen: dit klinisch relevante 
effect op de GMFM66 nam met 0.4 punten toe voor elk jaar dat het kind ouder is 
(op voorwaarde dat alle overige factoren gelijk blijven). De enkel hoek tijdens de 
midstance was dusdanig geassocieerd met het looppatroon dat het grootste lange 
termijn (48 weken) effect gevonden werd bij kinderen met meer enkel 
dorsaalflexie: per 1° toename in enkel dorsaalflexie neemt de knie hoek met 0.21° 
toename naar extensie. Ondanks dat deze relatie statistisch significant was, werd 
dit niet klinisch relevant geacht. Verder werd geconcludeerd dat de voorspellende 
power van de verschillende modellen zwak was; slecht 20%-40% van de totale 
variantie werd ermee verklaard. Benadrukt werd dat geen van de andere 
potientiële predictoren, geslacht, ernst aandoening op motorisch functioneren, 
lokalisatie van de motorische beperking, ROM en spasticiteit, op geen van de 
follow-up momenten voorspellend waren gevonden op de twee uitkomstmaten. Op 
basis van deze resultaten is leeftijd in deze patiëntengroep de enige significante en 
relevante predictor voor een gunstig effect op het grof motorisch functioneren na 
behandeling met multilevel BTX-A injecties en intensieve revalidatie.  
 
De algemene discussie in Hoofdstuk 7 bespreekt een aantal methodologische 
aspecten, alsook de voor- en nadelen van een aantal gekozen uitkomstmaten, en 
evalueert de effectiviteit van de multilevel BTX-A injecties en intensieve 
revalidatie. Geconcludeerd werd dat een gecombineerd pakket van multilevel BTX-
A en intensieve revalidatie effectief is in het verbeteren van mobiliteit in kinderen 
met CP die lopen met een flexie-patroon. Met betrekken tot het klinisch meten van 
spasticiteit werd geconcludeerd dat de snelheidsafhankelijke toename van 
weerstand als reactie op passieve rek altijd gemeten moet worden door het bepalen 
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 van de spierreactie bij twee verschillende snelheden van rek. Daarnaast worden in 
hoofdstuk 7 de implicaties voor de klinische praktijk besproken en worden er 
aanbevelingen gedaan voor toekomstig onderzoek.
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 Het is af! Veel mensen hebben bijgedragen aan het tot stand komen van dit 
proefschrift. Ik wil hen hier graag voor bedanken. Allereerst wil ik ‘dank jullie wel’ 
zeggen tegen alle kinderen en hun ouders die hebben deelgenomen aan mijn 
onderzoeken. In het bijzonder de kinderen in het Bolien onderzoek: jullie zijn de 
echte sterren van dit proefschrift. Jullie tomeloze inzet en doorzettingsvermogen 
heeft mij vaak doen verbazen. Jullie deden altijd enorm je best en ik ben dan ook 
heel erg trots op jullie.  
  
Allerbeste Jules. Mijn eerste begeleider en promotor. Onze eerste kennismaking 
was kenmerkend voor de rest van onze samenwerkingsperiode: ietwat chaotisch, 
maar zo enthousiast en energiek! Wat jou betreft kon ik direct beginnen, maar 
eerst wilde je me iets op je prikbord laten zien. Na even zoeken (verstopt onder 4 of 
5 lagen…) vond je het: een piepklein knipsel waarop stond: “Chaos op het buro van 
een onderzoeker getuigt van een creatieve geest”. Na een zwaaiende armbeweging 
over jouw bureau volgde de vraag of ik daar (met jou dus) wel mee kon 
samenwerken? “Natuurlijk!”, zei ik en nu, zes jaar later, ben ik heel blij dat ik die 
uitdaging aandurfde. Samenwerken met jou is zo leuk! Je had gelijk, je bent soms 
’n tikkeltje chaotisch, maar zo enorm creatief en vol van je vak, dat jouw 
enthousiasme mij altijd overal in mee heeft gekregen. Elke dag ging (en ga) ik met 
plezier weer aan het werk. Beste Jules, bedankt voor alle leuke, leerzame en mooie 
jaren. Je bent een inspirerend mens en een geweldige kinderrevalidatiearts. Ik ben 
er trots op dit onderzoek met jou te hebben uitgevoerd en zeer blij dat ik de 
komende tijd nog met je mag samenwerken.  
  
Allerbeste Annet, je kwam als senioronderzoeker om het kinderrevalidatie-
onderzoek te begeleiden en kwam zo halverwege het Bolien project in gestapt als 
mijn 2e begeleider. Wat was ik daar blij mee! Jouw onderzoekservaring heeft mij 
enorm geholpen om het onderzoek beter te structureren en door de bomen het bos 
weer te zien. Je bent een geweldige senioronderzoeker, en ik neem graag een 
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voorbeeld aan je. Ik ben dan ook blij dat ik weer samen met je mag werken en weet 
zeker dat ons volgend onderzoeksproject ‘Popeye’ een groot succes wordt. We gaan 
er weer voor! Ik wil ook Jaap bedanken voor je enthousiasme waarmee je samen 
met mij destijds het spasticiteit onderzoek wilde aanpakken, en ook voor je inzet 
voor het vervolgproject. Ik hoop in de toekomst hier nog verder aan samen te 
werken. Dirk Knol wil ik bedanken voor de hulp met de statistische analyses. Op 
deze plaats wil ik ook graag Anita Beelen bedanken. Vanuit het AMC wilde jij mij 
helpen met het schrijven van een review artikel. Dit bleek geen gemakkelijke klus. 
Bedankt Anita, voor de fijne samenwerking. Beste professor Guus Lankhorst, ik 
ben nog steeds heel dankbaar voor de mogelijkheid die mij gegeven werd om op de 
afdeling revalidatie te komen werken. Ik wil je daar graag hartelijk voor bedanken, 
als ook voor de tijd die ik gekregen heb om het onderzoek goed af te kunnen 
ronden.  
  
Alle collega’s uit de andere centra, de mede-Bolieners: hartelijk bedankt voor 
jullie inspanningen. De Bolieners van het eerste uur: o.a. Karel Maathuis, Hans 
Rietman, Jan Halbertsma, Ronald Davidz, Frouwien van der Hoek, Ronald de Jong 
en Rob Douma uit het Universitair Medisch Centrum Groningen, en Lucianne 
Speth, Yvonne Potten, Eugene Rameckers en Marcel Coenen uit Francicoord en 
het Academisch Ziekenhuis Maastricht. En natuurlijk de ´Bolien- redders in nood´ 
Peter Jongerius, Nique Rijs, Monique van Beneden, Esther van Bommel en Bart 
Nienhuis uit de Sint Maartenskliniek in Nijmegen: wat een fijne samenwerking! 
Jullie hebben alles uit de kast getrokken om het beoogd aantal kinderen te werven 
en het is ons (bijna) gelukt! Ik ben er trots op. Ook veel dank gaat uit naar al jullie 
overige collega’s voor het uitvoeren van de metingen en zij die er hard aan hebben 
gewerkt om het onderzoek succesvol te laten verlopen. Ik voel me een grote bofkont 
dat ik nu weer met een aantal van jullie mag samenwerken!  
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 Mijn (ex-)collega’s van het VUmc wil ik bedanken voor het assisteren bij de 
metingen. In het bijzonder Jeanine en Mirjam. Ook al hadden jullie het altijd zelf 
heel druk met jullie PERRIN onderzoek, er was altijd wel een gaatje te vinden voor 
het lichamelijk onderzoek of de GMFM. Daarnaast heb ik genoten van de tijd dat 
we kamergenoten waren. Samen konden we heel hard lachen én heel hard werken. 
Jullie zijn super! Ik kijk uit naar jullie boekjes. Zet ‘m op! Verder wil ik Caroline D. 
en Tanneke bedanken voor het meedenken en jullie hulp bij het uitvoeren van de 
metingen. De invoer- en onderzoeksassistenten Cootje, Goedele, Annelies en Betty 
bedank ik voor de hulp bij het verzamelen en invoeren van delen van de metingen. 
Ik bedank verder de studenten Bewegingswetenschappen en Geneeskunde die 
stage hebben gelopen bij het onderzoek, Roel en Lisette.  
Mijn overige (ex-)collega’s wil ik bedanken, omdat jullie het werken op de 
afdeling zo leuk maken: de collega’s van de ‘gouden gang’ Mirjam, Petra, Fred, 
Martijn, Annet, Merel, Alexander en Daan, ex-collega’s Maaike, Leo, Janneke en 
Herwin, en secretaresses Monique en Vicky. Ik bedank jullie voor alle 
kletspraatjes, grappen, koppen koffie/thee, samenwerking, interesses en ideeën. En 
Merel: PROOST! We hebben het inderdaad gered! 
  
De leden van de leescommissie, Prof. dr. Twisk, Prof. dr. Geurts, dr. Vermeulen, 
dr. Gorter en dr. Buurke, wil ik bedanken voor hun bereidheid mijn proefschrift te 
beoordelen.  
  
Mascha en Jolijn, lieve skatjes patatjes. Jullie vriendschap is onvoorwaardelijk 
en zo ontzettend heerlijk. Ik ben blij dat jullie mijn paranimfen (mijn watte?) 
willen zijn! Lieve vrienden, in het bijzonder Sonja, Madelon, Jennifer, Maartje, 
Alvin, Mirjam, Jordie en Ewout, en lieve broer Robin en zus Mirella, wat ben ik blij 
met jullie! De drukte is nu gelukkig voorbij, en ik kijk uit naar alle leuke 
weekendjes en avondjes die ik weer met jullie kan doorbrengen.  
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Mam en pap, lieve ouders. Bedankt… gewoon voor alles. Door jullie sta ik hier, 
wie had dat ooit gedacht? Bedankt voor jullie belangstelling en onvoorwaardelijke 
steun. Ik weet dat jullie trots op me zijn, maar dat ben ik ook op jullie.  
  
Tot slot Jasper, mijn lieve schatje. Je taak als ’ploegleider‘ zit er op en je hebt me 
laten zien dat geen berg te hoog is. Het leven met jou is zo geweldig, en ik kijk uit 
naar alles wat we samen nog gaan beleven! Ik heb er zin in! 
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 Over de auteur 
 
Vanessa Scholtes, geboren op 26 maart 1975 in Den Haag. Na het behalen van 
mijn VWO diploma, begon ik in 1994 met de opleiding Gezondheidswetenschappen 
aan de Universiteit Maastricht. Mijn eerste wetenschappelijke stage deed ik bij het 
NOC*NSF in Papendal, waar ik vragenlijsten over de incidentie van 
sportblessures ontwikkelde en evalueerde. In 1998 startte ik tevens met de 
opleiding European Masters in Adapted Physical Activity (EMDAPA), aan de 
Katholieke Universiteit Leuven. België werd mijn tijdelijke ‘thuishaven’. De 
wetenschappelijke stage voor deze studie liep ik aan de Universiteit van Exeter in 
Groot Brittannië. Hier begon mijn eerste kennismaking met kinderen met 
cerebrale parese: in deze groep onderzocht ik de betrouwbaarheid van een nieuwe 
vragenlijst over zelf-waargenomen competentie.  
In 1999 keerde ik terug naar Nederland en studeerde voor beide studies af. 
Hierna ging ik wonen en werken in Amsterdam. Ik begon mijn eerste baan als 
assistent in opleiding (aio) aan de afdeling reumatologie in het VU ziekenhuis (nu 
VU medisch centrum) en deed onderzoek bij volwassenen met reumatoide artritis. 
Hoewel het klinische onderzoek mij heel goed lag, miste ik het werken met 
kinderen. Blij was ik daarom dat ik in 2001 de gelegenheid kreeg om de overstap te 
maken naar de afdeling revalidatiegeneeskunde van het VU medisch centrum. 
Hier voerde ik als junior onderzoeker met groot plezier het ‘BOLIEN’ onderzoek uit 
bij kinderen met cerebrale parese.  
De resultaten van dit onderzoek kunt u in dit proefschrift lezen. Daarnaast 
ontwikkelde ik voor deze doelgroep samen met collega’s meetinstrumenten voor 
het meten van spasticiteit (de Spasticiteit Test [SPAT]) en mobiliteit (de 
Mobiliteitsvragenlijst [MOVRA]). 
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Op dit moment werk ik als post doctoraal onderzoeker op dezelfde afdeling en voer 
(wederom met groot enthousiasme) het ‘POPEYE’ onderzoek uit. Hierin onderzoek 
ik wat het effect van krachttraining is op het functioneren van kinderen met 
cerebrale parese. Van deze studie, waarvan de krachttraining in het najaar van 
2007 zal starten, worden eind 2008 de resulten verwacht. 
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